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Vaccination strategies and vaccine formulations for epidemic and pandemic 
influenza control
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Influenza viruses
Influenza A viruses belong to the family of the orthomyxoviridae that consists of 
five genera: Thogoto virus, Isavirus and Influenza virus A, B and C. The generae 
of influenza viruses are distinguished based on their membrane channel protein, 
genome size and surface glycoprotein(s).[1] Influenza A viruses are classified based 
on their surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA). So 
far 16 HA subtypes and 9 NA subtypes have been identified based on genetic and 
antigenic analysis.[2] The nomenclature of influenza viruses is based on: subtype, 
host of origin (except humans), isolation site (geographical), strain number, year of 
isolation and followed by the description of the antigenic subtype, e.g. A/Chicken/
Netherlands/1/03 (H7N7).
Structure of influenza A virus 
Influenza A virus particles are enveloped and have a diameter of 80-120nm. Their 
single stranded negative sense RNA genome is divided over eight gene segments that 
encode 11 different proteins (Figure 1).[3] The surface glycoproteins hemagglutinin 
(HA) and neuraminidase (NA) are located on the viral envelope. The M2 protein, 
which functions as an ion channel is also incorporated in the viral envelope. The other 
proteins are located inside the virion: the Matrix protein (M1), the nucleoprotein 
(NP), polymerases PB1, PB1-F2, PB2 and PA, and the non-structural protein NS2.[3, 
4] The M1 proteins form a layer that underlies the lipid bilayer of the viral envelope 
Figure 1 Impression of Influenza A virus particle and gene segments. The PB1 segment encodes also 
the PB1-F2 protein (present only in infected cells). The M segment encodes the M1 and M2 protein and 
the NS segment encodes the NS1 (present only in infected cells) and NS2 protein.
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CHAPTER 1
that was derived from the infected cell. The M1 protein, in combination with NP 
and polymerase proteins, is also associated with the ribonucleoproteins (RNPs) that 
contains the vRNA. The NP is abundant in the nucleocapsid of the RNP whereas the 
PB1, PB2 and PA proteins are located on one end. The PB1-F2 and non-structural 
protein NS1 are only found in infected cells and are not incorporated in the virion 
and the PB1-F2 is not expressed by every influenza A virus. NS2 is a structural 
component, present at a low copy number and associated with the M1 protein.
Influenza virus replication cycle
The influenza virus attaches to the cell by binding of the HA to galactose-linked 
sialic acids on the glycoprotein receptors of the host cell membrane (Figure 2).[5] 
Depending on the HA subtype the virus can either bind to alpha2-3 or alpha2-6 
galactose-linked sialic acids. Human influenza viruses prefer the alpha2-6 sialic 
acid, abundantly present in the upper respiratory tract but not in the lungs, whereas 
the alpha2-3 linked sialic acid, preferred by avian influenza viruses, is also present 
in the lower respiratory tract.[6, 7] Binding of the virus to and infection of cells in 
the upper respiratory tract, in combination with additional mutations that facilitate 
efficient replication at this site (e.g. PB2-E627K) are required for efficient human-
to-human transmission.[3] Human influenza A viruses are able to spread easily 
among humans whereas the avian influenza A/H5N1 viruses do not replicate in the 
upper respiratory tract and are not transmitted efficiently from human to human. 
Mutations that result in amino acid substitutions in the receptor binding pocket of 
the HA molecule could change its receptor specificity and result in a virus capable of 
human-to-human transmission.
After binding, the influenza virion enters the cell through receptor-mediated 
endocytosis and subsequently fuses with the mild acidic primary endosome.
[5] The low pH in the endosome triggers the membrane fusion activity of HA by 
conformational changes in the protein. This results in fusion of the viral and 
endosomal membranes releasing the RNPs into the cytoplasm. Prior to this event 
the M2 ion channels, activated by the low pH, allow H+ ions to enter the virion upon 
which they detach the M1 protein from the RNPs to prepare it for transport to the 
nucleus, chaperoned by the NP.[8] In the nucleus the three types of influenza virus 
RNA are formed. 
The template RNA, which consists of full length positive sense copies of vRNA from 
which new vRNA is transcribed that will constitute the genome of the newly formed 
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virus particles, and mRNA from which the viral proteins are translated after nuclear 
export, regulated by NS1. Once the viral RNA is produced, new RNPs are assembled 
in the nucleus, transported to the cytoplasm and then transported towards the 
apical membrane, chaperoned by M1. The membrane associated proteins HA, NA 
and M2 are produced by ribosomes bound to the membrane of the endoplasmatic 
reticulum (ER). Subsequently they enter the ER for post-translational modification 
and are transported to the Golgi apparatus where additional modifications take 
place. From there the HA and NA proteins, that use lipid rafts for transport, and the 
M2 proteins, are directed to the apical plasma membrane where virus assembly will 
take place.[9]To allow the newly formed virus particles to be separated from the 
cell, a process called budding, the cell membrane will bulge outward, most likely 
mediated by accumulation of M1 under the lipid bilayer. The virus then bulges out of 
the cell until the cell membrane fuses at the bottom of the virion, hereby closing it. 
The actual release of the virions from the cell is mediated by the enzymatic activity 
of NA that catalyses the cleavage of the sialic acids thus preventing binding of newly 
formed particles to the cell.[10]
Attachment
Endocytosis
Low pH
vRNA
Fusion & Uncoating
mRNA
ER
Packaging & Budding
Posttranslational
processing
Nucleus
Translation
Figure 2 Impression of Influenza virus replication cycle. (ER= Endoplasmatic Reticulum)(vRNA= viral 
RNA)(mRNA= messenger RNA)
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Influenza virus pathogenesis
Human influenza A virus predominantly infects cells in the upper respiratory tract. 
Fourty-eight hours after infection the peak in virus replication is reached.[11] The 
virus infects the epithelial cells on the surface of the larynx, trachea and bronchi 
and can infect type I and II pneumocytes in the alveolar walls.[3, 12] Infected cells 
vacuolize and die off due to necrosis or apoptosis, the latter induced by a shutdown 
of cell protein synthesis.[13] As a result of the infection and extensive cell death 
the tissue becomes inflammated, characterized by flooding of the lumen with 
proteinacious fluid and the influx of neutrophils and mononuclear cells. Normally, 
tissue regeneration starts around day 3 post infection. In the beginning cell loss 
and cell renewal are in balance, nevertheless regeneration will get the overhand 
and complete resolution of the damage to the epithelium of the respiratory tract is 
established within a month after infection.
A productive infection typically results in a tracheobronchitis [3] and clinical 
symptoms that have a rather acute onset: cough, shivers, headache and 
subsequently fever, total malaise and loss of apetite. The development of fever is 
the most prominent indication of infection and the highest body temperatures are 
reached between day 1 and 2 after onset of disease. Normally it will last no longer 
than six days. By that time viral shedding has also stopped, although it is known that 
children shed virus for a longer period of time.[3] After fever and viral shedding have 
resolved the infected individual can still have a cough and feel weak for an additional 
week. The most common complications caused by influenza A virus infection are 
primary viral pneumonia, as seen with many H5N1 cases in South East Asia [14, 15], 
a combination of viral and bacterial pneumonia or secondary bacterial pneumonia. 
These complications occur more often in risk groups: elderly, immunocompromised 
subjects, people suffering from cardiovascular disease, respiratory conditions (e.g. 
asthma) or diabetes, pregnant women and cigarette smokers. In these individuals 
at risk, also other complications occur as a result of the influenza virus infection such 
as, pulmonary and cardiac complications, respiratory exacerbations and diabetic 
ketoacidosis.[16] 
Influenza virus infection can thus result in serious illnes and complications and 
could eventually lead to death. Therefore, treatment of the infection, especially in 
the high-risk individuals, is desirable. Antiviral drugs are available that can be used 
prophylactically and therapeutically. There are two types of influenza antiviral drugs. 
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The M2 inhibitors amantadine and rimantadine that inhibit virus replication at the 
uncoating step of virus replication.[17] The NA inhibitors zanamivir and oseltamivir 
block the release of newly formed virions from the cell inhibiting the enzymatic 
acitivty of NA.[18] Treatment with oseltamivir may result in the emergence of 
strains resistant to this antiviral drug as was seen in patients infected with influenza 
A/H5N1 virus.[19, 20] Since the 2007-2008 northern hemisphere influenza season 
there has been a rise in oseltamivir-resistant influenza A/H1N1 strains, independent 
of the use of the drug.[21-23] Although it appears that the mutation was not 
introduced by direct selective pressure due to extensive use of oseltamivir, it is 
clear that viruses with this mutation can easily spread in the human population. 
Besides the emergence of resistant strains, long-term prophylactic use of antivirals 
is unfeasible. That is why for long-term protection it is recommended to vaccinate 
high-risk individuals against influenza annually.[3]
Influenza epidemics and pandemics
Although influenza A viruses of the H1N1 and H3N2 subtype cause annual epidemics 
amongst humans, aquatic birds are the reservoir of all known subtypes.[2, 24] 
Occasionally viruses are transmitted from this reservoir to mammals like pigs, 
horses, marine mammals (seals and whales), dogs, minks, cats, tigers and humans.
[3, 25-30]
Figure 3  Influenza A virus reservoirs (adapted from [3])
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Seasonal influenza epidemics
Yearly approximately 5-10% of the human population is infected with influenza A 
viruses of the H1N1 or H3N2 subtype or influenza B virus, globally causing illness in 
3-5 million people and 250,000 to 500,000 fatal cases.[31, 32] These epidemics take 
place in the winter months twice a year on the Northern and Southern hemisphere 
respectively. The responsible viruses are most likely seeded from East and South-
East Asia.[33] During the circulation in humans they gradually accumulate mutations 
in the RNA genome, resulting in amino acid substitutions preferentially located in 
the antigenic regions of the surface glycoproteins HA and NA recognized by virus 
neutralizing antibodies. Because of this antigenic drift, the vaccine composition of 
seasonal vaccines needs to be updated almost annually.[34]
Pandemics in the 20th century
Antigenic drift is thus based on minor changes in the HA or NA. The introduction of 
a new HA and/or NA subytpe results is a more drastic change and is called antigenic 
shift. This can happen by genetic reassortment of a human influenza virus with an 
avian or swine influenza virus or the introduction of a fully avian or swine influenza 
virus into the human population. The human population is immunologically naive for 
the new subtype and therefore the replication of virus is not hampered by specific 
antibodies and consequently, the new viruses may cause a pandemic: a worldwide 
outbreak of the new influenza A virus, affecting approximately 30% of the world 
population. This happened on three occasions in the 20th century: in 1918, 1957, 
1968.[3]
In 1918 an influenza A virus of the H1N1 subtype spread worldwide in three waves 
and within 6 months killed 25-50 million people. The influenza virus responsible for 
the outbreak is known as the ‘Spanish Flu’ and, based on phylogenetic analysis, it is 
thought that it was a fully avian virus that was introduced in the human population.
[35] However, conflicting results were obtained by others and the discussion on 
the exact origin is still ongoing.[36] Four decades after the ‘Spanish Flu’, in 1957, 
a new pandemic arose, this time caused by a reassortment of a human influenza 
A virus and an avian influenza A virus of the H2N2 subtype, resulting in a virus that 
contained the avian HA, NA and PB1 genes.[37, 38] This ‘Asian Influenza’ pandemic 
resulted in more than 1,000,000 deaths worldwide. This influenza A/H2N2 virus was 
replaced eleven years later by an influenza A/H3N2 virus. This strain originated from 
Southern China and caused the ‘Hong Kong influenza’ pandemic with an attack rate 
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of 40%.[3] Eleven years later the influenza A/H1N1 virus subtype was re-introduced, 
in the human population, probably by accidental release.[3] Since then, influenza A 
viruses of the H1N1 and H3N2 subtype ‘co-exist’.
Pandemic threats in the 21st century
Since the last pandemic in 1968, single cases and small scale introductions of avian 
and swine influenza A viruses of various subtypes were reported (for review see De 
Wit et al).[39-41] A large outbreak of an avian influenza A/H7N7 virus in poultry in the 
Netherlands in 2003 resulted in 89 bird-to-human transmissions with 1 fatal case.
[42, 43] In 1997 in South-East Asia the first human infections with highly pathogenic 
avian influenza A/H5N1 virus were reported.[44-46] Since 2003, over 400 human 
cases were reported to the World Health Organization (WHO) and more than 60% 
of the infected people succumbed to the infection.[47] So far, these viruses do not 
spread efficiently from human-to-human although sporadic clusters of human-to-
human transmissions have been described.[48, 49] Apparantly, these viruses require 
further adaptation to their new host, as described above, in order to be transmitted 
and spread in the human population efficiently.
Pandemic in the 21st century
After 41 years since the last influenza pandemic, the introduction of a new 
influenza A/H1N1 virus that contains gene segments from classical and Eurasian 
swine influenza viruses and triple reassortants (bird, human, swine) has resulted 
in the first influenza pandemic of the 21st century.[50, 51] Previously, humans have 
been infected with swine influenza viruses sporadically.[3, 40, 41] However, since 
March 2009, the new influenza A/H1N1 virus, originating from swine, spread to 74 
countries including the Netherlands and infected over 52,000 people and killed over 
230 within three months.[52] The clinical outcome of these infections is relatively 
benign, although the mortality rate is ~0.5%. This virus continues to spread and is 
capable of human-to-human transmission. 
The immune defense against influenza virus infections
The immune system responds in two different ways to influenza virus infection: the 
innate response that is quick and forms the first line of defense, and the adaptive 
immune response that is virus-specific and is based on humoral and cellular 
immunity.
17
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Innate immunity upon influenza virus infection
Cells infected with influenza virus produce proinflammatory cytokines and 
chemokines that attract immune cells like alveolar macrophages, natural killer 
(NK) cells and dendritic cells. These cell types are responsible for opsonization of 
viruses and cell debri, elimination of virus-infected cells and antigen presentation, 
respectively. Furthermore they produce cytokines, triggered by recognition of 
viral components such as single stranded viral RNA by e.g. Toll like receptor (TLR) 
7.[53] An important effect of the antiviral cascade is the activation of the interferon 
pathway that leads to the production of type I interferons: IFNα and IFNβ, key 
players in the innate immune response.[3] Binding of IFNα to cells in the respiratory 
tract triggers an antiviral state in which they downregulate their cellular processes, 
and hereby IFNα contributes to regulation of the infection. 
The influenza virus NS1 protein, found only in infected cells, functions as a an 
IFNa-antagonist and distorts the antiviral state of the cell hereby improving viral 
pathogenicity.[54, 55] However, IFNα not only acts on the host cell, it also recruits 
immune cells and plays an important role in initiating the adaptive immune response. 
IFNa activates dendritic cells resulting in enhancement of antigen presentation to 
virus-specific CD4+ T cells and CD8+ cytotoxic T cells (CTL), two key players of the 
adaptive immune response.[56, 57]
 
Adaptive immunity: the humoral response
Influenza virus infection results in the induction of virus-specific antibodies that, 
in the case of influenza A virus, are directed to the HA, NA, NP and M1 proteins 
predominantly.[58-61] Antibodies against the first two proteins can neutralize the 
virus and afford protective immunity against influenza virus infection. The two 
main antibody subtypes that are involved in virus neutralization in vivo are mucosal 
IgA and serum IgG that transudates into the lung. The HA-specific antibodies can 
prevent binding of the virus to and infection of the cell. They can also facilitate 
phagocytosis of virus particles by Fc receptor cells and activate the complement 
pathway. Antibodies directed to the NA can inhibit the enzymatic activity of this 
protein and prevent the release of newly formed virus particles from the cell surface.
[3] The antibody response also contributes to elimination of virus-infected cells 
through antibody-dependent cell-mediated cytotoxicity (ADCC).[62] Antibodies 
against the HA and NA can persist for a long time, however the breadth of protection 
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by these antibodies is limited. They are specific for one subtype of the glycoprotein 
(e.g. H3 and N2) and drift variants that are antigenically too distinct can no longer be 
recognized.[34] Therefore the components of the seasonal influenza vaccine, that 
at the induction of HA and NA antibodies, need to be updated frequently.
Figure 4 Immune responses to influenza virus infection. Adapted from: Influenza Report
19
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Adaptive immunity: the cellular response
The cellular immune response comprises various T cell subsets. CD4+ T lymphocytes 
recognize virus-derived peptides in association with Major Histocompatilibity 
Complex (MHC) class II molecules. 
These are present on professional antigen-presenting cells (APC), e.g. dendritic cells 
(DCs) with a CD11b-CD8a- phenotype, also known as migratory DCs.[63] CD4+ T cells 
mainly function as T helper cells (type 1 and 2) and to a certain extent display cytolytic 
activity. They function as catalysts for the production of antibodies by B cells (T 
helper 2 cells) and the activation of CD8+ CTL (T helper 1 cells). The T helper 2 (Th2) 
cells produce cytokines that stimulate the proliferation and differentiation of B cells 
into antibody-producing plasma cells.[64] Furthermore cytokines are produced by T 
helper 1 (Th1) cells that stimulate the proliferation and differentiation of CD8+ CTL 
that, upon encounter with MHC class I associated influenza virus-derived peptides 
(epitopes), presented by infected cells, by APC or via cross-priming, expand to 
effector cell populations. These CD8+ CTL are able to recognize virus-infected cells 
and eliminate them by the excretion of perforin and granzyme B that premeabilize 
the membrane of the infected cell and induce apoptosis respectively, contributing 
to viral clearance (Figure 6). CTL responses are mainly directed to epitopes derived 
from the internal proteins of the influenza virus: NP, M1, and the polymerases, that 
are relatively conserved.[65-70] Therefore, CTL responses are highly cross-reactive 
in contrast to antibodies and they contribute to heterosubtypic immunity since they 
are able to recognize and respond to influenza viruses of different subtypes.[67, 71-
73] A hallmark of the adaptive immune response is the formation of memory cells 
that can repond to second infection more rapidly and stronger.
Influenza vaccines
To encounter the seasonal influenza epidemics vaccines are available that are safe 
and have good efficacy. However new developments are made to improve and 
optimize vaccine production and improve immunogenicity. Furthermore, to limit a 
potential outbreak of a new influenza pandemic the availability of safe and effective 
vaccines is desirable and considered a high priority by the WHO.[74] Major efforts 
have been made to prepare H5N1 vaccines. However, there were a number of 
issues that complicated the development of such vaccines, including poor vaccine 
immunogenicity, long response times, limited production capacity and antigenic 
variation of circulating strains. Some of these issues have been addressed recently 
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and are discussed here. 
Vaccine immunogenicity: since the population at large is immunologically naïve and 
not primed for an H5-specific antibody response, conventional inactivated whole 
virus and subunit preparations are poorly immunogenic and higher doses and/or 
multiple administrations are required to induce appreciable antibody responses. 
However, the use of adjuvants that were developed and evaluated recently improves 
the immunogenicity of the classical vaccine preparations and lowers the amount of 
antigen required for the induction of protective levels of virus-specific antibodies.
Response time: it is of great importance that vaccines become available as soon 
as possible after the start of a new pandemic and when the strain responsible for 
the outbreak has been identified. However, classic technologies to prepare safe and 
effective vaccine strains are time consuming and based on the reassortment of a 
vaccine backbone strain with the epidemic strain by double infection of embryonated 
chicken eggs. Over the last years, there have been a number of developments 
that may contribute to the timely delivery of vaccines. Novel methods have been 
developed to produce safe vaccine strains more rapidly and with high yields. 
Recombinant DNA (reverse genetics) technology is now an established procedure 
to prepare low pathogenic reassortant vaccine strains. Furthermore, cell-culture 
technology has become available for the flexible production of vaccine antigens.
Figure 5: Vaccination strategies and hurdles
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Antigenic variation: the circulation of multiple antigenically distinct H5N1 viruses 
complicates the development of effective vaccines. These variants have been divided 
in clades and subclades.[75] Ideally a vaccine induces broad protective immunity 
against multiple viruses originating from different clades. With adjuvants that 
have become available recently it was possible to induce cross-reactive antibody 
responses in humans and cross-protective immunity in animal models.
Production capacity: at present the combined production capacity in embryonated 
chicken eggs of all vaccine manufacturers is limited and sufficient doses for 
a worldwide vaccination campaign cannot be produced in time. Alternative 
production technologies (e.g. cell culture) have become available to produce more 
vaccine doses in a flexible manner.
Novel vaccine developments were made during the last decade that overcome some 
of the difficulties described above and contribute to the rapid availability of sufficient 
doses of safe and effective vaccines for an influenza pandemic. The four areas of 
influenza vaccine production described above and the impact of implementation of 
the new developments are summarized in Figure 5.
Conventional influenza vaccines
Seasonal influenza vaccines are trivalent and contain components of influenza A 
viruses of the H1N1 and H3N2 subtypes and an influenza B virus, since these viruses 
are responsible for the annual influenza epidemics.[76]
For the production of vaccines, the growth characteristics of the influenza A vaccine 
strains and the yields of the viral antigens HA and NA are important issues. To 
obtain high yields of these antigens reassortant viruses are prepared by infecting 
embryonated chicken eggs simultaneously with a selected epidemic strain and an 
egg-adapted laboratory strain, typically influenza virus A/PR/8/34.
Reassortant viruses are selected that carry the hemagglutinin (HA) and neuraminidase 
(NA) of the epidemic strain and have the high-growth phenotype of the laboratory 
strain. To prepare effective vaccines, it is of great importance that the vaccine 
strains match the epidemic strains antigenically. Only then, protective immunity 
against these viruses will be induced most efficiently. Influenza viruses display a high 
extent of variation caused by a high mutation rate.[34] By accumulating amino acid 
substitutions in the antigenic sites that are recognized by the antibodies, variants 
are selected that can escape from the neutralizing activity of these antibodies that 
were induced by previous infections or vaccination. This form of variation, found 
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both in influenza A and influenza B viruses is called antigenic drift and necessitates 
the update of the vaccine composition when new drift variants emerge which are 
insufficiently recognized by antibodies induced by the existing vaccine.[76]
In order to assess the antigenic drift of influenza viruses, extensive global 
surveillance is necessary. Each year during the epidemics large numbers of influenza 
viruses are isolated and characterized antigenically by national influenza centers 
and World Health Organisation (WHO) collaborating reference centers. On the 
basis of this antigenic data and epidemiological data the WHO biannually provides 
recommendations for the composition of the influenza vaccine for the subsequent 
influenza season.[76] For example, it was recommended to replace all vaccine 
strains in the vaccine to be used in the Northern hemisphere 2008/2009 season.
Typically, for the seasonal influenza vaccines, one embryonated chicken egg is needed 
for the production of one dose that contains 15 micrograms of HA from each vaccine 
strain. In order to obtain the HA antigens, egg-derived virus is inactivated and used 
either as whole inactivated vaccine, split virion vaccine or subunit vaccine. For the 
preparation of whole-inactivated vaccines the virus is inactivated with formaldehyde 
or b-propiolactone before or after purification. Split virion vaccines are obtained 
by further treatment with a detergent to disrupt the virus. For the preparation of 
subunit vaccines, the HA and NA, which are important for the induction of virus-
neutralizing antibodies and protective immunity, are further purified by removing 
other viral proteins and lipids through additional centrifugation steps.
The use of these vaccines has been a cornerstone in preventing influenza-related 
morbidity and mortality for decades. Patients with certain underlying diseases and 
the elderly are at high risk for influenza-related complications and benefit especially 
from vaccination. Therefore, annual vaccination is recommended for these high-
risk groups. The vaccine is administered by intramuscular injection before the 
start of the influenza season. It is recommended also that children who have never 
been vaccinated and that have not been exposed to influenza viruses should be 
vaccinated twice with a four week interval. Since the vaccine is prepared with virus 
derived from embryonated chicken eggs, allergy to egg or egg-products is a contra-
indication. Overall, the vaccines provide protection against disease in 70-90% of 
healthy adults.[77] The efficacy is lower (30-70%) in elderly patients but protection 
against influenza-related complications and mortality is achieved in 70-90% of the 
vaccinees in this age group.[77]
23
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The production of these inactivated antigen preparations was also used as a 
template for the production of candidate H5N1 vaccines. However, it was found that 
without the use of adjuvants (see below) these antigens were poorly immunogenic 
in subjects naïve to H5N1 influenza viruses and antibody responses were only 
induced when high doses of vaccine were used.[78] This is of course not desirable 
considering the envisaged shortage of vaccines during a pandemic outbreak with 
these viruses.
Alternative formulations and production technologies
Live attenuated vaccines
The use of live attenuated viruses is another vaccine approach that has been 
applied successfully for various infectious diseases.[79]  Also for vaccination against 
influenza, live attenuated vaccines have been developed, particularly in Russia and 
the United States.[80] Influenza viruses can be attenuated by adapting them to 
replicate at lower temperatures (25-33°C). This way, cold-adapted or temperature-
sensitive virus strains can be obtained. To obtain cold-adapted vaccine strains 
these strains are re-assorted with selected epidemic strains which donate the gene 
segments encoding the HA and NA.
Instillation of these vaccine strains by the intranasal route does not result in the 
typical influenza-like symptoms.[81] Only in a small proportion of vaccinees some 
mild symptoms in the upper respiratory tract have been observed like runny nose 
and sore throat. These viruses seem sufficiently attenuated, are genetically stable 
and are not transmitted from vaccinated individuals to other subjects. Therefore, 
they are considered to be safe and a seasonal influenza vaccine based on this 
technology has been approved by the United States Food and Drug Administration 
(FDA) for use in humans 2-49 years of age (Flumist®).[82] Intranasal administration 
of live attenuated influenza vaccines (LAIV) usually induces good immune responses 
although the magnitude of the serum antibody response is dependent on the extent 
of virus replication. Furthermore LAIV induce mucosal IgA responses which are 
more cross-reactive than IgG responses and provide protection at mucosal sites 
and in addition, these vaccines induce CTL responses.[83-87] The effectiveness of 
live attenuated vaccines was found comparable to that of inactivated vaccines in 
a meta-analysis.[88] However, it has also been reported that, in young children, 
the effectiveness of LAIV was better than that of inactivated vaccines.[82, 89] The 
effectiveness of LAIV did not correlate with the magnitude of the serum antibody 
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response.[86] LAIV cold adapted H5N1 vaccines have also been evaluated in various 
animal models and it was found that these type of vaccines induced protective 
immunity against challenge infection with H5N1 viruses from different clades.[83, 
90]
Other ways to attenuate influenza viruses are being investigated and include 
removal of (part of) the non-structural protein-1 (NS1).[54, 91, 92] This protein is 
known as an antagonist of IFN-a and truncation of NS1 prevents inhibition of IFN-a 
production because of the loss of the capacity to sequester dsRNA and activation 
of the NF-κB signaling pathway.[54, 91] Indeed these viruses have an attenuated 
phenotype in experimental animals.[92] In individuals with defects in their IFN-a 
response these viruses may gain virulence. Also the possibility that LAIV reassort 
with a wildtype HPAI virus is considered a risk, although there is no evidence so 
far that this might occur. The ease of production of these type of vaccines may be 
attractive when production capacity of inactivated vaccines falls short and does not 
meet the demand.
Production of vaccine strains by reverse genetics
The classic way to produce reassortant vaccine strains, by double infection of 
embryonated chicken eggs, is laborious and time consuming and therefore delays 
the timely availability of vaccine strains suitable for vaccine production. In addition, 
when highly pathogenic avian influenza viruses are used low yields can be expected 
since these strains are lethal to the chicken embryo’s. Since the advent of reverse 
genetics technology for the genetic modification of influenza viruses, this procedure 
is used to generate safe pandemic vaccine strains in a well-defined fashion in the 
shortest time possible. To this end, cDNA of all viral gene segments is cloned into 
plasmids. To obtain a safe vaccine strain, the region encoding the basic cleavage 
site, associated with high virulence, is deleted from the HA gene by site directed 
mutagenesis. Upon transfection of Vero cells, the viral RNA is transcribed from 
the plasmids under control of a pol-I promotor and mRNA under control of a pol-
II promotor (typically the CMV promotor) and virus is produced and subsequently 
rescued in a suitable cell line. The rescued virus can then be used for vaccine 
production. Reverse genetics virus-based vaccines induced protective immunity 
against homologous and heterologous virus in mice, ferrets and birds.[93-98] 
An additional advantage of preparing vaccine strains this way, is that the risk of 
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extraneous contaminating agents is minimized, since the vaccines are entirely based 
on PCR amplified genes that are cloned into plasmids. Also the gene constellation 
is well-defined and can be selected at wish. In the light of pandemic preparedness, 
the accelerated availability of low pathogenic vaccine strains is undoubtedly the 
biggest advantage of this approach.[99, 100]  Fast-track licensing and registration 
of a vaccine by using mock-up files will also contribute to shorter response times and 
faster availability of vaccines.[101]
The use of cell lines for vaccine production
As indicated above, the use of embryonated chicken eggs for influenza vaccine 
production suffers from a number of disadvantages. In addition, embryonated 
chicken eggs may be available in limited quantities or not at all when HPAI viruses are 
circulating widespread. Therefore, the use of egg-independent vaccine production 
methods is considered as a highly attractive alternative. Recently, cell lines have 
become available for influenza vaccine production.[102] Cell cultures are easier to 
handle and can be scaled up in a short period of time. Since this technology does not 
suffer from some of the logistic problems associated with the use of embryonated 
chicken eggs, it is more flexible and will reduce the response time to a certain extent, 
although the down-stream processing of the vaccine production remains essentially 
unaltered.
Different cell lines are currently in various stages of development and evaluated 
as influenza vaccine production platform including Madin-Darby-Canine kidney 
(MDCK) cells, Vero cells and PER.C6 cells.
MDCK cells were isolated in 1958 and have been adapted to grow on micro-carriers 
and under serum-free conditions.[103] It has been the cell-line of choice for a number 
of vaccine manufacturers.[102],[104] So far, MDCK-derived influenza vaccines have 
proven to be safe and immunogenic in clinical trails and one is already licensed for 
the European market.[105]  
Vero cells are kidney fibroblasts from an African monkey and have been used for the 
production of polio vaccine for more than twenty years.[106, 107] The cells are also 
adapted  to grow on micro carriers under serum-free conditions and cultures can be 
scaled up to 6000 liters without loss of quality.[106] Vero cells are preferred as the 
primary cells to be transfected with plasmids for the purpose of generating vaccine 
strains by reverse genetics technology (see above).[100, 108] Pandemic influenza 
vaccine candidates were produced by propagating wildtype HPAI H5N1 strains in 
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Vero cells followed by inactivation of the virus with formalin and UV-irradiation.
[106] This WIV vaccine induced a protective immune response to homologous 
and heterologous H5N1 viruses in mice and was immunogenic in men.[106, 109] 
Surprisingly, this vaccine was immunogenic at a low dose (2x7.5 µg) without the use 
of an adjuvant.
PER.C6 cells originate from a human fetal retinoblast culture that was immortalized 
with recombinant DNA technology.[110] The cells are cultured in suspension 
under serum-free conditions and can be used to propagate influenza viruses or 
recombinant adenoviruses that express a selected influenza virus antigen.[111, 112] 
At present no data are available on the immunogenicity of PER.C6 derived influenza 
vaccines. Another advantages of the use of cell lines for the production of influenza 
vaccines is that no allergic reactions against egg-derived proteins will be evoked.
[113] Furthermore, influenza viruses propagated in cell lines more closely resemble 
the original virus isolate than viruses propagated in chicken eggs.[114, 115]
Recombinant HA
As an alternative for the conventional production of viral antigen in embryonated 
chicken eggs or cell culture, the influenza virus hemagglutinin can be produced as a 
recombinant protein. For this purpose the expression of HA genes by recombinant 
baculovirus in insect cells has been used.[116-119]
For the generation of recombinant baculoviruses, the gene of interest is inserted 
into a baculovirus shuttle vector that is transfected into SF9 cells derived from the 
insect Spodoptera frugiperda.[116] Baculovirus expressed HA has been evaluated as 
a seasonal influenza vaccine and was shown to effectively induce virus neutralizing 
antibodies, provided protection against the occurrence of influenza-like illness and 
a license application has been submitted to the FDA.[120-123] Promising results 
have also been obtained with rH5-based vaccine although high doses were required 
for the induction of appreciable antibody response.[124] 
Virosomes
Influenza virus antigens can also be incorporated in particles called virosomes. 
These are spherical unilamellar liposomal vesicles produced by the mixture of 
purified solubilized influenza virus with phospholipids.[125, 126] Upon vaccination 
these particles enter the cell in the same way as virions do, resulting in good 
immunogenicity due to virtually natural antigen-processing and presentation. Since 
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virosomes facilitate fusion with the endosomal membranes they can induce cellular 
immunity via the MHC class I pathway.[127, 128] Pre-existing HA-specific antibodies 
do not interfere with this process.[129] Virosomal vaccines are more immunogenic 
than conventional influenza vaccines in the elderly.[130-133]  Inflexal V® is the first 
licensed virosomal vaccine and has been administered to more than 40,000,000 
subjects. 
Virus-like particles
Another particulate antigen formulation of influenza vaccines are virus-like particles 
(VLPs), which are formed after expression of the HA and NA genes and optionally 
the M1 gene or other influenza virus genes in insect cells.[134] This can be achieved 
by infection of SF9 cells with recombinant baculoviruses expressing these influenza 
virus derived genes. With VLP protective immunity against various influenza virus A 
subtypes could be induced.[134, 135] Also H5N1 candidate VLP-based vaccines were 
evaluated and it was shown that these vaccines induced cross-reactive antibodies in 
mice, providing protective immunity against H5N1 influenza viruses from different 
clades.[136, 137]
Adjuvants
Whatever technology is used for their production, candidate H5N1 vaccines are 
poorly immunogenic in naïve individuals. To overcome this problem, higher vaccine 
doses could be used to induce protective antibody levels (for review see Bridges 
et al).[138] However this is an undesirable scenario resulting in an even smaller 
portion of the human population that may be vaccinated in the face of a pandemic 
outbreak. Therefore, there was an urgent need for adjuvants that could increase the 
immunogenicity of existing vaccine preparations and that could reduce the dose of 
antigen required for the induction of protective immune responses (dose-sparing). 
As a result, more human subjects can be vaccinated with the available amount of 
antigen that can be produced.
Despite the modest adjuvant effect of aluminum-containing influenza vaccines 
described in the past four decades, the evaluation of alum as an adjuvant in 
pandemic H5N1 influenza vaccines has been the subject of several studies probably 
since it is an already licensed adjuvant free of intellectual property rights and with a 
known track record in the human influenza vaccine field.[78, 83, 139-143] Again the 
adjuvant activity in split virion and WIV vaccines proved to be modest and it seems 
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unlikely that efficient dose-sparing can be achieved with alum. 
One concern about the use of alum in combination with formaldehyde-inactivated 
vaccines is that it could predispose for more severe disease upon subsequent 
natural infection as was described for alum-adjuvanted formaldehyde-inactivated 
respiratory syncytial virus and measles virus vaccines.[144, 145] However, with an 
experimental alum-adjuvanted H5N1 vaccine protective immunity was induced in 
macaques against challenge infection without any signs of disease exacerbation.
[139]
Clearly there is a need for novel adjuvants that improve the immunogenicity and 
efficacy of influenza vaccines and pandemic influenza vaccines in particular and 
that would allow dose-sparing. Recently, promising adjuvants, that fulfill these 
requirements, have been developed (see below). 
Oil-in-water emulsions
MF59 is an oil-in-water emulsion consisting of the oil squalene (a terpenoid 
cholesterol precursor) and the surfactant sorbitan triolate (Span 85) and 
polyoxyethylenesorbitan monooleate.[153] Addition of the adjuvant to an influenza 
subunit vaccine improved its immunogenicity.[152] MF59 most likely works through 
the activation of the macrophages and dendritic cells that phagocytose it.[148, 149, 
153, 155] The adjuvant is well-tolerated and improved the immunogenicity of the 
infuenza vaccine and the breadth and longevity of protection especially in the elderly, 
one of the largest high-risk groups for influenza virus infection.[146, 147, 150-152] A 
seasonal MF59-adjuvanted influenza vaccine (Fluad®) has been licensed for use in 
the elderly in twenty countries and administered to over 20 million individuals.[153, 
154] The oil-in-water emulsion was also used in candidate H5N1 vaccines and it was 
found that with 7.5mg of HA, protective antibodies could be induced compliant with 
the EU licensing criteria.[152]
More recently, another oil-in-water adjuvant, known as AS03, has been developed. 
It contains DL-a-tocopherol, squalene and Tween-80.[158] AS03 has been evaluated 
as an adjuvant in candidate pandemic vaccines. It improved the immunogenicity 
of H5N1 split virion vaccines in ferrets and humans and was well-tolerated.[156-
159] The induced antibody responses were cross-reactive with H5N1 viruses from 
different clades and an antigen dose of only 3.8mg was sufficient for the induction 
of serum antibody titers in humans, compliant wit the license criteria.[157] 
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Collectively, it is envisaged that the development of these type of adjuvants will 
contribute to the production of more efficacious seasonal and pandemic influenza 
vaccines and will improve the availability of these vaccines. 
Immune stimulating complexes (ISCOMs)
ISCOMs are cage-like structures with a diameter of approximately 40nm, consisting 
of cholesterol, phospholipids and purified saponins of the tree Quillaja Saponaria 
Molina.[160, 162] The antigen of interest, e.g. the influenza HA or other viral proteins 
can be incorporated into this structure but this is not essential for its adjuvant effect.
ISCOMs are in advanced stage of development and have been tested for a variety of 
different viruses.[163] As an adjuvant system for influenza vaccines its use resulted 
in strong antibody responses, Thelper cell responses and cytotoxic T lymphocyte 
responses in mice, chickens, macaques and humans (for review see Rimmelzwaan 
et al).[164] Its use improved immunogenicity and effectiveness of a candidate H5N1 
vaccine considerably.[161] Over the years the composition of ISCOMs have been 
Table 1: Summary of vaccine formulations, production methods, adjuvants 
and alternative delivery methods discussed in the introduction
Development Example References
Formulations
Inactivated
(whole virus, split 
virion, subunit)
[77, 78]
Live-attenuated Cold-adapted [79-90]
Defective NS1 [54, 91, 92]
Virosomes [125-133]
Virus-like particles [134-137]
Production
Cell-culture 
production
antigen [102-115]
Reverse genetics reassortant strain [93-101]
Recombinant HA antigen [116-124]
Adjuvants
Alum [78, 83, 139-145]
Oil-in-water 
emulsion
MF59 [146-155]
AS03 [156-159]
ISCOMs [160-164]
Alternative antigen 
delivery
DNA [165-175]
viral vector adenovirus [112, 176-180]
MVA [181-191]
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modified and improved to reduce reactogenicity with full retention of its adjuvant 
effect. 
Other adjuvants
Many other adjuvants are in various stages of development (for review see Vogel 
et al).[192] Their potential in (pandemic) influenza vaccines needs to be assessed 
but it is likely that some of these will be promising since their adjuvant effects have 
already been demonstrated in combination with other antigens.[192] 
Alternative antigen delivery
DNA vaccines
After it was shown that intramuscular injection of DNA expression vectors resulted 
in the expression of protein encoded by the DNA this approach has been explored as 
a vaccination strategy aiming at the induction of immune responses directed to the 
expressed proteins.[172, 175] Ulmer et al have shown that injection of DNA encoding 
influenza virus nucleoprotein can confer protection in mice against infection with 
homologous and heterologous virus strains.[173] This protection correlated with the 
induction of virus-specific and cross-reactive CTL responses. Numerous studies in 
various animal species have demonstrated the induction of influenza virus-specific 
cell-mediated and humoral immune responses by plasmid DNA encoding influenza 
virus proteins.[165, 167, 170-172, 174] During the last decade a lot of information has 
become available about how the outcome of DNA vaccination is affected by the 
dose of DNA used, the route of administration (epidermal delivery), delivery systems 
(e.g. gene gun), the role of dendritic cells and muscle cells in antigen presentation 
and the presence of CpG motifs in the DNA.[168] The advantages of the use of DNA 
expression vectors are obvious. Plasmid DNA can be produced rapidly and at low 
costs in bacteria and its production is independent of classical vaccine production 
technology. Although a lot of information has been obtained in animal models, 
knowledge on the efficacy of this type of vaccines in humans is sparse.[166] 
The main reason for this gap of knowledge probably is the concern over the safety 
of such vaccines.[169] Some of the safety issues that need to be addressed include 
the risk of integration of the vaccine derived DNA in the host genome, increasing 
the risk of malignancies and the risk of inducing tolerance rather than immunity. 
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Viral vectors
Several viruses have been used as recombinant vector vaccines for the delivery of 
antigens of interest, for example a foreign viral protein. Herpes viruses, measles 
virus, alpha viruses, lentiviruses, adenoviruses and pox viruses are examples of 
viruses that have been used for this purpose.[193, 194] The latter two have been 
tested preclinically as candidate H5N1 vaccines.
Adenovirus
Recombinant adenoviruses have been modified genetically rendering them unable 
to replicate in normal human cells and enabling them to express one or more genes 
of interest e.g. influenza virus HA, NA and M1 genes. Recombinant adenoviruses 
can be produced rapidly and at a large scale in specialized cell lines that support 
packaging of the otherwise replication deficient viruses.[178] Recently, candidate 
H5N1 vaccines based on recombinant adenoviruses were tested in animal models.
[112, 176-180] It was shown that immunization with an adenoviral vector expressing 
the HA gene alone or in combination with other genes of H5N1 influenza viruses 
induced protective immunity against a lethal challenge which was mediated by 
virus-specific antibodies and CTL.[112, 176-180] The presence of antibodies specific 
for adenoviruses in the human population may interfere with vaccine efficacy, but 
the availability of various serotypes of recombinant viral vectors may circumvent 
this problem and may allow repeated vaccination with this type of vaccine.
Modified Vaccinia virus Ankara
Also replication deficient poxviruses can be used as a vaccine vehicle for the delivery 
of foreign antigens. Especially the modified vacccinia virus Ankara (MVA) is a 
promising candidate and has been used for this purpose in many studies. recMVA 
expressing the HA and NP gene of influenza virus A/PR/8/34 was originally tested 
as a candidate influenza vaccine and it was shown that in mice it induced HA-
specific antibodies and NP-specific CTL and conferred protection against challenge 
infection.[190] 
More recently, recombinant MVA were constructed that express the HA gene of 
H5N1 influenza viruses. The evaluation of the MVA-HA vaccine is described in this 
thesis. The use of recombinant MVA vectors has many advantages. First of all, these 
vectors are safe and well-tolerated in humans, also in immunocompromised subjects.
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[183, 187] MVA has already been administered to >120,000 subjects as a smallpox 
vaccine.[183] It can be produced at large scale under GMP BSL-1 conditions, is stable 
and can be stored for long periods of time, which may be relevant for stockpiling of 
vaccines. [181, 184, 186, 188, 189, 191] Furthermore the presence of pre-existing 
antibodies to the vector does not interfere with vaccine efficacy and so repeated 
vaccinations are possible. [182, 185]
Alternative vaccine administration methods
The conventional inactivated influenza vaccines are administered by intramuscular 
injection. Live attenuated influenza vaccines typically are administered by the 
intranasal route and this way elicit a mucosal immune response, in addition to a 
systemic immune response. Sublingual administration is another mucosal route and 
eliminates the risk of virus reaching the olfactory bulbs. Intradermal immunization is 
being explored as an alternative, needle-free, dose-sparing route of administration. 
For review of these and other alternative administration routes that are in various 
stages of development see Girard et al and Weniger et al.[195, 196] 
Cross-protective immunity
Intra-subtypic cross-protection
The production of effective vaccines is complicated by the antigenic variation 
Figure 6 Recombinant MVA expressing the HA-gene (adapted from a figure by G. Sutter)
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that influenza viruses display within a certain subtype. This holds true for seasonal 
influenza virus strains and necessitates the annual update of the vaccine composition 
to match the epidemic strains as closely as possible. Ideally vaccines confer the 
broadest possible protection against a variety of viral antigenic variants. The 
addition of the adjuvant MF59 to conventional vaccine preparations has broadened 
the cross-reactivity of the vaccine-induced antibodies response to a certain extent. 
[146, 147] The induction of intra-subtypic cross-reactive antibodies is also relevant 
for the development of candidate H5N1 vaccines, since multiple antigenically 
distinct clades of influenza H5N1 viruses have been identified. [75] Again, the use 
of an adjuvant can broaden the reactivity of the antibody response against H5N1 
viruses resulting in the induction of protective immunity against viruses derived 
from different clades.
Also NA-specific antibodies can be cross-reactive and it has been shown that 
some humans have serum antibodies directed to the N1 of human A/H1N1 viruses 
that cross-react with the NA of H5N1 viruses. [197] This may afford some level of 
protective immunity against H5N1 viruses.
Inter-subtypic cross-protection
Until March 2009 the main pandemic threat came from bird-to-human transmissions 
of H5N1 viruses. Then, a new influenza A/H1N1 virus emerged in Mexico, spread 
worldwide within two months and the WHO declared the start of a pandemic on the 
11th of June 2009.[51] Avian influenza A virus have also caused infections of humans 
include H9N2 and H7N7 and it cannot be excluded that other subtypes known to 
be able to cause a pandemic, like H2N2 viruses, will return. [42, 43, 198] Therefore, 
there is considerable interest in the development of “universal” vaccines that induce 
inter-subtypic cross-reactive immunity (or heterosubtypic immunity) and that can 
afford protection against different subtypes of influenza A virus. [74] To achieve 
this, immunity should be directed to alternative viral target proteins that are more 
conserved than HA and NA, like the nucleoprotein (NP) and the matrix proteins M1 
and M2. NP and M1 are targets for cellular immunity, in particular CTL responses, 
and it has been demonstrated that CTL specific for seasonal influenza viruses can 
cross-react with H5N1 viruses. [73, 199] Furthermore it has been shown that cross-
reactive CTL responses also afford heterosubtypic immunity (for review see Kreijtz 
et al).[67, 200] Vaccines that aim at the induction of cross-reactive CTL responses 
need to deliver the antigens in such a way that the proteins enter the endogenous 
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antigen processing and MHC class I presentation pathway, which is important for 
the efficient induction of CTL responses. Examples of such antigen delivery systems 
include the use of live attenuated viruses, viral vectors and DNA vaccination.[80, 
172, 194] 
The M2 protein, an ion channel in the virus replication cycle involved in uncoating 
of the viral genome, is relatively conserved and a target for antibodies. M2 is a 
minor antigen on virus particles but is expressed on virus infected cells. The antiviral 
effect of M2-specific antibodies is most likely based on the induction of antibody 
dependent cell-mediated cytotoxicity (ADCC) and may contribute to protective 
immunity.[201-204] Candidate vaccines based on the induction of M2-specific 
antibodies have been evaluated preclinically and with some of them promising 
results have been obtained.[201-204]
Vaccination strategies
For the prevention of seasonal influenza, vaccines are typically administered just 
before the beginning of the influenza season in the winter months. For individuals 
at high risk for complications of an influenza virus infection, including the elderly, 
vaccination is recommended. For children under six years of age, which are less 
likely to be primed for a secondary antibody response, two immunizations with 
an interval of four weeks are recommended. In the USA, it is also recommended 
to vaccinate all healthy children from the age of six months, since influenza is an 
important cause of hospitalization in this age group and children are important 
vectors for spreading the disease.[205]
For the use of pandemic influenza vaccines there are several options.[206] It has been 
demonstrated that H5N1 vaccines can be used as pre-pandemic vaccines in order to 
prime individuals for anamnestic antibody responses against an antigenically variant 
strain that would match the pandemic strain.[207] This may be an attractive strategy, 
however it cannot be predicted with certainty whether influenza viruses of the H5N1 
subtype will cause the next pandemic and if so, which variant. The H5N1 viruses 
that have been isolated so far differ considerably genetically and antigenically and 
subdivision of these viruses in clades and subclades was necessary.[75] As indicated 
above, also other subtypes of influenza viruses have pandemic potential, H2N2, 
H7N7 and H9N2. And the newly emerged influenza A/H1N1 virus caused the first 
influenza pandemic of the 21st century (Mexican flu). Therefore, preparing and using 
prepandemic vaccines is taking a risk and the resources required to produce the 
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antigen and in particular an adjuvant, which would be the most expensive component 
of the vaccine, may be used in a different way. It could be envisaged that as soon as 
the pandemic strain will be identified, the corresponding vaccine strain will become 
available quickly (through reverse genetics) and subsequent vaccine production 
can start immediately. The availability of stockpiled adjuvant would allow the rapid 
formulation of the final vaccine. The most important advantage of this strategy is 
that antibody responses of the proper specificity will be induced and that protective 
immunity is induced which would reduce shedding of virus in the population. This 
in turn may contribute to optimal control of the outbreak at the population level. 
Nevertheless, drawbacks of this strategy are the delay in vaccine availability and the 
need for more than one vaccination to achieve protective antibody levels. In case 
of the current situation with A/H5N1 viruses, the use of vaccine antigen stockpiled 
before the start of the pandemic could prime for secondary antibody responses 
even against a variant pandemic vaccine strain.[207] 
During the last decade, big strides have been made in the development of more 
efficacious and safe influenza vaccines, spurred by the pandemic threat caused by 
influenza A viruses of the H1N1 and H5N1 subtype. Undoubtedly, the advent of 
novel procedures (reverse genetics) to prepare vaccine reassortant strains, novel 
production technologies like the use of cell culture and the development of safe 
and potent adjuvants will contribute to faster availability of more doses of safe and 
effective vaccines. Although the emergence of a pandemic cannot be prevented, 
the fast availability of such vaccines most likely will contribute to a better control of 
a pandemic outbreak of influenza.
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Outline of the thesis
In this thesis, protection against influenza A(H5N1) induced by primary infection 
with influenza A(H3N2) and MVA-based vaccination was assessed. The first form of 
protection is based on heterosubtypic immunity which has been studied extensively. 
CTL are considered to be key players in this type of immune defense. In the light of 
a new pandemic, a situation in which neutralizing antibodies against the causative 
agent are virtually absent, CTL, induced by previous infection(s), might play a crucial 
role in protection against infection. 
To assess the protective role of pre-existing immunity we infected mice with influenza 
A virus X-31 (H3N2) and subsequently challenged them with influenza virus A/Puerto 
Rico/8/34 (A/PR/8/34) (H1N1). These viruses have identical internal proteins and 
priming with influenza virus X-31 induced protective immunity against the A/PR/8/34 
virus, as described in chapter 2. This proof-of-principle with mouse-adapted strains 
with fully matched internal proteins warranted a second experiment with a more 
realistic combination of viruses used for primary and challenge infection. In chapter 
3, a human influenza virus of the H3N2 subtype A/HongKong/2/68 (A/HK/2/68) was 
used for the primary infection, followed by a lethal challenge with HPAI A/H5N1 
virus A/Indonesia/5/05 (A/IND/5/05). H3N2-infected animals were protected against 
the lethal challenge and survived the H5N1 infection whereas naïve animals suffered 
from severe disease and succumbed. The observed protection correlated with the 
induction of virus-specific CTL. It was hypothesized that vaccination against the 
human influenza A/H3N2 virus would interfere with the induction of heterosubtypic 
immunity by H3N2 infection. To test this hypothesis mice were vaccinated prior 
to infection with human influenza virus A/HK/2/68, followed by a lethal challenge 
with influenza virus A/IND/5/05. Indeed, animals effectively vaccinated against the 
primary infection were not protected against the lethal challenge which correlated 
with the absence of anamnestic CTL responses after challenge infection. The results 
of this experiment are described in chapter 4. Thus, cross-reactive virus-specific CTL 
are associated with protection against H5N1 influenza virus infection. In chapter 5, 
we assessed the cross-reactivity of human CTL specific for seasonal influenza viruses 
with H5N1 influenza viruses. Cells that expressed the H5N1-derived NP and cells 
infected with H5N1 influenza virus were recognized by in vitro expanded human CTL 
and the level of recognition of H5N1 influenza virus was similar to that of human 
influenza A virus. Thus, pre-existing CTL immunity to influenza viruses in the human 
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population may provide a certain level of protection against heterosubtypic viruses. 
Subsequently, the cross-reactive T cells can be targeted by ‘universal’ vaccines that 
are based on conserved antigens in the influenza viruses and boost the strength and 
breadth of the pre-existing T cell immunity.
The role of pre-exisiting immunity to influenza A viruses of the H5N1 subtype and 
other potentially pandemic strains could be of great importance during a pandemic 
outbreak. However for the induction of optimal protective immunity against these 
viruses, there is a need for the availability of safe and effective vaccines that can 
induce antibody responses of the proper specificity. MVA is a promising candidate 
vaccine platform that also could be used for the development of pandemic 
influenza vaccines. This replication deficient poxvirus is relatively easy to produce 
at large scale, has an excellent safety profile in humans and can be used as a vector 
for foreign proteins, e.g. HA. MVA expressing the HA gene of influenza virus A/
Vietnam/1194/04 (A/VN/1194/04) was evaluated as a (pre)pandemic H5N1 vaccine 
in two preclinical models (chapter 6 and 7). In chapter 6 it is described that mice 
vaccinated twice with MVA-HA-VN/04 were protected against infection with 
the homologous strain and a antigenically distinct strain of H5N1 virus. Since the 
predictive value of results obtained in the mouse model is limited for humans, this 
promising vaccine candidate was also tested in a non-human primate model. To this 
end, cynomolgus macaques were vaccinated twice with a high dose of MVA-HA-
VN/04 and challenged with the homologous and a heterologous influenza A/H5N1 
virus strain. Vaccinated animals were protected, irrespective of the challenge virus 
that was used (chapter 7). For application in a (pre)pandemic situation it is desirable 
that a low dose can be used for the induction of protective immunity which would 
allow dose-sparing and would maximize the number of subjects that can be 
protected from infection. Preferentially a single immunization would be sufficient 
for the induction of protective immunity. In chapter 8, the minimal dose of MVA-
HA-VN/04 required for protection was determined in mice. They were vaccinated 
once or twice using five different doses of MVA-HA and it was found that the vaccine 
dose could be lowered dramatically without loss of protective efficacy against 
homologous and heterologous H5N1 viruses. In addition it appeared possible to 
protect mice with a single immunization of MVA-HA-VN/04.
The results presented in this thesis illustrate the protective efficacy of heterosubtypic 
immunity against influenza A(H5N1) virus infection and the potential of recombinant 
MVA as a (pre)pandemic influenza vaccine.

Chapter 2
Primary influenza A virus infection induces cross-protective immunity against a 
lethal infection with a heterosubtypic virus strain in mice
J.H.C.M. Kreijtz, R. Bodewes, G. van Amerongen, T. Kuiken, R.A.M. Fouchier, 
A.D.M.E. Osterhaus, G.F. Rimmelzwaan
Department of Virology, Erasmus Medical Centre, Rotterdam, the Netherlands
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Abstract
In order to assess the level of protection against a lethal influenza virus 
infection provided by a primary infection with a virus strain of another subtype, 
C57BL/6 mice were infected with the sublethal influenza virus X-31 (H3N2) 
and subsequently challenged with the lethal strain A/PR/8/34 (H1N1). The 
outcome of the challenge infection was compared with that in mice that did 
not experience an infection with influenza virus X-31 prior to the challenge 
infection. The X-31 experienced mice cleared the infection with influenza 
virus A/PR/8/34 in an accelerated fashion, displayed less clinical signs and a 
reduction of lesions in the lungs resulting in improved survival rates of these 
mice compared to the naive mice. The improved outcome of the challenge 
infection with influenza virus A/PR/8/34 in the X-31 experienced mice correlated 
with priming for anamnestic virus-specific CD8+ cytotoxic T lymphocyte (CTL) 
responses as was demonstrated by the detection of CTL specific for the H-2Db 
restricted NP
366-374
 epitope that was shared by the influenza viruses X-31 and A/
PR/8/34. Thus previous exposure to influenza A viruses affords partial protection 
against infection in the absence of virus-neutralizing antibodies specific for the 
hemagglutinin and the neuraminidase. The implications of these observations 
are discussed in the light of the current pandemic threat and development of 
vaccines that aim at the induction of virus-specific CTL. 
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Introduction
Since 1997 several examples of direct transmission of avian influenza A viruses 
from birds to humans have been reported [15, 44-46, 208, 209]. Especially infection 
of humans with the H5N1 subtype caused severe morbidity and mortality: since 
December of 2003, 218 confirmed cases were reported in Azerbaijan, Cambodia, 
China, Djibouti, Egypt, Indonesia, Iraq, Thailand, Turkey and Vietnam; 124 of these 
cases proved to be fatal [209]. These virulent H5N1 viruses are considered to have 
the potential to cause a new pandemic and the further global spread of these viruses 
is feared [210, 211]. If these viruses acquire the capacity to be transmitted from 
human to human efficiently, then antibodies raised to human influenza A viruses 
of the H3N2, H1N1, or H2N2 subtypes will provide little or no protection against 
infection. However, other viral proteins like the nucleoprotein (NP) and the matrix 
protein are more conserved than the hemagglutinin and the neuraminidase and are 
major targets for virus specific CD8+ cytotoxic T lymphocytes (CTL) [67, 212, 213]. 
Therefore, it could be anticipated that T cell immunity induced after infection with 
human influenza A viruses is cross-reactive with avian influenza viruses and could 
provide some degree of protection against infection with these highly pathogenic 
viruses.
Indeed CTL cross-reactive with avian influenza viruses were demonstrated in 
humans [70, 73]. Furthermore, it was demonstrated in experimentally infected 
individuals that the extent of viral excretion inversely correlated with CTL activity in 
the absence of antibodies specific for the virus that was used for infection [67].  Also 
in various animal models a protective role for CTL against heterotypic viruses was 
confirmed [174, 214-218]. Since it is not clear which variant of H5N1 virus, or even 
which influenza virus subtype ultimately will cause the next pandemic, the selection 
of a vaccine strain that should induce an adequate HA-specific antibody response 
is still not possible. Therefore there is considerable interest for the development 
of a universal vaccine that could induce cross-reactive and long-lasting protective 
immunity against a variety of viruses with a different subtype [219, 220].
In the present study we assessed the extent of protection afforded by exposure to 
influenza viruses against a secondary infection with a heterosubtypic influenza virus. 
To this end we took advantage of a mouse model that has been used previously 
for the detection of heterosubtypic immunity. In contrast to these previous studies, 
we integrated clinical, virological, immunological and pathological parameters to 
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evaluate the extent of protection provided by a primary infection. C57BL/6 mice were 
infected sublethally with influenza virus X-31 (H3N2) and subsequently infected with 
a lethal dose of influenza virus A/Puerto Rico/8/34 (A/PR/8/34) (H1N1) [213, 221-223]. 
Influenza virus X-31 is a reassortant virus containing the internal proteins of influenza 
virus A/PR/8/34 and the haemagglutinin and neuraminidase glycoproteins of A/
Aichi/2/68 (H3N2). A/PR/8/34 is a human H1N1 influenza virus adapted and lethal to 
mice [217, 218, 224, 225]. 
Protective immunity following challenge infection was assessed by measuring survival 
rates and lung virus titers, and using histopathology and immunohistochemistry. 
These results were correlated with the detection of virus specific CTL responses 
before and after challenge infection by tetramerstaining [223, 226, 227]. The 
integrated approach provided evidence for the induction of cross-protective 
immunity by primary infection to heterosubtypic influenza A strains. The findings 
are discussed in the light of the current pandemic threat and the design of candidate 
vaccines, which aim at the induction of cross-protective CTL responses.
Material and Methods
Mice
Female specified pathogen free 6-8 weeks old C57BL/6J mice were purchased from 
Charles River  (Sulzfeld, Germany).  Mice (n=14) were infected with 2*104 TCID50 of 
influenza virus X-31 (in 50ml PBS) by the intranasal route (Group I) and five of these 
animals were sacrificed on day 4, five on day 7 and four on day 28 post infection 
(p.i.). Group II mice (n=16) were first infected with influenza virus X-31 as described 
above and were subsequently infected with 5*104 TCID50 of influenza virus A/
PR/8/34 on day 28 p.i.. Six of these animals were sacrificed on day 4 post challenge 
infection, six on day 7 and four on day 28. A third group of twelve naive mice (Group 
III) was infected with influenza virus A/PR/8/34 only as described above, and were 
sacrificed on day 4 (n=9) and day 7 (n=3). Mice in Group IV were inoculated with PBS 
and were included as negative controls and at day 4, 7 and 28 after inoculation two 
of these mice were sacrificed. According to protocol mice were euthanized when 
they showed a weightloss of >20% after infection. Mice in all four groups were age-
matched at the time point of challenge infection with influenza virus A/PR/8/34.
The experimental protocol was approved by an independent animal ethics 
committee prior to the start of the experiment. On all timepoints (day 4, day 7 and 
day 28 p.i.), spleen and lungs were resected from the sacrificed mice. Blood was 
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drawn by orbita puncture (exsanguination) from mice that were sacrificed on day 
28 after infection with influenza virus X-31 and 4, 7 and 28 days after infection with 
influenza virus A/PR/8/34. Intranasal infections, orbita punctures (and euthanasia) 
were carried out under anaesthesia with inhalative isoflurane. The animals were 
housed in filter-top cages and had access to food and water ad libitum. 
Influenza viruses
Influenza viruses A/PR/8/34 and X-31 (MRC, Cambridge, England) [224] were 
inoculated in the allantoic cavity of 11-day-old embryonated chicken eggs. The 
allantoic fluid was harvested after 2 days. Infectious virus titers were determined 
in Madin-Darby Canine Kideny (MDCK) cells (ATCC: Product CCL-34 (NBL-2)) as 
described previously [228].
Lung virus titers
Lungs were snap frozen on dry ice with ethanol and stored at -70°C. Lungs were 
homogenized with a Polytron homogenizer (Kinematica AG, Littau-Lucerne, 
Switzerland) in infection medium (Eagles Minimal Essential Medium (EMEM), Bovine 
serum albumin (fraction V 7,5%, 1:25), 4mg/ml trypsin, 2mM L-glutamin, 100U/
ml penicillin, 100mg/ml streptomycin, 7,5% NaHCO3, 1M Hepes). Quadruplicate 
ten fold serial dilutions of these samples were used to determine the virus titers in 
MDCK cells as described previously.[228]
Serology
Sera were obtained on day 28 after infection with influenza virus X-31 and on day 4, 
7 and 28 after infection with influenza virus A/PR/8/34 and stored at -20°C until use. 
After treatment with cholera filtrate and heat-inactivation at 56°C, the sera were 
tested for the presence of anti-HA antibodies. For this purpose a hemagglutination 
inhibition assay (HI) was used following a standard protocol using 1% turkey 
erythrocytes and four HA-units of either influenza virus X-31 or A/PR/8/34 [229]. 
Rabbit sera, raised against influenza viruses A/Hongkong/2/68 and A/PR/8/34 were 
used as positive controls. Sera were also tested for the presence of virus-neutralising 
antibodies specific for both influenza viruses X-31 and A/PR/8/34 using a micro virus-
neutralisation (VN) assay with 100 TCID50 of the respective viruses [230]. The same 
rabbit sera were used as positive controls. 
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Detection of virus-specific CTL by tetramer-staining
Single cell splenocyte suspensions were obtained and red blood cells were removed 
using erythrocyte lysis buffer (Roche, Almere, the Netherlands). The cells were 
washed with 0,5% BSA in PBS and stained for flow cytometry with antibodies: 
CD3e-PerCP, CD8b.2-FITC (PharMingen, San Diego, United States), ToPro 3-APC 
(Molecular Probes, Eugene, United States) and PE labeled H-2Db-PE tetramer with 
the NP
366-374
 epitope ASNENMETM (Sanquin Research, Amsterdam, Netherlands). 
Cells were analysed on FACSCalibur  in combination with Cellquest Pro software 
(Becton Dickinson, Alphen a/d Rijn, Netherlands).
 
Histopathology
After sacrificing the mice lungs were resected and inflated with formalin. After 
fixation in 10% neutral buffered formalin and embedding in paraffin, the lungs 
were sectioned at 4mm and stained with hematoxylin and eosin for histological 
evaluation. Furthermore, slides were stained using an immunoperoxidase method 
with a monoclonal antibody (Clone HB65 IgG2a (American Type Culture Collection)) 
directed against the nucleoprotein of influenza A virus. A Goat-anti-mouse IgG2a 
HRP (Southern Biotech, Birmingham, Alabama, USA) was used as the secondary 
antibody. The peroxidase was revealed using diamino-benzidine as a substrate, 
resulting in a deep red precipitate in the nuclei of influenza A infected cells and a 
less intense red staining of the cytoplasm. The sections were counterstained with 
hematoxylin. 
Statistical analysis
Data for weight and tetramerstaining were analysed using the two-sided Student’s 
t test and differences were considered significant at P < 0.05. Survival rate was 
analysed using a logrank test.
Results
Clinical signs
Weight loss and survival rate were used as clinical parameters to evaluate protective 
immunity. Four days p.i. with influenza virus A/PR/8/34 the naive mice (Group III) 
had lost 17.6% (SD=9.2) of their body weight. The loss of body weight in the X-31 
experienced mice (Group II) was 12.3% (SD=6.9), which was a statistically significant 
difference (p=0.013) (Figure 1A). This difference was greater seven days p.i.: the 
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unprimed animals (Group III) that were still alive on day seven continued to lose 
body weight. 
The average loss of body weight in this group was 15.7% (SD=3.7) whereas the X-31 
experienced mice (Group II) gained weight from day 4 p.i. onwards (data not shown). 
The mean weight loss in this group seven days p.i. was 1.1% (SD=4.3) which was 
significantly lower than in the naive mice (Group III). Since a loss of >20% of body 
weight was used as a criterium for euthanizing the animals, we used this criterium as 
correlate for infection-induced mortality. Indeed mice that lost >20% of their body 
weight were severely ill, were lethargic, had ruffled fur and were moribund. Seven 
days p.i. only 33% of the naive mice (Group III) survived infection with influenza 
virus A/PR/8/34 (Figure 1B). In the group of X-31 experienced mice (Group II) 87.5% 
survived the challenge infection. This difference in survival rate was statistically 
significant (p=0.02).
Lung virus titers
The virus titers in the lung at day 4 and day 7 p.i. were compared between the 
groups of mice infected with influenza virus A/PR/8/34 with or without a history 
Figure 1 (A) Mean loss in body weight of mice after infection with influenza virus A/PR/8/34 in the X-31 
experienced mice (Group II) (   ) and the naive mice (Group III) ( ). (*) indicates that the difference 
between the two groups on day 4 is statistically significant (p=0.013). (B) Survival rate of mice after 
infection with influenza virus A/PR/8/34 in the X-31 experienced mice (Group II) (
 
) and the naive 
mice (Group III) (
 
). The proportion of survival was determined based on euthanasia-criteria. Animals 
that lost >20% of their bodyweight were considered moribund. At day 3 one naive animal had to be 
euthanized. At day 4 eight naïve animals were euthanized based a weightloss of more than 20% and 
six X-31 experienced animals with less than 20% weightloss were sacrificed according to the study-
protocol   At day 7 three naive animals and ten X-31  experienced mice were alive.  (*) Indicates that the 
difference in survival rate is statistically significant (p=0.02).
46
heterosubtypic immunity to influenza i
CH
AP
TE
R 
2
of infection with influenza virus X-31. The influenza virus A/PR/8/34 titers (Figure 
2) in X-31 experienced mice and naive mice (Groups II and III respectively) at day 4 
after challenge infection did not differ significantly (Figure 3). However, seven days 
p.i. the average virus titers in the lungs of naive mice (Group III) was still 1.9*106 
(SD=2.9*103) TCID
50  
where as in none of the X-31 experienced mice (Group II) virus 
was detected. This indicated that a prior infection with a heterosubtypic virus 
resulted in the induction of immunity that was responsible for accelerated clearance 
of the infection with influenza virus A/PR/8/34 by day 7 p.i..
Serology
After infection with influenza virus X-31, mice developed virus-specific antibodies 
that were detected by HI- and VN assay that did not crossreact with influenza virus 
A/PR/8/34. Twenty-eight days after infection with influenza virus X-31 the HI- and 
VN GMT were 1076 and 67 respectively. X-31 experienced mice (Group II) that were 
infected with influenza virus A/PR/8/34 developed antibodies against this virus. The 
mean titer was 190 in the HI assay and 20 in the VN-assay as soon as seven days 
p.i.. In the X-31 experienced mice (Group II), infection with influenza virus A/PR/8/34 
induced similar titers as those observed in the naive animals (Group III). In the 
X-31 experienced mice (Group II) 28 days after challenge infection these influenza 
virus A/PR/8/34 titers had increased up to 640 in the HI- and 67 in the VN-assay. 
Antibodies induced after infection with influenza virus A/PR/8/34 did not crossreact 
with influenza virus X-31 and vice versa.
Figure 2 Virus titers in the lungs of mice after infection with influenza virus A/PR/8/34 at day 4 and day 
7 post infection. The results are shown for the naive group (Group III) (     ) the X-31 experienced group (Group II) (     ) and the PBS-inoculated group (     ). (<3= cut-off value)
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Detection of virus-specific CTL by H-2Db-NP366-374 tetramerstaining
Seven days post infection with influenza virus X-31 NP
366-374 
specific T cells (Tm+ cells) 
were readily detectable and constituted 5.4% (SD=2.3) of the CD8+ T lymphocyte 
population in the spleen of X-31 experienced mice (Group II). In PBS-inoculated 
mice (Group IV) these cells were virtually absent (Figure 3A). On day 28 p.i. the 
percentage of Tm+ cells in X-31 experienced mice (Group II) had declined to 1.9% 
(SD=0.5). Subsequently mice were challenged with influenza virus A/PR/8/34, which 
shares the NP
366-374 
epitope with influenza virus X-31. 
The percentage of NP
366-374 
specific CD8+ lymphocytes in the spleen increased to 
2.7% (SD=1.3) on day 4 post challenge infection, 10.3% (SD=4.9) on day 7 and 18.1% 
(SD=8.7) on day 28 (Figure 4). Comparison of the frequencies of NP
366-374 
specific 
CD8+ T cells after infection with influenza virus A/PR/8/34 in X-31 experienced (Group 
II) and naive mice (Group III) showed that heterosubtypic priming predisposed for 
stronger virus specific CTL responses. On day 7 post challenge infection, the NP
366-374 
specific CTL response was significantly stronger (P=0.046) in X-31 experienced mice 
(Group II) (Figure 4).
Figure 3 Detection of virus specific CD8+ T lymphocytes in mouse spleen by H-2Db NP
366-374
 tetramer 
staining. The proportion of TM+ cells in the CD3+ CD8+ population was determined in a PBS-inoculated 
mouse (A) and a X-31 experienced mouse 28 days after challenge with influenza virus A/PR/8/34 (B). For 
the calculation of the percentage of TM+ cells the mean percentage in PBS-inoculated mice was used 
as background and was subtracted from the percentage measured in other groups. 
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Histopathology 
Lungs of mice were examined histologically four or seven days after infection 
with influenza virus A/PR/8/34. At four days after infection, naive mice (Group III) 
had severe multifocal broncho-interstitial pneumonia, centred on the bronchioles 
and characterized by loss of alveolar epithelium and flooding of the alveolar 
lumina predominantly with cell debris, neutrophils, and oedema fluid. There was 
a mild infiltration of lymphocytes around pulmonary blood vessels, bronchi, 
and bronchioles (Fig 5A+B). A small number of type II pneumocytes was present 
in the alveoli. In contrast, the lungs of X-31 experienced mice (Group II) at 4 days 
after infection with influenza virus A/PR/8/34 had only mild broncho-interstitial 
pneumonia, whereas the lymphoid infiltration around blood vessels and airways 
was more extensive (Fig 5C+D). The lungs of the naive animals (Group III) at seven 
days after infection with influenza virus A/PR/8/34 differed from those at four days 
by a more extensive peribroncheal and –vascular lymphoid infiltrate and prominent 
type II pneumocyte hyperplasia. (Fig 5E+F). At seven days after infection with 
influenza virus A/PR/8/34, the animals in the X-31 experienced group (Group II) had 
less evidence of pneumonia, whereas marked lymphoid infiltrates around blood 
Figure 4 Detection of virus specific CD8+ cells in mouse spleens by H-2Db NP
366-374
 tetramerstaining. (A) 
The population of CD8+ Tm+ cells in the X-31 experienced mice (Group II) (   ) after influenza virus X-31 and influenza virus A/PR/8/34 infection. (B) The populations of CD8+ Tm+ cells in the naive mice (Group 
III) (   ) and the X-31 experienced group (Group II) (   ).
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Figure 5 Histology of the lungs of mice infected with either influenza virus X-31, influenza virus A/
PR/8/34 or both sequentially. A+B: lung of a naive mouse 4 days after PR/8 infection with flooding 
of the alveoli (A) and peri-broncheolar and –vascular lymphoid infiltrate (B). (C+D) lung of an X-31 
experienced mouse 4 days after PR/8 challenge lacking flooding of the alveoli (C) and stronger 
peri-brocheolar and –vascular lymphoid infiltrate (D). (E+F) lung of a naive mouse 7 days after PR/8 
infection, The alveoli are filled with cell debri and fluid, and type II pneumocyte hyperplasia is seen 
in the alveolar walls (E) combined with strong peri-brocheolar and –vascular lymphoid infiltrate (F). 
(G+H) lung of an X-31 experienced mouse 7 days after PR/8 challenge, with mild type II pneumocyte 
hyperplasia (G) and marked peri-brocheolar and –vascular lymphoid infiltrate (H).  (I+J) lung of an X-31 
experienced mouse on day 28 after PR/8 challenge with normal looking alveoli (I) and a peri-brocheolar 
and –vascular lymphoid cuff (J). (full colour figure: APPENDIX I)
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vessels and airways were still present (Fig 5G+H). 28 days after infection with 
influenza virus A/PR/8/34 lungs of mice in the X-31 experienced group (Group II) had 
minimal evidence of pneumonia. The lymphoid infiltrate remained present, but was 
less prominent (Fig 5I+J).
Immunohistochemistry
Mouse lung sections were stained for influenza virus A NP. The cytoplasms of 
influenza A virus infected cells stained red, the nuclei stain deep red (Figure 
6). Virus antigen was detected in naive mice (Group III) on day 4 and day 7 after 
infection with influenza virus A/PR/8/34 (Figure 6A+B). Infected cells were located 
at the bronchioles (epithelial cells) and in the alveolar walls (type I pneumocytes) at 
multiple sites in the lung. On day 7 the number of virus infected cells was lower. Four 
days p.i. with influenza virus A/PR/8/34 the X-31 experienced mice (Group II) had 
influenza A virus positive cells predominantly around the bronchioles (Figure 6C). 
On day 7 no virus-infected cells were detectable in lungs of these mice (Figure 6D).
Figure 6 Mouse lung sections stained for influenza virus A NP. Cytoplasm of influenza A virus infected 
cells stains red, the nuclei stain deep red (A) naive mouse on day 4 after infection with influenza A virus 
A/PR/8/34 with virus antigen positive epithelial cells alining the bronchiole, and positive cells in the 
alveoli (B) naïve mouse on day 7 p.i.. with virus antigen positive cells in the alveoli (C) X-31 experienced 
mouse on day 4 after infection with Influenza virus A/PR/8/34 with virus antigen positive cells around 
the bronchioles (D) X-31 experienced mouse on day 7 p.i. lacking virus antigen positive cells. (full colour 
figure: APPENDIX II)
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Discussion
In the present study the extent of protective immunity against a lethal influenza A 
virus infection induced by a primary infection with an influenza A virus of another 
subtype was examined. To this end, C57BL/6J mice were infected with influenza 
A virus X-31and subsequently with influenza virus A/PR/8/34 which is lethal to 
mice. These viruses share the NP-gene, containing the immunodominant CTL 
epitope NP
366-374
 that is restricted by H2-Db. CTL responses against this epitope 
were monitored using H2-Db/NP
366-374
 tetramerstaining and it was found that the 
CTL responses correlated with protection in the absence of virus neutralising 
antibodies. Protective immunity was assessed by scoring clinical outcome of 
disease measured by loss of body weight and mortality, measuring virus titers in 
the lungs and evaluating the histopathological changes in the lungs. The outcome 
of this integrated approach supported the notion that virus specific CTL contributed 
to protective immunity. Upon infection with influenza virus A/PR/8/34 both naive 
and X-31 experienced mice (Group II) lost weight. Whereas the naive mice became 
moribund and kept losing weight up until day 7, the X-31 experienced mice (Group 
II) regained weight from day 4 onwards.
The development of clinical signs in these animals correlated with virus replication 
in the lungs. In both groups of mice high lung-virus titers were observed on day 4 
p.i. with influenza virus A/PR/8/34. In the naive mice that survived the challenge 
infection more than four days high virus titers were still observed in the lungs on 
day 7 p.i.. Of course there is a bias in the observations: only mice that were relatively 
resistant to the infection could be followed up post day 4 after infection. Despite 
this bias a striking difference was observed with mice from group II that experienced 
an infection with influenza virus X-31. In none of these mice, virus was detectable 
in the lungs indicating that the resolvement of clinical disease correlated with an 
accelerated clearance of virus from the lungs.
To correlate the protective effect of a priming infection with influenza virus X-31 
with immunity to these viruses, humoral and cell-mediated immunity was assessed 
by serology and the detection of virus specific CD8+ T lymphocytes by H2-Db/ 
NP
366-374
 tetramerstaining. Antibodies induced by infection with influenza virus X-31 
failed to neutralize influenza virus A/PR/8/34 and vice versa. The reduced clinical 
manifestations of influenza virus A/PR/8/34-induced disease and the accelerated 
clearance of virus from the lungs did correlate with the anamnestic CTL responses 
in X-31 experienced mice (Group II). 
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The CTL response to the NP
366-374 
epitope is immunodominant, especially during 
secondary infections, which explains the magnitude of this response; ~20% of all 
CD8+ T lymphocytes in the spleen were specific for this epitope [223, 231]. Recently 
it has been demonstrated that memory CTL can also reside in the lungs [232-234]. 
This would allow an immediate recall response upon a secondary infection. This 
also could have contributed to the protective effect induced by a primary infection 
with influenza virus X-31 [67, 213]. It could be argued that antibodies directed to 
the M2 protein contributed to the heterosubtypic protection that was observed. 
This protein is relatively conserved and shared between influenza viruses X-31 and 
A/PR/8/34. However, M2 is known as a minor antigen, and antibody responses 
induced after infection are very low [235] and cannot be detected in HI or VN 
assays.  A protective effect of M2-specific antibodies only has been demonstrated 
after hyperimmunization with this antigen or the use of monoclonal antibodies. Its 
neutralizing effect is dependent on antibody dependent cell mediated cytotoxicity 
[201, 202, 236, 237]. In addition to reducing disease severity and reducing virus 
replication in the lungs, the cross-reactive CTL responses also correlated with the 
prevention of severe alveolar damage. Seven days post infection with influenza virus 
A/PR/8/34, naive mice developed a severe interstitial pneumonia which correlated 
with the moribund state of these mice. Primary infection with influenza virus X-31 
prevented these severe pathological changes and in these mice the presence of type 
II pneumocyte hyperplasia was indicative for recovery from disease. The presence 
of virus infected cells in the lungs by immunohistochemistry on day 4 and day 7 after 
infection with influenza virus A/PR/8/34 correlated with the virus titers in the lungs 
and the degree of alveolar damage. These observations may have some important 
implicationsFirst, most patients infected with highly pathogenic avian influenza 
viruses (HPAI) of the H5N1 subtype developed severe interstitial pneumonia. Post 
mortem necropsies confirmed this [208, 238, 239].
In addition most of the human H5N1 cases that were recorded involved children and 
young adults. We speculate that these individuals might not have been exposed to 
human influenza A viruses and were unable to mount a secondary cross-reactive 
and cross-protective CTL response. Indeed CTL cross-reactive with avian influenza 
viruses have been demonstrated in subjects immune to human influenza viruses 
[70, 73]. As a consequence of the widespread presence of human influenza A viruses 
and the high attack rate with these viruses it is likely that a majority of the human 
population has developed cross-reactive CTL responses and may be protected 
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against severe morbidity and mortality caused by infection with HPAI H5N1 viruses. 
The second implication is, that it may be worthwhile to investigate possibilities of 
the development of universal vaccines which aim at the induction of cross-reactive 
CTL responses. In the light of the pandemic threat and the long production time of 
conventional HA based vaccines that might be a favourable strategy [219, 220].
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Abstract
The transmission of highly pathogenic avian influenza (HPAI) A viruses of the 
H5N1 subtype from poultry to man and the high case fatality rate fuels the fear 
for a pandemic outbreak caused by these viruses. However, prior infections with 
seasonal influenza A/H1N1 and A/H3N2 viruses induce heterosubtypic immunity 
that could afford a certain degree of protection against infection with the HPAI 
A/H5N1 viruses, which are distantly related to the human influenza A viruses. 
To assess the protective efficacy of such heterosubtypic immunity mice were 
infected with human influenza virus A/Hong Kong/2/68 (H3N2) four weeks prior 
to a lethal infection with HPAI virus A/Indonesia/5/05 (H5N1).
Prior infection with influenza virus A/Hong Kong/2/68 reduced clinical signs, 
body weight loss, mortality and virus replication in the lungs as compared to 
naïve mice infected with HPAI virus A/Indonesia/5/05. Priming by infection with 
respiratory syncytial virus, a non-related virus did not have a beneficial effect on 
the outcome of A/H5N1 infections, indicating that adaptive immune responses 
were responsible for the protective effect. In mice primed by infection with 
influenza A/H3N2 virus cytotoxic T lymphocytes (CTL) specific for NP366-374 epitope 
ASNENMDAM and PA
224-232
 SCLENFRAYV were observed. A small proportion of 
these CTL was cross-reactive with the peptide variant derived from the influenza 
A/H5N1 virus (ASNENMEVM and SSLENFRAYV respectively) and upon challenge 
infection with the influenza A/H5N1 virus cross-reactive CTL were selectively 
expanded. These CTL, in addition to those directed to conserved epitopes, 
shared by the influenza A/H3N2 and A/H5N1 viruses, most likely contributed 
to accelerated clearance of the influenza A/H5N1 virus infection. Although also 
other arms of the adaptive immune response may contribute to heterosubtypic 
immunity, the induction of virus-specific CTL may be an attractive target for 
development of broad protective vaccines. Furthermore the existence of pre-
existing heterosubtypic immunity may dampen the impact a future influenza 
pandemic may have.
57
CHAPTER 3
heterosubtypic immunity to influenza ii
Introduction
Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to cause 
outbreaks in domestic birds and are transmitted regularly from infected poultry to 
humans. Since 2003, 409 human cases have been reported of which >60% had a fatal 
outcome [47]. It is feared that these viruses adapt to their new host and become 
transmissible from human to human. Since neutralizing antibodies against these 
viruses are absent in the human population at large, this may spark a pandemic 
outbreak. However, previous infections with influenza A virus of the H1N1 and H3N2 
subtypes responsible for seasonal influenza activity, can induce heterosubtypic 
immunity, which may afford a certain degree of protection against viruses of a novel 
subtype e.g. H5N1. The induction of heterosubtypic immunity by primary influenza 
virus infection was already recognized more than four decades ago [240] and has 
been demonstrated in various animal models including mice [200, 216], pigs [241, 
242], ferrets [243], chickens [244] and cotton rats [245], using various combinations 
of influenza A virus subtypes for priming and challenge infection. There is also direct 
and indirect evidence for the existence of heterosubtypic immunity in humans. It 
was demonstrated that individuals that experienced an infection with influenza 
A(H1N1) virus in preceding years were partially protected from infection with the 
pandemic H2N2 virus in 1957 [71].
Several lines of evidence indicate that cell-mediated immunity and in particular CD8+ 
cytotoxic T lymphocytes (CTL) contribute to heterosubtypic immunity [246, 247]. 
The majority of CTL is directed to conserved epitopes located within the relatively 
conserved proteins of the virus [214] like the nucleoprotein (NP) and the matrix (M1) 
protein, which implies a role for CTL in heterosubtypic immunity. The cross-reactive 
nature of CTL not only has been demonstrated in various animal models but also in 
man. Human CTL directed to human influenza A virus of the H1N1 or H3N2 subtype 
can recognize and eliminate cells infected with highly pathogenic avian influenza 
viruses of the H5N1 subtype [72, 73, 199]. A protective effect of virus-specific CTL 
was demonstrated after adoptive transfer of these cells to naive mice or in mice 
from which CTL were depleted (for review see Rimmelzwaan 2007)[243, 247, 248]. 
Also the use of vaccine preparations that induce (cross-reactive) CTL responses 
supported a protective role of virus specific CTL in heterosubtypic immunity. In 
humans evidence is sparse, but it was demonstrated that in the absence of virus-
specific antibodies, the presence of cross-reactive CTL correlated with reduced viral 
shedding after experimental infection [67].
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Recently we confirmed in a mouse model that a prior infection with influenza A 
virus X-31 (H3N2) protected against a lethal challenge infection with influenza 
virus A/Puerto Rico/8/34 (A/PR/8/34) (H1N1), which correlated with anamnestic 
CTL responses [200]. However, influenza virus X-31 and A/PR/8/34 share the gene 
segments that encode the internal viral proteins which, of course, favors the 
induction of cross-reactive CTL responses. Therefore, we wished to investigate the 
protective efficacy of heterosubtypic immunity, induced by infection with a human 
influenza A virus, against infection with a highly pathogenic avian influenza virus 
of the H5N1 subtype to mimic the natural situation and the order of infections 
more closely. For this purpose, influenza viruses A/Hong Kong/2/68 (H3N2) and A/
Indonesia/5/05 (H5N1) were used. 
Again, prior infection with a heterosubtypic strain (H3N2) had a beneficial effect on 
the clinical outcome of the H5N1 challenge infection and control of virus replication. 
The CTL response against the H-2Db restricted CTL epitopes NP
366-374
 and PA
224-232
 
primed for an anamnestic CTL response to the H5N1-derived peptide variants that 
correlated with the observed protection.
Material & Methods
Influenza viruses
Influenza viruses A/Hong Kong/2/68 (A/HK/2/68) (H3N2) and A/Indonesia/5/05 (A/
IND/5/05) (H5N1) were propagated in Madin-Darby Canine Kidney (MDCK) cells. 
Infectious titers of the virus stocks were determined in MDCK cells as described 
previously [228].
Mice
Female specified pathogen free 6-8 weeks old C57BL/6J mice were purchased from 
Charles River (Sulzfeld, Germany) and age-matched at the time point of challenge 
infection. Mice (n=34) were infected intranasally with 5x102 TCID
50 
of influenza virus 
A/HK/2/68 in a volume of 50μl PBS. This virus was chosen since it replicates well in 
mice without the need for adaptation.
Control mice were mock-infected with PBS (n=16) or were infected with 5x106 TCID
50 
of respiratory syncytial virus (RSV) (n=28) in a volume of 50ml. Productive infection 
with influenza virus A/HK/2/68 and RSV was confirmed by virus isolation from the 
lungs of infected animals on day 4 post infection (p.i.). Four, seven and twenty-eight 
days after infection, mice were euthanized by exsanguination and their lungs and 
59
CHAPTER 3
heterosubtypic immunity to influenza ii
spleen were resected. After twenty-eight days, remaining mice were subsequently 
challenged with 2x102 TCID
50
 of influenza virus A/IND/5/05. This is the minimal dose 
that resulted in a lethal infection in >90% mice reproducibly. Mice were monitored 
daily for weight loss and morbidity after infection. Four, seven and fourteen days 
after challenge infection mice were euthanized and their lungs and spleen were 
resected. Intranasal infections, blood sampling and euthanasia were carried out 
under anesthesia with isoflurane (3%/O
2
). The animals were housed in filter-top 
cages and had access to food and water ad libitum. During the infection with the 
influenza A/H5N1 virus, animals were housed in bio-safety level 3 containment 
facilities. The experimental protocol was approved by an independent animal ethics 
committee. 
Serology
Serum samples were obtained before primary infection, four weeks later and four, 
seven and fourteen days after challenge infection. After treatment with cholera 
filtrate and heat-inactivation at 56°C, the sera were tested for the presence of anti-
HA antibodies. For this purpose a hemagglutination inhibition assay (HI) was used, 
following a standard protocol using 1% turkey erythrocytes and four HA-units of 
either influenza virus A/HK/2/68 or A/IND/5/05 [229]. For this purpose a reverse 
genetics influenza A/IND/5/05 virus was produced from which the basic cleavage site 
in the HA molecule was deleted. The antibody titers obtained with this virus were 
comparable with those obtained with the wild type strain (data not shown). Sera 
were also tested for the presence of virus-neutralizing antibodies specific for the 
two influenza viruses using a micro virus neutralization (VN) assay with 100 TCID
50
 of 
the respective viruses [230]. Influenza virus A/HK/2/68 specific serum was obtained 
by injecting a rabbit with sucrose gradient purified virus [249]. Hyper-immune serum 
obtained from a swan immunized twice with inactivated influenza H5N2 virus A/
Duck/Potsdam/1402/86 (Intervet, Boxmeer, The Netherlands) was used as a positive 
control against the influenza A/H5N1 virus [250].
Lung virus titers
Lungs (from 6 animals of each group) were snap frozen on dry ice with ethanol and 
stored at -70°C. Subsequently they were homogenized with a FastPrep-24® (MP 
Biomedicals, Eindhoven, The Netherlands) in transport medium (Hanks medium 
(MEM) containing: 10% Glycerol, 100U/ml penicillin, 100mg/ml streptomycin, 
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polymyxin B, Nystatin, Gentamicin, 7,5% NaHCO3, 1M Hepes) and centrifuged 
briefly. Quintuplicate ten-fold serial dilution of these samples were used to 
determine the virus titers on confluent layers of MDCK cells as described previously 
[228].
Virus-specific T cells
Tetramer staining
Single-cell splenocyte suspensions were obtained using 100μm cell strainers (BD, 
Alphen a/d Rijn, The Netherlands) (from 6 animals of each group). Red blood cells 
were removed using erythrocyte lysis buffer (Roche, Almere, The Netherlands). The 
cells were washed with 2% FCS in PBS and stained for flow cytometry with antibodies: 
CD3e-PerCP, CD8b.2-FITC (BD Pharmingen, Alphen a/d Rijn, The Netherlands) 
and APC labeled H-2Db tetramer with the NP
366-374
 epitope ASNENMEVM or an PE 
labelled H-2Db tetramer with the NP
366-374
 epitope ASNENMDAM (Sanquin Research, 
Amsterdam, The Netherlands). Cells were analysed using a FACSCalibur with a high 
throughput sampler in combination with Platemanager and Cellquest Pro software 
(BD Pharmingen).
Intracellular cytokine staining of splenocytes after peptide stimulation
Single-cell splenocyte suspensions were obtained as described above. CTL 
epitopes NP
366-374
 (ASNENMDAM and ASNENMEVM derived from influenza virus A/
HK/2/68 and A/IND/5/05 respectively) and PA
224-232
 (SSLENFRAYV) were purchased 
as synthetic peptides (immunograde, >70% purity) (from Sanquin Research, 
Amsterdam, The Netherlands and Eurogentec, Seraing, Belgium, respectively) 
[213, 223]. Four hundred thousand splenocytes were cultured for 6 h at 37°C in the 
presence of 5μM of peptide in IMDM (Lonza, Breda, The Netherlands) with 5% FCS 
and Golgistop (BD Pharmingen). The cells were then incubated overnight at 4°C 
and subsequently intracellular IFN-γ staining was performed. In brief, cells were 
washed with PBS containing 2% FCS and Golgistop, stained for flow cytometry 
with monoclonal antibodies: CD3e-PerCP or CD8b.2-FITC (BD Pharmingen), fixed 
and permeabilized with cytofix and cytoperm (BD Pharmingen) and stained with a 
monoclonal antibody specific for IFN-γ (BD Pharmingen). Cells were analysed on a 
FACSCalibur with HTS module in combination with Platemanager and Cellquest Pro 
software (BD Pharmingen).
After euthanasia, the lungs of the mice were inflated with 10% neutral buffered 
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formalin. After fixation the lungs were embedded in paraffin, sectioned at 4mm and 
stained with hematoxylin and eosin for histological evaluation. Sequential slides were 
stained using an immunoperoxidase method with a monoclonal antibody (Clone 
HB65 IgG2a (American Type Culture Collection)) directed against the nucleoprotein 
of influenza A virus. a Goat-anti-mouse IgG2a HRP (Southern Biotech, Birmingham, 
Alabama, USA) was used as secondary antibody. The peroxidase was revealed using 
diamino-benzidine as a substrate, resulting in a deep red precipitate in the nucleus 
of influenza A virus infected cells and a less intense red staining in the cytoplasm. 
The sections were counterstained with hematoxylin.
Statistical analysis
Data for weight loss, viral titers, antibody titers and virus-specific T cell populations 
were analyzed using the two-sided Student’s t test and differences were considered 
significant at P<0.05. Cumulative survival was calculated with the Kaplan Meyer log 
rank test.
Results
Clinical outcome of influenza virus A/IND/5/05 infection
To determine whether primary infection with a human influenza A virus can protect 
against a subsequent infection with a highly pathogenic avian influenza virus two 
experiments were performed. In the first experiment the mice were primed with 
5x102 TCID50 of influenza H3N2 virus A/HK/2/68 or mock-infected with PBS, and 
four weeks later they were challenged with 2x102 TCID
50
 of influenza H5N1 virus A/
IND/5/05. After challenge infection all animals lost weight until day 6. Subsequently, 
all but one H3N2-primed animals gained weight and these animals had only mild 
symptoms compared to immunologically naïve control mice (Figure 1A). The 
proportion survival in the H3N2-primed group was significantly higher than that in 
the mock-infected group (p<0.05)(Figure 1B). 
The experiment was repeated with larger groups and an extra control group, 
primed by infection with respiratory syncytial virus (RSV) to exclude non-specific 
innate immune responses as basis for the observed protection. The first two days 
post challenge infection (p.i.) all groups of mice displayed similar weight loss. From 
day 3 p.i. onwards, the mean body weights between the three groups differed. Four 
days p.i. H3N2-primed mice had lost 12.6% (SD=3.7) of their body weight, whereas 
PBS and RSV inoculated mice lost 16.8% (SD=3.1) and 18.1% (SD=3.2) of their 
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bodyweight, respectively (Fig 1C). The weight loss in the H3N2-primed group was 
significantly lower than in the two other groups (p<0.05). On day 6 the mean loss of 
body weight was 26.5% (SD=1.6) and 27% (SD=0.9) for the PBS and RSV inoculated 
mice and 19.8% (SD=3.4) for the H3N2-primed mice, which was significantly lower 
(p<0.05) (Figure 1D). From day 6 onwards the latter animals gained weight and 
fully recovered within two weeks after challenge infection with influenza virus A/
IND/5/05 (H5N1).
Between day 4 and 6 p.i. one out of eleven H3N2-primed animal and all animals 
from the PBS and RSV control groups became less active, showed reduced muscle 
strength and started to develop respiratory distress, observed as heavy breathing 
in combination with hunched posture. In combination with a weight loss of more 
than 20%, animals had to be euthanized for ethical reasons. The survival rate on day 
5 p.i. was 100% for the H3N2-primed group and 71.4% and 37.5% for the animals 
previously inoculated with PBS and RSV respectively (Figure 1D). Eventually, all 
animals of the PBS and RSV group had to be euthanized (0% survival), whereas only 
Figure 1 Bodyweight after challenge infection with influenza virus A/IND/5/05 in H3N2-primed mice (
  ) and mock-infected control mice (  ) or RSV-primed mice (  ) (A,C). Survival of these animals after infection with influenza virus A/ IND/5/05 (B,D), which was significantly higher after day 6 for the H3N2-
primed mice.*(indicates statistical significant difference (p<0.05)
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one of the H3N2-primed mice had to be taken out of the experiment (91% survival). 
This difference in survival rate was statistically significant (p<0.05).
Serology
Twenty-eight days after primary infection with influenza virus A/HK/2/68, mice 
developed GMT HI antibody titers of 905.1 (SD=1.49) and VN antibody titers of 226.3 
(SD=1.49) against the homologous strain. The sera did not react with influenza virus 
A/IND/5/05 in either of the assays. 
Lung virus titers
Four and seven days p.i. with influenza virus A/IND/5/05 lung virus titers were 
assessed. In the first experiment lung virus titers of the H3N2-primed mice 
were significantly lower at these time points p.i. than those of unprimed mice 
(p<0.05)(Table 1). In the second experiment the lung virus titers on day 4 p.i were 
significantly lower for the H3N2-primed animals: 108.1 TCID50 (SD=100.4) than for 
the naïve mice of the PBS group: 109.0 TCID50 (SD=100.4) (p<0.05) and RSV group: 
108.8 TCID50 (SD=100.3) (p<0.05) (Table 1). Only the H3N2-primed animals survived 
the infection post day 7 and the mean virus titer in the lungs on that day was 104.6 
TCID50 (SD=100.7). Fourteen days p.i. infectious virus was no longer detectable in 
the lungs of these animals. 
Table 1: Lung virus titers after infection with influenza virus A/IND/5/05 (H5N1) 1
Days post infection
4 7 14
Experiment 1
HK/2/68  infection 7.7 ± 0.12 4.8 ± 0.52   n.d.3
Mock infection 8.8 ± 0.5 7.0 ± 0.6 n.d.
Experiment 2
HK/2/68  infection 8.1 ± 0.44 4.6 ± 0.7 <1.55
Mock infection 9.0 ± 0.4 † †
RSV infection 8.8 ± 0.3 † †
1 titers are expressed as TCID
50
 per gram tissue (Log10)
2 significantly lower than the mock-infected mice (p<0.05)
3 n.d. = not done 
4 significantly lower than the mock-infected and RSV-infected mice (p<0.05)
5 average virus titer below the cut-off value, all animals tested negative by virus isolation
† animals did not survive until these time points.
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Detection of virus-specific CTL
Tetramers were used to detect CTL specific for the NP
366-374 
epitope: ASNENMDAM 
(influenza virus A/HK/2/68) and ASNENMEVM (influenza virus A/IND/5/05). Four 
and seven days after infection with influenza virus A/HK/2/68 no tetramer-positive 
T lymphocytes were detected in the spleen (data not shown). However, twelve 
days p.i. an NP
366-374
 (ASNENMDAM) specific response was observed (Figure 2A). A 
small fraction of these cells stained positive with both the ASNENMDAM tetramer 
and the tetramer prepared with the NP
366-374
 epitope (ASNENMEVM) derived from 
influenza virus A/IND/5/05 (H5N1). Upon challenge infection with this virus, this 
double positive fraction was selectively expanded (Figure 2B) in the majority of 
mice. After challenge infection with the influenza A/H5N1 virus, A/IND/5/05-derived 
NP
366-374
 (ASNENMEVM)-specific cells were detected as early as day seven p.i. in 
both experiments. Of all CD8+ T lymphocytes the mean frequency of Tetramer 
positive (Tm+) CD8+ cells was 5.3% (SD= 5.7) and 6.2% (SD=4.6) respectively (Table 
2). In mock-primed mice this frequency was significantly lower. Two weeks p.i. the 
frequency of NP
366-374
 specific CTL had declined to 3.6% (SD=2.8). In addition to 
tetramer-staining also intracellular IFNγ-staining was used to assess the presence 
of virus-specific CTL in the spleen. 
In mice that were primed by infection with influenza virus A/HK/2/68, the 
stimulation of splenocytes with the NP
366-374
 peptide resulted in the detection of 
IFNγ in CD8+ T cells in both experiments with mean frequencies of 2.0% (SD=1.1) 
and 1.8% (SD=0.8), respectively (Table 2). The frequency of IFNγ positive cells was 
significantly higher than in mock-infected animals (p<0.05). Fourteen days p.i. the 
Table 2: NP
366-374
 specific CD8+ T lymphocytes on day 7 post infection with influenza  
     virus A/IND/5/05
Infection Experiment 1 Experiment 2
epitope IFNgamma+ Tm+ IFNgamma+ Tm+
NP
366-374
ASNENMEVM
HK/2/68 2.0 ± 1.11 5.3 ± 5.71 1.8 ± 0.8 6.2 ± 4.6
Mock -0.5 ± 0.2 0.9 ± 0.7 † †
RSV n.d.2 n.d. † †
PA
224-232
SSLENFRAYV
HK/2/68 3.0 ± 1.41 n.d. n.d. n.d.
Mock 0.2 ± 0.3 n.d. † n.d.
RSV n.d. n.d. † n.d.
1 significantly higher than the mock-infected mice (p<0.05)
2 n.d.= not done
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frequency had declined to 0.4% (SD=0.5). Also the frequency of IFNγ positive CD8+ 
T cells specific for the PA
224-232
 epitope (SSLENFRAYV) was significantly higher in 
H3N2-primed mice than in mock-infected animals (Table 2).
Histopathology
Twenty-eight days after infection with influenza virus A/HK/2/68, multifocal 
hyperplasia and hypertrophy of the bronchiolar epithelium and peribronchiolar 
lymphocytic infiltrates were visible, but not after PBS or RSV inoculation. 
Four days after infection with influenza virus A/IND/5/05, multifocal moderate 
necrotizing broncho-interstitial pneumonia covering almost complete lobes 
was observed in the lungs of both the mock- and RSV-infected mice. There was 
loss of bronchiolar epithelium in combination with necropurulent material in the 
bronchiolar lumen. Infiltration of inflammatory cells, mainly neutrophils and 
lymphocytes, was present in the PBS- and RSV-inoculated mice (Figure 3B, C). In 
contrast, multifocal mild to moderate broncho-interstitial pneumonia with marked 
inflammatory infiltrates consisting of predominantly lymphocytes and neutrophils 
(Figure 3A) was observed in the lungs of H3N2-primed mice. The bronchiolar wall 
was rather conserved although some cellular debris was present in the lumen. In the 
alveoli, hypertrophy of the type II pneumocytes was seen.
Seven days p.i. the lungs of the H3N2-primed animals still displayed mild to 
Figure 2 Expansion of a cross-reactive CD8+ T cell population, induced by primary infection, after 
subsequent infection with influenza virus A/IND/5/05 (H5N1). On day 12 after infection with influenza 
virus A/HK/2/68 (H3N2) a CD8+ T cell population was detected that recognized both the A/HK/2/68 
derived NP
366-374
 epitope (ASNENMDAM) and the A/IND/5/05 derived analog (ASNENMEVM) (A). This 
cross-reactive population was expanded constituting the majority of NP
366-374
 specific CTL on day 7 
after infection with influenza virus A/IND/5/05 (H5N1) (B).
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moderate broncho-interstitial pneumonia. The bronchiolar epithelium displayed 
hyperplasia and hypertrophy (indication of regeneration) and the peribronchiolar 
and perivascular infiltration of lymphocytes was stronger, also in iBALT formations, 
compared to day 4.  Regeneration of alveoli was visible and a mild lymphocytic 
infiltrate was found in the alveolar lumen. No data were available for the mock- and 
RSV-primed mice on day seven and fourteen p.i. with influenza virus A/IND/5/05, 
since none of these animals survived past day 6.
Detection of virus-infected cells in the lungs by immunohistochemistry
The presence of influenza A/IND/5/05 virus-infected cells was assessed by 
immunohistochemistry using a monoclonal antibody directed to the viral NP. 
Four days p.i. with influenza A/IND/5/05 virus, virus-infected cells were abundantly 
present in the lungs of mock and RSV-primed mice (Figure 4B, C). The infected cells 
were located in and around lesions. Almost 50% of the bronchioles was infected with 
more than 75% of the epithelial cells staining positive for viral antigen. The infected 
cells in the alveoli were predominantly type II like pneumocytes. In contrast, only 
a small number of bronchiolar epithelial cells stained positive in mice that were 
primed by infection with influenza virus A/HK/2/68, although especially in the alveoli 
virus-infected cells, mainly type II like pneumocytes, were readily detectable (Figure 
4A). Seven days p.i. infected cells only were detected sporadically in the lungs of 
these mice, which resolved the infection completely by day 14 p.i. (data not shown). 
Discussion
Figure 3 Histopathology was examined in the lungs of mice after infection with influenza virus A/
IND/5/05. Four days after infection the lungs of H3N2-primed animals showed a multifocal mild 
broncho-interstitial pneumonia with mild inflammatory infiltrates consisting of predominantly 
lymphocytes and neutrophils (A). The mock-infected control mice (B) and RSV-primed mice (C) 
displayed a multifocal moderate necrotizing broncho-interstitial pneumonia with marked infiltration, 
consisting of inflammatory cells, mainly neutrophils and lymphocytes, in the alveoli.  (full colour figure: 
APPENDIX III)
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In the present study, the protective efficacy was assessed of heterosubtypic 
immunity induced after infection with a human influenza A/H3N2 virus against a 
lethal challenge infection with a highly pathogenic avian influenza A/H5N1 virus. 
A prior exposure to the human A/H3N2 strain protected mice from severe clinical 
signs and mortality which correlated with control of virus replication in the lungs 
and the induction of anamnestic cross-reactive CTL responses upon influenza A/
H5N1 virus infection.
Inoculation of naive C57BL/6J mice with influenza virus A/IND/5/05 (H5N1), which 
was chosen for its high virulence in mice [251] caused a productive infection of 
these animals with infectious virus titers four days p.i. of up to 109 TCID
50
 per gram 
of lung tissue. These animals developed a severe necrotizing interstitial pneumonia 
and eventually succumb to the infection. Although the kinetics of the development 
of disease differed somewhat between experiment 1 and 2, in both experiments 
a prior infection with influenza virus A/HK/2/68 (H3N2) had a significant effect on 
virus replication rates, loss of body weight and mortality rates. In experiment 2 a 
prior infection with RSV did not prevent influenza A/H5N1 virus-induced disease, 
indicating that the observed protection was dependent on adaptive immune 
responses induced by infection with influenza virus A/HK/2/68 (H3N2) rather than a 
non-specific innate immune response.
In contrast, the protection of H3N2-primed mice against influenza A/H5N1 virus 
infection correlated with the induction of anamnestic CTL responses specific for 
the NP
366-374
 (ASNENMEVM) and PA
224-232
 (SSLENFRAYV) epitopes derived from 
influenza virus A/IND/5/05 (H5N1). These epitopes differ from their counterparts 
(ASNENMDAM and SCLENFRAYV, respectively) in influenza virus A/HK/2/68 that 
Figure 4 Detection of virus-infected cells by immunohistochemistry in the lungs of influenza virus A/
IND/5/05 (H5N1)-infected mice on day 4 p.i. in mice primed by infection with influenza virus A/HK/2/68 
(H3N2) (A), mock-infected mice (B), or RSV-primed mice (C). (full colour figure: APPENDIX III)
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was used for priming of the animals. Apparently, infection with influenza virus A/
HK/2/68 primed for cross-reactive CTL against these two epitopes, in addition to 
epitopes that are conserved and shared between influenza viruses A/HK/2/68 and A/
IND/5/05. A similar result was obtained previously after subsequent infection with 
influenza viruses A/NT/60/68 (H3N2) (NP
366-374
 ASNENMDAM) and A/PR/8/34 (H1N1) 
(ASNENMETM) [226].
Consecutive infections with these two variant viruses lead to the selective expansion 
of cross-reactive CTL responses specific for the NP
366-374
 epitope. After infection with 
only one of these viruses the cross-reactive CTL only form a minor proportion that 
is expanded after the second infection with the variant strain. Thus, also with the 
combination of viruses we used, cross-reactive CTL were selectively expanded after 
infection with influenza virus A/IND/5/05. A similar result was obtained in vitro with 
human CTL specific for the HLA-B*3501 restricted NP
418-426
 epitope that differed 
between human influenza A/H1N1 and A/H3N2 viruses [252].
Although it has been described that the NP
366-374
 epitope is more immunodominant 
than the PA
224-232
 epitope in a secondary CTL response [253], a stronger response 
was observed against the PA
224-232
 epitope after infection with influenza virus A/
IND/5/05. Possibly, the cross-reactivity of CTL directed to the NP
366-374
 epitope 
is lower than that of CTL specific for PA
224-232
. Thus, the induction of memory CTL 
responses induced by infection with influenza virus A/HK/2/68 (H3N2) correlated 
with protective immunity against infection with influenza A/IND/5/05 virus (H5N1). 
Furthermore, cross-reactive T cells are also induced to various other (unknown) 
epitopes located in all viral proteins. Also human CTL directed against seasonal 
influenza A viruses are highly cross-reactive with influenza A/H5N1 viruses [72, 73, 
199].
Additionally, it cannot be excluded that other arms of the adaptive immune response 
contributed to the observed protection. It is possible that prior infection with an 
influenza A virus also primed for a secondary T helper cell response. 
In addition, it has been demonstrated that antibodies directed to NP [60] or the 
M2 protein can have a protective effect against challenge infection [201, 203, 204]. 
However, the protective role of NP-specific antibodies only could be demonstrated 
after hyper-immunization of mice with a high dose of recombinant NP in combination 
with LPS. With post-vaccination rNP-immune serum the protective effect could be 
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transferred to B-cell deficient µMT mice but not to intact recipient C57BL/6J mice. 
For M2-specific antibodies the protective effect was demonstrated after hyper-
immunization or the transfer of high doses of M2-specific monoclonal antibodies 
[59, 201]. In addition, transfer of post-infection serum to naïve recipient mice failed 
to protect the animals from infection with a heterosubtypic strain [254] including 
influenza virus A/IND/5/05 (H5N1) (data not shown). Therefore, it is unlikely that 
NP or M2 specific antibodies contributed to a great extent to the infection-induced 
heterosubtypic immunity against influenza virus A/IND/5/05 (H5N1) observed in the 
present study. We used a time interval of four weeks between the two infections but 
previous studies have shown that heterosubtypic immunity is long-lived, up to 5 and 
18 months in mice and ferrets, respectively [243, 255].
Protection of mice against lethal influenza A/H5N1 virus infection induced by 
primary infection with a heterosubtypic influenza virus has been demonstrated 
before [216]. However the internal genes of the influenza A/H9N2 and A/H5N1 
viruses used for priming and challenge infection respectively were closely related 
and displayed 98% sequence homology [256]. Therefore, this scenario resembled 
that with the use of influenza X-31 (H3N2) and A/PR/8/34 (H1N1) virus for priming 
and challenge infection respectively since these two viruses share identical internal 
genes [200]. Here we demonstrate for the first time that infection with a human 
influenza virus induces protective immunity to a highly pathogenic avian influenza 
virus of the H5N1 subtype. The findings reported may have a number of important 
implications. Although this type of immunity did not protect against infection per 
se, it contributed to control of virus replication and as a result dampened the clinical 
impact of the H5N1 infection. It can be expected that this type of immunity is also 
effective against less virulent H5N1 strains. The observed protection against the 
development of severe disease correlated with the induction of cross-reactive CTL 
responses in the spleen. In addition, lymphocytic infiltrates were still present in the 
lungs 28 days post priming infection. The persistence of virus-specific T cells in the 
lungs was demonstrated previously [232, 257] and may contribute to protection 
against a subsequent infection [233]. Interestingly, also in humans virus specific T 
cells have been found in lung tissue, which indicates that also in humans similar 
protective mechanisms are at work [258].
Since human CTL raised against seasonal influenza virus strains of the H1N1 and 
H3N2 subtypes are highly cross-reactive with highly pathogenic avian influenza 
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A/H5N1 viruses it is anticipated that they will contribute to protective immunity 
against these viruses, when they might become pandemic [73, 199]. Similarly, cross-
reactive CTL may have contributed to heterosubtypic immunity and a reduction of 
lethal influenza A/H2N2 cases observed during the pandemic in 1957 [71]. It even 
may be speculated that the history of infections with seasonal influenza viruses and 
the cross-reactive CTL responses associated with these infections is at the basis of 
the disproportional age distribution of severe H5N1 cases [259]. Last but not least, 
the induction of cross-reactive CTL may be an attractive target for the development 
of vaccines that could induce broad-protective immune response, even against 
influenza A viruses of a novel subtype.
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Abstract
Annual vaccination against seasonal influenza viruses is recommended for certain 
individuals that have a high risk for complications resulting from infection with 
these viruses. Recently it was recommended in a number of countries including 
the USA to vaccinate all healthy children between 6 and 59 months of age as 
well. However, vaccination of immunologically naïve subjects against seasonal 
influenza may prevent the induction of heterosubtypic immunity against 
potentially pandemic strains of an alternative subtype, otherwise induced by 
infection with the seasonal strains. 
Here we show in a mouse model that the induction of protective heterosubtypic 
immunity by infection with a human A/H3N2 influenza virus is prevented by 
effective vaccination against the A/H3N2 strain. Consequently, vaccinated 
mice were no longer protected against a lethal infection with an avian A/H5N1 
influenza virus. As a result H3N2-vaccinated mice continued to loose body 
weight after A/H5N1 infection, had 100-fold higher lung virus titers on day 7 post 
infection and more severe histopathological changes than mice that were not 
protected by vaccination against A/H3N2 influenza.
The lack of protection correlated with reduced virus-specific CD8+ T cell 
responses after A/H5N1 virus challenge infection. These findings may have 
implications for the general recommendation to vaccinate all healthy children 
against seasonal influenza in the light of the current pandemic threat caused by 
highly pathogenic avian A/H5N1 influenza viruses.
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Introduction
Since 2003, more than 380 human cases of infection with highly pathogenic avian 
influenza A virus (IAV) of the H5N1 subtype have been reported to the World Health 
Organization (WHO) of which more than 60% were fatal[260]. Because of the 
continuous spread of these viruses among domestic birds, the frequent introduction 
into wild birds and the increasing number of human cases, a pandemic outbreak 
caused by influenza A/H5N1 viruses is feared[44, 46, 261]. It has been demonstrated 
in animal models that prior exposure to an IAV can induce heterosubtypic immunity 
to infection with an IAV of an unrelated subtype (for review see[262]). Also in humans 
there is evidence that infection with IAV can induce heterosubtypic immunity[71]. 
Individuals that had experienced an infection with an H1N1 IAV before 1957 less 
likely developed influenza during the H2N2 pandemic of 1957[71]. In particular, 
the induction of cell-mediated immune responses after infection contributes to 
protective immunity against infection with heterosubtypic IAVs. The presence 
of cross-reactive cytotoxic T lymphocytes (CTL) in humans inversely correlated 
with the amount of viral shedding in the absence of antibodies directed against 
the virus used for experimental infection[67]. It is well documented that seasonal 
human IAVs and avian IAVs share CTL epitopes located in the internal viral proteins 
like the nucleoprotein[72, 73, 199]. Thus, cell-mediated immunity induced by 
natural infection with seasonal IAVs may confer protection against heterosubtypic 
pandemic influenza viruses. In this respect, the disproportional age distribution of 
severe human H5N1 cases is of interest[263]. Especially younger individuals are at 
risk and although other confounding factors cannot be excluded, it is tempting to 
speculate that young subjects have been infected with seasonal influenza viruses 
less frequently and therefore have not developed protective heterosubtypic immune 
responses against infection with the highly pathogenic avian A/H5N1 viruses. 
Since seasonal IAVs of the H3N2 and H1N1 subtypes cause epidemic outbreaks 
annually associated with excess morbidity and mortality mainly among infants, the 
elderly, immuno-compromised and other high-risk patients, influenza vaccination 
is recommended for these high-risk groups. In general, the influenza vaccines most 
frequently used are inactivated vaccines, including subunit preparations that consist 
of the viral hemagglutinin (HA) and neuraminidase (NA). Due to the higher risk of 
complications and hospitalizations secondary to influenza in children[264, 265], 
annual vaccination of all healthy children 6 to 59 months of age was recommended 
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in various countries including the United States since 2007[266].
However, annual vaccination may prevent the induction of heterosubtypic 
immunity by infection with seasonal influenza virus strains. In addition, it is unlikely 
that seasonal inactivated influenza vaccines, unlike live attenuated vaccines, 
induce heterosubtypic immunity since they induce cross-reactive CTL responses 
inefficiently[267, 268]. Thus, we hypothesized that vaccination against seasonal 
flu prevents the induction of cross-protective cell-mediated immunity, which 
consequently may lead to more severe clinical outcome of infection with a future 
pandemic virus. Here we show in a mouse model that protective immunity against 
lethal infection with H5N1 IAV Indonesia/5/05 (IND/05) was induced by infection with 
H3N2 IAV HongKong/2/68 (HK/68), which was prevented by effective vaccination 
against the A/H3N2 virus. The lack of protection against IAV IND/05 correlated with 
reduced virus-specific CTL responses. 
Materials and methods 
Viruses
Virus stocks of influenza viruses A/Hong Kong/2/68 (IAV HK/68) and A/
Indonesia/5/05 (H5N1) (IAV IND/05) were prepared by infecting confluent Madin-
Darby-Canine-Kidney (MDCK) cells. After cytopathologic changes were complete, 
culture supernatants were cleared by low speed centrifugation and stored at –70°C. 
Infectious virus titers were determined in MDCK cells as described previously[228]. 
Vaccine preparation 
Influenza subunit antigen derived from IAV X-31 (H3N2) was essentially prepared as 
described previously[98].  X-31 is a reassortant vaccine strain of A/Aichi/2/68 and A/
PR/8/34, of which the HA and NA resemble that of IAV HK/68 closely. The purity of 
the subunit preparations was tested by SDS-polyacrylamide gel electrophoresis and 
the absence of the nucleoprotein and matrix protein of the subunit preparations 
was tested by western blotting using monoclonal antibodies against the influenza 
A nucleoprotein and the influenza A matrix protein. The protein concentration was 
determined using a BCA Protein Assay Kit (Pierce, Rockford, USA).
Immunization and infection of mice
Female specified pathogens free 6-8 weeks old C57BL/6J (H-2b) mice were purchased 
from Charles River (Sulzfeld, Germany). Mice were immunized twice with an interval 
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of four weeks intramuscularly (i.m.) in both hind legs in a total volume of 100μl. Mice 
(n=19-40 per group) received PBS (phosphate buffered saline) (Groups 1,3 and 4), 
15μg subunit vaccine with (Groups 2 and 5) or without (Group 6) 1mg Aluminium 
hydroxide gel (Alum) (Sigma-Aldrich, Zwijndrecht, The Netherlands) or Alum only 
(Group 7). Eight days after the second vaccination, four mice of each group were 
bled and spleens were resected. Four weeks after the second vaccination, mice 
of groups 2, 3, 6 and 7 were infected intranasally with 5x102 TCID
50 
IAV HK/68 in a 
volume of 50μl. Four and twelve days post infection (p.i.), 5-7 mice were bled and 
lungs and spleens were resected. Four weeks after infection with IAV HK/68, all mice 
except mice of group 1 were challenged with 2x 102 TCID
50 
IAV IND/05. A dose of 2x 
102 TCID
50 
was used because this was the minimal dose resulting in a lethal infection 
in >90% mice reproducibly. 
The day before challenge with IAV IND/05, mice of each group (n=2-4) were 
euthanized and lungs and spleens were resected as well as on day four (n=4-6), 
seven (n=2-9) and fourteen (n=3-8) days after challenge. Vaccinations, intranasal 
infections, orbital punctures and euthanasia were performed under anesthesia with 
isoflurane in O
2
. After infection with IAV HK/68 and IAV IND/05, mice were monitored 
for the presence of clinical signs, including weight loss. All experiments with IAV 
IND/05 were performed under Biosafety Level 3 conditions. An independent animal 
ethics committee (DEC consult) approved the experimental protocol before the 
start of the experiments. 
Table 1. Experimental groups and design of the study
Experimental
group
Vaccination Infection
Subunit Adjuvant HK/68 IND/05
1 - - - -
2 + + + +
3 - - + +
4 - - - +
5 + + - +
6 + - + +
7 - + + +
Mice were divided over seven groups and were either vaccinated twice with subunit vaccine with or 
without adjuvant (Alum), PBS, or adjuvant only as indicated. Four weeks after the second vaccination, 
mice were infected with IAV HK/68 (H3N2) or mock-infected. Twenty-nine days after the infection with 
IAV HK/68, mice were challenged with IAV IND/05 (H5N1).
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Serology
Serum samples of mice were collected at various time points during the experiment 
and tested for the presence of HA-specific antibodies against IAV HK/68 and IAV 
IND/05 using the hemagglutination inhibition (HI) assay[280] and virus neutralising 
(VN) antibodies using the VN assay[230].To determine the titer of antibodies against 
IAV IND/05 before infection with IAV IND/05, a reverse genetics virus was produced 
from which the basic cleavage site was removed. Antibody titers obtained with 
this reverse genetics virus was comparable with that against the wild-type strains 
(data not shown). Positive control serum specific for IAV HK/68 was obtained by 
injecting a rabbit with sucrose gradient purified virus[249]. Hyper-immune serum 
obtained from a swan immunized twice with inactivated H5N2 influenza virus A/
Duck/Potsdam/1402/86 (Intervet, Boxmeer, the Netherlands) was used as a positive 
control against IAV IND/05[250].
Lung virus titers
Lungs of mice were snap frozen on dry ice with ethanol and stored at –70°C. 
Lungs were homogenized with a FastPrep-24 (MP Biomedicals, Eindhoven, The 
Netherlands) in medium consisting of Hank’s balanced salt solution containing 
0.5% lactalbumin, 10% glycerol, 200 U/ml penicillin, 200 μg/ml streptomycin, 
100 U/ml polymyxin B sulfate, 250 μg/ml gentamycin, and 50 U/ml nystatin 
(ICN Pharmaceuticals, Zoetermeer, The Netherlands) and centrifuged briefly. 
Quintuplicate 10-fold serial dilutions of these samples were used to infect MDCK 
cells as described previously[228]. HA activity of the culture supernatants collected 
5 days post inoculation was used as indicator of infection. The titers were calculated 
according Spearman-Karber[281].
Flow cytometry of virus-specific CD8+ T cells
Peptides and intracellular IFN-γ staining
Single cell suspensions of spleens were prepared as described previously[200]. 
CD8+ T cell responses after infection were measured by incubation with peptides 
representing two immunodominant epitopes of IAVs in C57BL/6J mice (H2-b), PA224-
233 
and NP
366-374 
[221, 223]. The peptides of the PA
224-233 
epitope of influenza A virus 
were manufactured at Eurogentec (Seraing, Belgium), while peptides of the NP
366-374 
epitope were manufactured at Sanquin Research (Amsterdam, The Netherlands). 
Four hundred thousand splenocytes were cultured for 6 h at 37°C in the presence 
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of 5μM of either the NP
366-374
 ASNENMDAM (NP
HK
), PA
224-233 
SCLENFRAYV 
(PA
HK
) peptides derived from IAV HK/68 or the NP
366-374
 ASNENMEVM  (NP
IND
) or 
SSLENFRAYV (PA
IND
) peptides (derived from IAV IND/05) in IMDM (Lonza, Breda, 
The Netherlands) with 5% FCS and Golgistop (BD). After incubation, cells were 
o/n stored at 4°C, stained with monoclonal antibody directed to CD3e-PerCP and 
CD8b.2-FITC, fixate and permeabilized with Cytofix and Cytoperm and stained with 
monoclonal antibody specific for IFN-γ-PE (all from BD Pharmingen, Alphen a/d 
Rijn, The Netherlands). Data were acquired using a FACSCalibur and analysed with 
Cellquest Pro Software (BD).
Tetramerstaining
Splenocytes were washed and stained with mAbs CD3e-PerCP, CD8b.2-FITC (BD 
Pharmingen, Alphen a/d Rijn, The Netherlands) and either the Phycoerythrin 
(PE)-labeled H-2Db tetramer with the immunodominant NP
366-374 
epitope derived 
from IAV X-31 ASNENMETM (Tm
X-31
) or IAV HK/68 ASNENMDAM (Tm
HK
) or the 
APC labeled tetramer derived from IAV IND/05 NP
366-374 
ASNENMEVM (Tm
IND
). All 
tetramers were purchased from Sanquin Research, Amsterdam, The Netherlands. 
Following incubation with tetramers and mAbs for 20 minutes, cells were washed 
twice and analysed by flow cytometry using a FACSCanto in combination with FACS 
Diva software (BD).
Histopathology and immunohistochemistry
After euthanasia, lungs of mice were inflated with 10% neutral buffered formalin. 
After fixation and embedding in paraffin, lungs were sectioned at 4μm and tissue 
sections were examined by staining for hematoxylin and eosin (HE). Using an 
immunoperoxidase method, sequential slides were also stained with a monoclonal 
antibody directed against the nucleoprotein of IAV[282]. 
Statistical analysis
Data for weight loss after infection, viral load in the lungs, tetramerstaining, 
and peptide pulsing were analysed statistically using the two-sided student’s T 
test. Survival was analysed using the Logrank test. Differences were considered 
significant at P<0.05.
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Results
Antibody responses against IAV HK/68 (H3N2) after vaccination 
Mice were vaccinated with subunit vaccine with or without Alum or were 
‘mock’ vaccinated (table 1). HI antibody titers were detected 28 days after the 
first vaccination with subunit and Alum (groups 2 and 5) and in 3 out of 26 mice 
vaccinated with unadjuvanted subunit vaccine (group 6). Four weeks after the 
second vaccination, geometric mean titers (GMTs) increased to 244 and 218 
in mice from group 2 and group 5, respectively. Four mice of group 6 developed 
detectable HI-antibody responses with a GMT of 48, the other mice of this group 
did not seroconvert (figure 1A). Sera of mice were also analysed for the presence of 
virus neutralizing (VN) antibodies. Four weeks after the second vaccination, mice 
vaccinated with adjuvanted subunit vaccine developed VN antibodies with a GMT 
of 38 and 29 in group 2 and group 5 respectively, while only two mice of group 6 
developed detectable VN antibody titers (figure 1B).
Outcome of infection with IAV HK/68 (H3N2)
Mice that developed HI-antibodies against IAV HK/68 (all mice of group 2 and four 
of group 6) were protected from weight loss after infection with IAV HK/68, while 
mice of other groups lost weight until day seven post infection (p.i.) and showed 
Figure 1 Induction of serum antibodies against IAV HK/68 (H3N2) by vaccination. Serum antibody 
levels were determined before and at the indicated time points after vaccination of mice with PBS 
(groups 1, 3 and 4; O), subunit vaccine with alum (groups 2 and 5; p), subunit vaccine only (group 6; 
¢) and alum only (group 7; Ï) by HI assay (A) and VN assay (B).
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mild clinical symptoms for 2-3 days (figure 2A). Clinical signs and weight loss after 
infection correlated well with virus titers in the lungs of infected mice 4 days p.i.. 
No virus was detected in lungs of mice vaccinated with adjuvanted subunit vaccine, 
while the average lung virus titer of mock-vaccinated mice was 108.1 TCID
50
/gram 
lung. 
Figure 2 Outcome of infection with IAV HK/68 (H3N2). Mice were inoculated with IAV HK/68 (groups 2 
(p), 3 (O), 6 (¢) and 7 (Ï)) or PBS (groups 1 (Â), 4 (s) and 5 (¯)). (A) Body weight after infection was 
determined daily and expressed as the percentage of the original body weight before infection. (B) Lung virus 
titers measured on day 4 p.i. in mice from the indicated experimental groups. Horizontal bars represent the 
average titers of five mice. The dotted line represents the cut-off value for obtaining a positive result. *This 
mouse from group 6 had before infection an HI antibody titer of 40. (C) Vaccination prevented the induction 
of iBALT after infection. Twenty-eight days post infection with IAV HK/68 iBALT was detected in mice from 
group 3, but not in mice from group 2. Lung tissue sections were stained with HE. (D) Virus-specific CD8+ T 
cell responses detected 28 days post infection. Splenocytes of mice from the indicated experimental groups 
were tested for the presence of CD8+ T cells that bound the H2-Db NP
HK 
Tetramer. Horizontal bars represent 
the average of 2-4 mice. The difference in %CD8+ Tm+ T cells between groups 2 and 3 was statistically 
significant (P=0.030). (full colour figure: APPENDIX IV)
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Similar titers were observed for the mice in groups 6 and 7 with the exception of 
one mouse in group 6 with a HI antibody titer of 40 induced by vaccination with 
unadjuvanted subunits that had a lung virus titer of 105.7 TCID
50
/gram lung (figure 
2B). The virus titers detected on day 4 p.i. correlated with the absence or presence 
of virus infected cells in the lungs detected by immunohistochemistry (data not 
shown).
Virus-specific CTL and antibody responses after infection with IAV HK/68 (H3N2)
Four days p.i. with IAV HK/68 the frequency of splenic CD8+ T lymphocytes specific 
for the NP
366-374
 epitope of IAV HK/68 (CD8+ Tm
HK
+ T-cells) as determined by tetramer 
staining remained at background levels in all groups (data not shown).
In all infected mice a raise in the frequency of CD8+ Tm
HK
+ T-cells was detected 
twelve days p.i.. No statistically significant differences were observed between the 
experimental groups. Essentially the same results were observed using intracellular 
IFN-γ staining after re-stimulation with peptides representing the NP
366-274 
and PA
224-
233
 epitopes of IAV HK/68 (NP
HK
 and PA
HK
). The NP
HK 
and PA
HK
 specific CTL induced 
by infection with IAV HK/68 cross-reacted to various extents with their counterparts 
derived from IAV IND/05 (NP
IND
 and PA
IND
). The cross-reactive nature of a proportion 
of the NP
366-374
 specific CTL was confirmed by double staining with Tm
HK
 and Tm
IND 
(data not shown). 
By day 28 p.i. with IAV HK/68, just before challenge infection with IAV IND/05, the 
frequency of virus-specific CTL in the spleen had declined and virus-specific CTL 
were not detectable by intracellular IFN-γ staining. However, Tm
HK
 and Tm
IND
 positive 
cells were detected in mice that were mock vaccinated prior to infection (group 3). 
Strikingly, the frequency of Tm
HK 
positive CD8+ T lymphocytes was significantly 
lower in mice of group 2 that were effectively vaccinated against infection with IAV 
HK/68 (p=0.030) (figure 2D).  
Vaccination prevents induction of iBALT after IAV HK/68 infection 
Following infection with IAV HK/68, no significant lesions were found in lungs of 
mice vaccinated with adjuvanted subunit vaccine (group 2), whereas mice that were
 mock-vaccinated or vaccinated with Alum or subunit preparation only (mice of groups 
3, 6 and 7) developed a multifocal mild subacute necrotizing bronchopneumonia 
four days after infection, which on day 12 p.i. progressed into a multifocal moderate
chronic necrotizing bronchopneumonia. 
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Figure 3 Outcome of infection with IAV IND/05 (H5N1). Mice were inoculated with IAV IND/05 (groups 2 (p), 
3 (O), 4 (s), 5 (¯), 6 (¢) and 7 (Ï)) or PBS (group 1 (Â). (A) Body weight after infection was determined 
daily and expressed as the percentage of the original body weight before infection. (B) Survival rates after 
infection with IAV IND/05. The proportion of mice from the indicated groups that survived infection is shown 
in a Kaplan-Meier plot. Moribund animals were euthanized when they reached pre-fixed criteria regarding 
weight loss (>20%) and disease severity score, which was used to determine mortality rates. (C) Lung virus 
titers measured on 7 days p.i. in mice from the indicated groups. Horizontal bars represent the average of 
2-6 mice. The difference in virus titers between mice of group 2 and group 3 was statistically significant 
(p=0.025). N.S.: not significant. (D) Virus-specific CD8+ T cell responses on day 7 p.i.. The frequency of 
CD3+ CD8+ splenocytes specific for peptide NP
366-374
 and PA
224-233
 derived from IAV IND/05 was determined 
by intracellular IFN-γ staining. The horizontal bars represent the average frequency of IFN-γ+ cells in the 
CD8+ T cell population of 2-7 mice in the indicated groups. Differences between group 2 and group 3 were 
statistically significant for both peptides.
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On day 28 p.i., these mice had developed perivascular moderate proliferation of 
inducible Bronchus Associated Lymphoid Tissue (iBALT), consisting mainly of 
mononuclear cells, which was absent in mice effectively vaccinated against infection 
with IAV HK/68 (figure 2C). 
Effective vaccination prevents heterosubtypic immunity against IAV IND/05 (H5N1)
After infection with IAV IND/05, all mice developed clinical signs (weight loss, ruffled 
fur, lethargy) from day two p.i. onwards. Mice that developed clinical signs p.i. with 
IAV HK/68 (groups 3, 6 and 7) lost weight until day 6-7 after infection with IAV IND/05 
and then started to gain weight and fully recovered, while mice of other groups, 
not previously infected with IAV HK/68 (groups 4 and 5) and more strikingly, those 
effectively vaccinated against infection with IAV HK/68 (group 2) lost significantly 
more weight (group 2 versus group 3: p=0.0001) on day 7 p.i. with IAV IND/05 and 
showed more severe clinical signs (lethargy, ruffled fur, hunched posture) than 
mice of the other groups (figure 3A). Moribund animals were euthanised when they 
reached pre-fixed criteria regarding weight loss (>20%) and clinical signs, which was 
used to determine mortality rates.  One mouse out of 10 (10%) of group 2 survived 
lethal challenge, while all mice but one (91%) of group 3 survived lethal challenge 
(n=11). This difference in survival rate was statistically significant (p= 0.0003) as was 
calculated with the Logrank test (figure 3B). All other mice not previously exposed to 
IAV HK/68 became moribund, whereas all mice not adequately vaccinated against 
IAV HK/68 (groups 6 and 7) survived. 
Replication of IAV IND/05 (H5N1) in the lungs
The lung virus titers at days four and seven p.i. were compared between groups 
of IAV IND/05 infected mice. Four days p.i. no significant differences were found 
between mice of different groups. The average virus titer in mice of group 3 was 107.7 
TCID
50
/gram lung, which was similar to that observed in mice from group 2 that were 
effectively vaccinated against IAV HK/68 (107.6 TCID
50
/gram lung). In contrast, there 
were significant differences in lung viral titers between mice of the different groups 
seven days p.i. (figure 3C). Group 3 mice, not vaccinated against infection with IAV 
HK/68, had virus titers of 104.8 TCID
50
/gram lung while mice of group 2, vaccinated 
with adjuvanted subunits, had significantly higher virus titers with an average of 
106.5 (p=0.025), which was similar to that observed in naïve mice infected with IAV 
IND/05 virus (group 4) or those that were vaccinated against, but not infected 
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with IAV HK/68 virus (group 5). Mice unsuccessfully vaccinated against IAV HK/68 
infection with adjuvant or subunits only also displayed lower lung viral titers (groups 
6 and 7). 
Induction of CD8+ T cell responses p.i. with IAV IND/05 (H5N1)
Four and seven days p.i. infection with IAV IND/05, splenocytes were stained for 
intracellular IFN-g after incubation with peptides NP
IND
 and PA
IND
. Four days p.i., no 
virus-specific CD8+ T cell responses were detected in any of the IAV IND/05 infected 
mice . However, seven days p.i, anamnestic NP
IND 
and PA
IND
 specific IFN-g+CD8+ 
T-cell responses were observed in mice from group 3, which were significantly lower 
in mice effectively vaccinated against IAV HK/68 (group 2)  (p=0.038 and p=0.002 
respectively) (figure 3D)
Histopathology and detection of infected cells after infection with IAV IND/05 (H5N1)
On day four p.i. with IAV IND/05, mice developed a multifocal severe subacute 
necrotizing bronchopneumonia, of which the severity was similar for all 
experimental groups. However, seven days p.i. there were marked differences 
between the groups. The mock-vaccinated mice or those vaccinated with adjuvant 
only prior to infection with IAV HK/68 had a multifocal moderate chronic necrotizing 
bronchopneumonia characterized by a perivascular core of lymphocytes and plasma 
cells, proliferation of bronchiolar epithelium and hyperplasia of pneumocytes with a 
type II appearance. In contrast, mice of groups 4, 5 and especially group 2 had more 
severe lung pathology characterized by a multifocal to coalescing severe subacute 
necrotizing bronchopneumonia.  
In general, the extent of lung histopathology and the lung virus titers after infection 
with IAV IND/05 correlated with the presence of virus-infected cells in the lungs 
as determined by immunohistochemistry. Four days p.i., virus-infected cells were 
detected in all IAV IND/05 infected mice. In contrast, seven days p.i., antigen 
positive cells were found sporadically in lungs of mice of groups 3 (figures 4C-D) and 
7 (figures 4I-J), whereas in the lungs of mice from group 2 (figures 4A-B), 4 (figures 
4E-F) and 5 (figures 4G-H) virus-infected cells were still abundantly present. 
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Figure 4 Histopathological analysis and immunohistochemistry of the lungs of mice infected with IAV 
IND/05. Mouse lung sections were stained for influenza A virus nucleoprotein. Cytoplasm of infected 
cells stain red, the nuclei of infected cells stain deep red. In the groups without a history of productive 
A/H3N2 infection, including group 2 (A,B), infection with IAV IND/05 led to severe histopathological 
changes and to viral antigen expression in cells of the bronchiolar walls and in the alveoli (group 4: E,F 
and group 5: G,H). In mice of groups 3 (C,D) and 7 (I,J) that had experienced a productive infection 
with IAV HK/68 only moderate histopathological changes were observed and virus infected cells were 
detected sporadically (see insert in panel D). For more information please see text. (full colour figure: 
APPENDIX V)
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Discussion
Here we demonstrate that successful vaccination of mice against human IAV 
HK/68 (H3N2) prevented the induction of heterosubtypic immunity against a lethal 
challenge with IAV IND/05 (H5N1). As a result, H3N2 vaccinated mice had a fatal 
clinical outcome of infection with IAV IND/05, associated with higher virus titers and 
more severe histopathological lesions in the lungs seven days p.i. and reduced virus-
specific CD8+ T cell responses compared to mice that experienced a productive, 
self-limiting infection with IAV HK/68. It has been well established that infection 
with IAV can induce a certain degree of protective immunity against infection with 
an heterosubtypic strain of IAV, which was already recognized more than 40 years 
ago[240]. This so-called heterosubtypic immunity was not only demonstrated in 
animal models[216, 234, 240, 244] but there is also direct and indirect evidence that 
it exists in humans[67, 71] and that cell-mediated immune responses contribute to 
this type of immunity (for review see[247]).
To test the hypothesis that successful immunization against seasonal influenza 
could interfere with the induction of heterosubtypic immunity, mice were vaccinated 
with an Alum-adjuvanted subunit vaccine. The use of an adjuvant was necessary 
since vaccination with subunit alone induced detectable antibody responses in a 
small proportion of mice only and would not provide a useful model for successful 
vaccination against seasonal influenza. Indeed, all mice vaccinated with Alum alone 
and most mice vaccinated with subunits alone were not protected against infection 
with A/H3N2 virus. In contrast, all mice vaccinated with adjuvanted subunits, were 
fully protected against infection with IAV HK/68. This prevented the induction of 
heterosubtypic immunity against infection with IAV IND/05 normally seen in mice 
that had experienced a productive IAV HK/68 infection. The severity of the clinical 
signs and histopathological lesions, the extent of weight loss, lung virus titers and 
mortality rates of these mice was comparable of those that were immunologically 
naïve prior to infection with IAV IND/05 (group 4) or that were vaccinated against 
IAV HK/68 virus, but not subsequently infected with IAV HK/68 virus (group 5). 
Four weeks after infection with IAV HK/68 virus, the number of virus-specific CD8+ 
T cells in the spleen was significantly lower in mice vaccinated against IAV HK/68 
than in unvaccinated mice. The differences were not observed at earlier time points 
p.i.. Further evaluation of the CD8+ TmHK+ T cells indicated that the numbers of 
CD62Lhigh and CD127+ cells were higher in unvaccinated mice than in vaccinated 
mice on day 28 p.i. (data not shown). This may indicate that the control of IAV HK/68 
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replication in the lungs had prevented the efficient induction of virus-specific central 
and effector memory CD8+ T cell responses. These results resemble those found in 
a mouse model for Listeria monocytogenes infection, in which shortening of the 
duration of the infectious period did not impact the size of the primary CD8+ T cell 
response, but diminished the memory population of CD8+ T cells[269].  The analysis 
of the CD8+ T cells responses seven days after challenge infection with IAV IND/05 
further indicated that indeed prior vaccination against HK/68 (H3N2) prevented 
the efficient induction of memory CTL responses. Both the secondary response to 
the NP
IND
 and the PA
IND 
epitope were reduced compared to the responses observed 
in un-vaccinated mice. Although it has been described that the NP
366-374 
is more 
immunodominant than the PA
224-233 
epitope in secondary CTL responses[223], a 
stronger response was observed against the PA
224-233
 epitope after infection with IAV 
IND/05. This could be explained by the lower cross-reactivity of CTL directed to the 
NP
366-374
 epitope derived from IAV HK/68 (ASNENMDAM) with that derived from 
IAV IND/05 virus (ASNENMEVM) compared to the cross-reactivity  of CTL specific 
for the PA
224-233 
epitope as was observed after the analysis of the CTL measured 
by tetramerstaining p.i. with IAV HK/68 and  IND/05 (data not shown). Apart from 
systemic CTL responses measured in the spleen also local CTL responses may 
contribute to protective immune responses, such as in the draining lymph nodes 
and in the lung tissue itself[257, 270]. Since the frequency of virus-specific CD8+ T 
cells in the spleen reflected that in the lymph nodes[232, 271] , we analysed CTL 
responses in the spleen only. It was of interest to note that infection with IAV HK/68 
resulted in the formation of iBALT structures. Prior vaccination against IAV HK/68 
infection prevented the formation of iBALT completely. iBALT consists mainly of 
B cells, T cells and dendritic cells and it has been shown that mice with iBALT but 
without peripheral lymphoid organs can clear virus infection[272]. Also in humans, 
T cells specific for viral respiratory pathogens have been detected in lung tissue 
and may play a protective role against subsequent infections in this species as 
well[258].  Although no IAV IND/05 cross-reactive antibodies were detected by VN 
or HI assay on the day of challenge infection, it is possible that infection with IAV 
HK/68 induced M2 specific antibodies that potentially cross-reacted with the M2 
protein of IAV IND/05. However it is unlikely that these antibodies accounted for the 
heterosubtypic immunity induced by primary infection with IAV HK/68[237, 254].
Thus prior infection with seasonal influenza viruses, which generally results in a 
self-limiting upper respiratory tract infection, may afford at least partial protection 
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against potentially pandemic heterosubtypic influenza virus strains. At present 
vaccination against seasonal influenza is recommended for all healthy children 6-59 
months of age in a number of countries, including the USA[266]. Also in Europe 
vaccination of children is currently considered and a number of countries already 
decided to recommend vaccination of healthy children[273]. Although vaccination 
is (cost-) effective in this age group[274-278], it may interfere with the induction of 
heterosubtypic immunity against potentially pandemic strains of a novel subtype, 
e.g. H5N1, by creating an immunological “blind spot”. Furthermore, the use of 
adjuvants is considered to increase vaccine efficacy in young children[279]. Thus 
during a next pandemic, especially children that received the annual flu-shot would 
be at higher risk to develop severe illness and a fatal outcome of the disease than 
those that experienced an infection with a seasonal IAV strain. This of course, would 
be of great concern and is supported by the data obtained in our mouse model. 
Ideally, seasonal influenza vaccines are used that also induce heterosubtypic 
immunity[219, 268]. More research is required in this field to define vaccine 
preparations that not only induce protective immunity against seasonal influenza, 
but also induce heterosubtypic immunity. With the current pandemic threat caused 
by A/H5N1 viruses this would be highly desirable[195].
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Abstract
Since the number of human cases of infection with avian H5N1 influenza viruses 
is ever increasing, a pandemic outbreak caused by these viruses is feared. 
Therefore, in addition to virus-specific antibodies, there is considerable interest 
in immune correlates of protection against these viruses, which could be a target 
for the development of more universal vaccines. After infection with seasonal 
influenza A viruses of the H3N2 and H1N1 subtypes, individuals develop virus-
specific cytotoxic T lymphocyte responses, which are mainly directed against 
the relatively conserved internal proteins of the virus, like the nucleoprotein 
(NP). Virus-specific cytotoxic T lymphocytes (CTL) are known to contribute to 
protective immunity against infection but knowledge about the extent of cross-
reactivity with avian H5N1 influenza viruses is sparse. In the present study, we 
evaluated the cross-reactivity with H5N1 influenza viruses of polyclonal CTL 
obtained from a group of well-defined HLA-typed study subjects. To this end, 
the recognition of synthetic peptides representing H5N1 analogues of known 
CTL epitopes was studied. In addition, the ability of CTL specific for seasonal 
H3N2 influenza virus to recognize the NP of H5N1 influenza virus or H5N1 virus-
infected cells was tested. It was concluded that, apart from some individual 
epitopes that displayed amino acid variation between H3N2 and H5N1 influenza 
viruses, considerable cross-reactivity exists with H5N1 viruses. This pre-existing 
cross-reactive T cell immunity in the human population may dampen the impact 
of a next pandemic. 
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Introduction
Since the first documentation of bird-to-human transmissions of highly pathogenic 
avian H5N1 influenza viruses these viruses have spread from South East Asia to 
other regions of the world [44-46, 283]. Since 2003 the number of human cases 
continues to increase, as of December 18 2007, 340 human cases have been 
reported of which 209 were fatal [284]. It is feared that the H5N1 virus may cause 
the next influenza pandemic when they are able to replicate in mammalian species 
by adaptation through genetic reassortment or accumulation of point mutations 
in relevant gene segments [285]. Although neuraminidase subtype 1 crossreactive 
antibodies have been demonstrated in human subjects, antibodies to H5 molecules 
are hardly existent in the human population as a result of limited exposure to H5N1 
viruses which contributes to a scenario for these viruses to become pandemic [197]. 
In general, the exposure history and the immune status of the human population 
will influence the size and the severity of pandemics [67, 70, 71, 73]. The presence of 
T cell immunity induced by infection with human influenza virus strains may provide 
some degree of cross-protective immunity against the H5N1 viruses. CTL responses 
are predominantly directed to internal viral proteins, the nucleoprotein (NP) in 
particular [65, 286], which is much more conserved than the surface glycoproteins 
HA and NA [65, 212, 287, 288]. It has been suggested that cross-reactive CD8+ 
T cells may temper the impact on the human population a pandemic potentially 
could have [67, 73, 289]. In humans, the presence of cross-reactive CTL responses 
inversely correlated with the amount of shedding of a heterosubtypic strain that 
was used for experimental infection of study subjects [67]. Although pre-existing 
CTL immunity against influenza virus may be of importance in the face of the current 
H5N1 pandemic threat, our knowledge on the cross-reactive nature of the human 
CTL response is limited [73]. 
In the present study we tested the cross-reactivity of polyclonal virus specific CD8+ 
T cell populations obtained from well-defined HLA-typed study subjects with H5N1 
virus. The recognition of target cells pulsed with peptide variants, transfected with 
the nucleoprotein gene from a human or an avian influenza virus, or infected with 
viruses of the H3N2 or H5N1 subtype was tested, respectively.
It was concluded that the human CTL response displays a high degree of cross-
reactivity with avian H5N1 influenza viruses and could reduce morbidity and 
mortality during a pandemic caused by these H5N1 strains.
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Material & Methods
Cells
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
blood obtained from fifteen HLA-typed healthy blood donors (Sanquin 
Bloodbank, Rotterdam, the Netherlands) by density gradient centrifugation using 
lymphoprep (Axis-Shield PoC AS, Oslo, Norway) and then cryopreserved at -135°C. 
Genetic subtyping was performed in the laboratory for Histocompatibility and 
Immunogenetics at the Sanquin Bloodbank using a commercial typing system 
(Genovision, Vienna, Austria). Three groups of study subjects were selected on 
basis of their MHC class I alleles, for which influenza CTL epitopes were identified. 
Within groups the subjects shared identical HLA-A and B alleles, between groups 
one, or two alleles differed: group I: HLA A*0101, A*0201, B*0801, B*3501, group 
II: HLA A*0101, A*0201, B*0801, B*2705 (2702) and group III: HLA A*0101, A*0301, 
B*0801, B*3501 (3503) [68]. Subject #15 was not tested since PBMC of this donor 
were no longer available.
Peptides
Amino acid sequences of all known human influenza A virus CTL epitopes were 
compared with their counterparts in H5N1 influenza viruses, isolated since 2003, 
which were obtained from the influenza sequence database [290]. All possible 
variants that could be identified in the H5N1 sequences are listed in table 1. A set 
of immunograde peptides, representing immunodominant CTL epitopes and the 
most prevalent analogues in H5N1 strains were synthesized, analyzed by mass 
spectrometry and were >70% pure (Eurogentec, Seraing, Belgium). Variant peptide 
analogues from the NP, which is the main target for CTL responses, were synthesized 
when they had a prevalence in H5N1 strains of >0.25%, with the exception of the 
NP383-391 epitope since the G384K mutation observed in H5N1 viruses was known 
to abrogate recognition by specific CTL completely [291]. For the remaining viral 
proteins all variants with a prevalence of >2.25% were synthesized and tested. Only 
peptides were considered that match the HLA-alleles of the study subjects.
Target cells
B-lymphoblastoid cell lines (BLCL) were established as described previously 
[162] and used as target or stimulator cells. Thirty thousand cells were incubated 
in the absence or presence of 10mM peptide for one hour at 37°C, washed once 
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and resuspended in RPMI 1640 medium (Cambrex, East Rutherford, NJ, USA) 
containing antibiotics, L-glutamine and 10% FCS (R10F). Cells of the BLCL were 
also infected at a multiplicity of infection (MOI) of five TCID50/cell [228] with 
influenza viruses A/Netherlands/18/94 (A/NL/18/94)(H3N2) or A/Vietnam/1194/04 
(A/VN/1194/04)(H5N1) which were propagated and titrated in MDCK cells using 
standard procedures. After an incubation period of one hour at 37°C, the cells were 
washed and resuspended in R10F and incubated for 16-18 hours at 37°C prior to 
their use for the stimulation of CD8+ T cells. Infection rates were determined by an 
immunofluorescence assay and were similar for both viruses (data not shown). The 
human influenza virus A/Netherlands/18/94 (H3N2) was used as a representative of 
seasonal influenza viruses, whilst influenza virus A/Vietnam/1194/04 was used as an 
example for H5N1 influenza virus.
T cell clones
CD8+ T cell clones directed against the HLA-A1 restricted NP
44-52
 CTELKLSDY 
epitope, HLA-A3 restricted NP
265-273
 ILRGSVAHK epitope, HLA-B27 restricted NP
174-
184
 RRSGAAGAAVK epitope and the HLA-B*3501 restricted NP
418-426
 LPFEKSTVM 
epitope were generated as described previously [291].
In vitro expansion of influenza A virus specific T cell populations
PBMC were stimulated with influenza virus A/NL/18/94 infected cells as previously 
described [68]. Eight days after stimulation cells were harvested and used as effector 
cells in the ELIspot- or FATT-CTL assays. For the ELIspot assays CD8+ T cells were 
purified from the in vitro expanded PBMC by MACSÒ bead sorting (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Typically a purity of >96% was obtained.
Fluorescent-antigen-transfected target cell (FATT) – CTL assay
The NP genes of influenza viruses A/NL/18/94 and A/VN/1194/04 without their 
stopcodons were cloned into the plasmid pEGFP-N1 (Becton Dickinson, Alphen 
a/d Rijn, the Netherlands) in frame with the ORF of the green fluorescent protein 
(GFP) as previously described [292]. Plasmid DNA was purified using the Genopure 
plasmid midi kit (Roche, Woerden, the Netherlands). Nucleotide sequences of 
the recombinant plasmids were confirmed using a Big Dye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems). Primer and plasmid sequences are available 
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on request.
The plasmids were used in the FATT-CTL assay for the detection of lytic activity of 
virus specific CTL as described previously [292]. In brief, BLCL were nucleofectedâ 
using cell line nucleofector® kit V (Amaxa Biosystems, Cologne, Germany) with 
program T16 and subsequently incubated in R10F for four hours at 37°C. Then they 
were co-cultured for another four hous in triplicate with PBMC cultures, in vitro 
expanded after stimulation with influenza virus A/NL/18/94, at various E:T ratios. 
The number of viable GFP positive cells was measured using a FACSCalibur (Becton 
Dickinson). The % nucleoprotein specific lysis was then calculated by the following 
formula: 100*((viable GFP-positive cells in sample without effector – viable GFP-
positive cells in sample with effector)/viable GFP+ cells in sample without effector).
Figure 1 The presence of known CTL epitopes in H5N1 strains. The percentage of H5N1 viruses with 
an epitope sequence identical to human influenza viruses (white bars) is shown in Figure 1. The 
black bars indicate the percentage of H5N1 viruses with one or more amino acid substitutions in the 
epitope sequence. The absolute numbers of each variant of an epitope are shown in Figure 1B, each 
color represents a single variant (sequences can be found in table 1). For this analysis almost 900 
H5N1 viruses were analyzed for which sequence information was available in the influenza sequence 
database [290]. (full colour figure: APPENDIX VI)
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IFN-gamma assay
ELIspot assays were performed with in vitro expanded CD8+ T cells as effector cells 
and peptide-pulsed or virus-infected HLA-matched BLCL as stimulator cells as 
described previously [68]. The number of spots was determined using an ELIspot 
reader and image analysis software (Aelvis, Sanquin Reagents, Amsterdam, the 
Netherlands) and the average number was calculated of triplicate wells.
Results
Comparison of amino acid sequences of known influenza A virus CTL epitopes
The amino acid sequences of known human influenza A virus CTL epitopes were 
compared with the corresponding sequences in approximately 900 H5N1 viruses 
obtained from the influenza sequence database [290]. As shown in Figure 1A, the 
epitope sequences were identical in >95% of the H5N1 viruses for the majority of 
the known epitopes analyzed including PB1
591-599
, M1
13-21
, M1
128-135
, NS1
158-160
, NP
44-
52
, NP
146-154
, NP
174-184
, NP
265-273
, NP
380-388, 
NP
381-388
 and NP
383-391
. For some of the other 
epitopes the percentage of H5N1 viruses with identical sequences was variable and 
ranged from 79% for epitope M1
58-66
, to 4% for epitope NS1
122-130
. For the epitopes 
NP
91-99
, NP
188-198
, NP
339-347 
and NP
418-426
, no identical sequences were found in the 
H5N1 viruses. In order to identify the most prevalent variant sequences in H5N1 
viruses the number of individual variants was analyzed (Figure 1B). 
In some cases a single variant was identified that accounted for almost all variant 
sequences observed in H5N1 viruses (Table 1, Figure 1B). For other epitopes multiple 
variants were identified, although for some of these the number was low and the 
number of major variants was limited [290]. 
The recognition of known CTL epitopes and their avian analogues
All subjects in group I (HLA A*0101, A*0201, B*0801, B*3501) displayed T cell 
reactivity with the epitopes NP
44-52
, NS1
122-130
, NP
418-426 
and M1
58-66 
as they are 
present in human influenza A viruses, although the frequency of specific CTL varied 
between study subjects and the peptides tested (Figure 2A). In none of the subjects 
of this group reactivity was observed with the peptide variants of epitopes NP
44-
52
 and NS1
122-130
, obtained from H5N1 influenza viruses. Three out of four subjects 
responded to the NP
418-426
 variant LPFERSTIM and all subjects responded to the 
M1
58-66 
variant GMLGFVFTL. Of group II (HLA A*0101, A*0201, B*0801, B*2705 
(2702)) most subjects responded to the peptides representing epitopes from 
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human influenza A viruses (Figure 2B), although the magnitudes of the responses 
varied considerably. Only one subject in this group had an appreciable response 
to the H5N1 analogue sequence of the NS1
122-130
 epitope. Four out of five subjects 
responded to the H5N1 variants of the HLA B*2705 restricted NP
174-184
 epitope 
whereas all five of them responded to the M1
58-66 
variant. The subjects of group III 
(HLA A*0101, A*0301, B*0801, B*3501 (3503)) responded to the original epitopes 
to variable extent.
Some subjects were poor responders and hardly displayed CTL reactivity with some 
of these epitopes (Figure 2C). However the in vitro expanded  PBMC of subject #14 
responded strongly to the NP
418-426
 and also reacted with both epitope variants from 
H5N1 viruses indicating that at least a fraction of the CTL population was capable of 
cross-recognizing these analogues. The same holds true for the NP
44-52
- and NP
265-
273
-specific CTL response in this study subject. Clones were used as positive and 
negative controls and the clonal responses supported the results obtained with the 
polyclonal populations (data not shown).
Cross-recognition of the NP derived from influenza virus A/VN/1194/04
The capacity of polyclonal T cell populations directed to the human influenza virus 
A/NL/18/94 to cross-react with the NP of influenza virus A/VN/1194/04 was assessed 
Figure 2 Epitope-specific IFN-gamma production by CTL after stimulation with peptide-pulsed BLCL. 
The number of IFN-gamma producing cells per 10,000 CD8+ T cells (5,000 cells for subject #3) from 
subjects from group I: HLA A*0101, A*0201, B*0801, B*3501 (A), group II: HLA A*0101, A*0201, 
B*0801, B*2705 (2702) (B) and group III: HLA A*0101, A*0301, B*0801, B*3501 (3503) (C) were 
measured by ELIspot assay. CD8+ T cells were isolated from PBMC populations expanded in vitro with 
influenza virus A/NL/18/94 and subsequently stimulated with peptide variants as indicated. (*= peptide 
sequence of the known human influenza virus CTL epitopes). 
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in the FATT-CTL assay. PBMC from all study subjects were stimulated with influenza 
virus A/NL/18/94 and allowed to proliferate. As shown in Figure 3, two out of the 
fifteen subjects tested (#5 and #8) were low- or non-responders (Figure 3), since no 
NP-specific lytic activity could be demonstrated. In the remaining thirteen subjects 
lytic activity was observed against the homologous NP. In most cases the PBMC 
cross-reacted with the NP of influenza virus A/VN/1194/04 to a considerable extend 
(Figure3). 
Figure 3 Recognition of NP derived from H3N2 and H5N1 influenza virus by in vitro expanded PBMC 
specific for influenza virus A/NL/18/94 (H3N2). The lytic activity of in vitro expanded PBMC was tested 
with MHC class I matched BLCL nucleofectedÒ with NP-GFP coding plasmid (NP of either influenza 
virus A/NL/18/94 (black dots) or A/VN/1194/04 (white dots) ) or empty GFP plasmid (grey dots). This 
was tested for the subjects from group I (subjects 1-4), II (subjects 5-9) and III (subjects 10-14 and 16). 
E:T ratios were 0, 3.125, 6.25, 12.5, 25, and 50 respectively. For subject #13 and #14 the E:T ratios were 
0, 0.3, 1, 3, 10 and 30 respectively. The lytic activity against control-plasmid transfected target cells is 
not visible for subjects 13 and 14 as a result of negative values for the percentage of specific lysis, which 
was caused by a slight increase of GFP+ viable cells. Standard deviation of the means was 10%. 
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Only for subject #3 (group I) and subject #9 (group III) the influenza virus A/NL/18/94 
NP-specific CTL failed to recognize the NP of influenza virus A/VN/1194/04 (Figure 
3). 
Cross-recognition of BLCL infected with influenza virus A/VN/1194/04
Next we wished to assess the cross-reactive nature of the whole repertoire of CD8+ 
T lymphocytes specific for the human influenza virus A/NL/18/94. To this end, PBMC 
were stimulated with this virus and after eight days the CD8+ cells were isolated to 
obtain virus-specific polyclonal CTL populations. These cells were used as effector 
cells in an IFN-gamma ELIspot assay using MHC class I-matched BLCL infected with 
influenza virus A/NL/18/94 or A/VN/1194/04 as stimulator cells.
As shown in Figure 4, the in vitro expanded PBMC population that recognized 
cells infected with influenza virus A/NL/18/94, also recognized cells infected with 
influenza virus A/VN/1194/04 . The average number of IFN-gamma spots per 104 
cells observed after stimulation with A/NL/18/94 infected cells was 151 (SD=58) and 
the number observed after stimulation with A/VN/1194/04 was even slightly higher 
at 192 (SD=65) , although this difference was not statistically significant.
Figure 4 Recognition of influenza virus infected BLCL by CTL. The number of IFN-gamma producing 
cells per 10,000 CD8+ T cells was measured by ELIspot assay after stimulation with BLCL infected 
with influenza virus A/NL/18/94 or A/VN/1194/04. Each symbol represents an individual subject either 
from group I (A), II (B) or III (C). Uninfected BLCL were used as negative controls. The horizontal bars 
represent the average response of all study subjects in group I, II and III.
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Discussion
In the present paper the cross-reactive nature of the human influenza virus-specific 
CTL response was investigated. It was concluded that a considerable portion of 
CTL populations specific for the H3N2 influenza virus A/NL/18/94 cross-reacted 
with the H5N1 strain A/VN/1194/04. For most CTL epitopes, it was found that a vast 
majority of the H5N1 strains contained identical epitope sequences as those present 
in human influenza A viruses. This conservation of epitopes is responsible for the 
cross-reactive nature of CTL responses in humans against seasonal influenza A 
viruses of the H3N2 and H1N1 subtypes. However, some variation in these epitopes 
was observed also and for a number of CTL epitopes the H5N1 strains did not 
contain identical sequences. Apart from the NP
174-184
 and M1
58-66 
epitope restricted by 
HLA-B*2705 and HLA-A*0201 respectively, very little cross-reaction was observed 
of polyclonal CTL populations with variant peptides derived from H5N1 viruses. 
However, as indicated above most epitopes are relatively conserved including those 
located in the NP which contributed to the cross-reactive nature of the NP-specific 
CTL response. Most of the study subjects that responded to NP derived from 
seasonal H3N2 influenza viruses also responded to the NP derived from influenza 
virus A/VN/1194/04 (H5N1). The polyclonal virus-specific T cell populations of two 
of these subjects failed however to cross-react with the NP of influenza virus A/
VN/1194/04 for unclear reasons. Possibly the most immunodominant responses in 
these subjects were directed to CTL epitopes in the NP that were not conserved.
To account for the full repertoire of virus-specific CD8+ T lymphocytes also the 
reactivity with MHC class I-matched cells infected with influenza virus A/NL/18/94 
or A/VN/1194/04 was analyzed. In all cases A/VN/1194/04 infected target cells were 
recognized to a similar extent as A/NL/18/94-infected cells, indicating that the level 
of cross-reactivity of human CTL responses to seasonal H3N2 influenza viruses with 
H5N1 strains is substantial.
Thus apart from some individual epitopes that display amino acid sequence 
variation between H3N2 and H5N1 influenza A viruses, the level of cross-reactivity is 
considerable and does not seem to be influenced by the HLA-phenotype of the study 
subjects. Although it is unknown to what extent pre-existing T cell-immunity can 
dampen the impact of a next influenza pandemic, it is speculated that the protective 
effect of cross-reactive CTL responses has a beneficial effect on the outcome of 
infection with new pandemic influenza virus strains. This speculation is supported by 
a number of different observations. First, in animal models it has been shown that 
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virus-specific CTL contribute to heterosubtypic immunity [200, 216, 232], secondly 
it was found in 1957 that individuals that had experienced documented infections 
with H1N1 influenza A viruses, less likely developed severe disease or succumbed 
to infection with the pandemic strain of the H2N2 subtype [71].  In this respect it is 
of interest to note that during the current outbreak of H5N1 infections in humans 
especially younger individuals are at risk for severe disease and a fatal outcome of 
infection [259]. It can be hypothesized that younger individuals are less likely to have 
been exposed to seasonal influenza A viruses of the H3N2 and H1N1 subtype and 
thus have not mounted a (cross-reactive) CTL response to an alternative subtype. 
However, it cannot be excluded that confounding factors play a role in the observed 
disproportionate age distribution of severe H5N1 human cases. Last but not least, 
the human CTL response against epidemic strains is largely cross-reactive with H5N1 
influenza virus strains as was demonstrated in the present study. Although these 
cross-reactive CTL populations may not prevent infection with pandemic strains, 
they may contribute to a certain degree of heterosubtypic immunity and facilitate a 
more rapid clearance of the infection than in immunologically naïve individuals who 
lack cross-reactive T cell populations. This may determine the difference between 
life and death during a pandemic outbreak. In addition, the induction of cross-
reactive CTL responses may be an attractive target for the development of universal 
vaccines that could confer broadly protective immunity against influenza viruses of 
various subtypes. 
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Abstract
Since 2003, the number of human cases of infections with highly pathogenic 
avian influenza  viruses of the H5N1-subtype is still increasing and therefore the 
development of safe and effective vaccines is considered a priority. However, the 
global production capacity of conventional vaccines is limited and insufficient 
for a worldwide vaccination campaign. In the present study an alternative H5N1 
vaccine candidate, based on the replication deficient modified vaccinia virus 
Ankara (MVA) was evaluated. C57BL/6J mice were immunized twice with MVA 
expressing the HA-gene from influenza virus A/Hongkong/156/97 (MVA-HA-
HK/97) or A/Vietnam/1194/04 (MVA-HA-VN/04). Subsequently, recombinant 
MVA-induced protective immunity was assessed after challenge infection 
with three antigenically distinct strains of H5N1 influenza viruses: A/Hong 
Kong/156/97, A/Vietnam/1194/04 and A/Indonesia/5/05. Our data suggest that 
recombinant MVA expressing the HA of influenza virus A/Vietnam/1194/04 is a 
promising alternative vaccine candidate that could be used for the induction of 
protective immunity against various H5N1 influenza strains.
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Introduction
Since the first human cases of H5N1-infections in 1997, influenza viruses of 
this subtype caused outbreaks of avian influenza worldwide associated with an 
accumulating number of bird-to-human transmissions. As of November 19th, 258 
human cases were recorded of which 154 proved to be fatal [293]. In addition, the 
H5N1 virus infections have spread from South-East Asia to other continents [294].
Since these viruses not only infect avian species but also various mammalian species 
[25-27, 295] including humans [15] there is a risk of the emergence of a new pandemic 
strain, either through adaptation of the avian viruses to replication in mammalian 
species or through the exchange of gene segments with normal epidemic influenza 
A viruses.  For these reasons the development of effective and safe H5N1 vaccines is 
considered a priority [296].
However, the development of such vaccines and the production of sufficient 
quantities of vaccine doses is not straight forward: at present the combined vaccine 
production capacity of all manufacturers is not sufficient to timely provide for 
a worldwide vaccination campaign. There is a clear need for alternative vaccine 
delivery systems and production technologies that could help to overcome this 
problem.
Since different antigenically distinct clades of H5N1 viruses have been identified 
recently [296], an ideal vaccine would also induce cross-protective immunity against 
these antigenic variants. Recently, conventional inactivated vaccine preparations 
have been evaluated, such as whole-inactivated virus (WIV) and split-virion vaccines 
[78, 143, 152]. In addition, vaccines based on recombinant HA expressed by 
baculoviruses have been tested [116, 117, 124]. In immunologically naïve individuals 
these vaccines were poorly immunogenic and appreciable antibody responses were 
only induced when high doses, or a combination with an adjuvant such as alum was 
used [78, 143, 152]. Clearly, additional development efforts are urgently needed 
to overcome a catastrophic shortage of vaccine in the case of a H5N1 influenza 
pandemic. New promising influenza vaccine candidates include recombinant DNA-
based vaccines and adenoviral vector vaccines [167, 176, 177, 297]. However, the 
efficacy of these experimental vaccines in humans still needs to be confirmed, and 
at present, they are not considered widely acceptable for use in human populations 
[297].
In the present study we evaluated another candidate vector vaccine based on a 
replication deficient poxvirus vaccine strain: modified vaccinia virus Ankara (MVA). 
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MVA has been tested originally in >120,000 individuals and proved to  be a safe 
and effective vaccine against human smallpox [183]. More recently, recombinant 
MVA expressing foreign genes proved successful in evoking immune responses 
and providing protection against diseases caused by viruses, bacteria, parasites or 
tumors from which the antigens were derived [182, 188, 191, 298-301].
The advantages of using MVA vector vaccines include their established safety profile 
in humans, their efficacy upon delivery of heterologous antigens in clinical trials, and 
the availability of technologies for large scale production under the requirements 
of Good Manufacturing Practice (GMP) [189, 191, 300]. Other properties are: good 
immunogenicity, extreme host-range restriction, possibility of long term storage 
(stockpiling) and easy production at BSL-1 conditions in chicken embryo fibroblasts 
(CEF) and baby hamster kidney cells [181, 184, 186, 188, 191, 302]. 
Here we describe the construction and evaluation of two different recombinant 
MVA viruses expressing the HA-genes of H5N1 influenza viruses A/Hongkong/156/97 
(A/HK/156/97) or A/Vietnam/1194/04 (A/VN/1194/04). These recombinant viruses 
were evaluated as vaccines in a mouse model to assess the induction of protective 
immunity against three different H5N1 viruses. A two-dose immunization regimen 
induced strong antibody responses that partially cross-reacted with heterologous 
H5N1-strains. The elicited antibody responses correlated with protection against 
challenge infection with homologous and heterologous influenza virus strains. 
Thus, MVA can be considered as a promising alternative vaccine candidate for the 
induction of protective immunity against H5N1 influenza viruses. 
Material and Methods
Vaccine preparation
The influenza H5N1 viruses A/HK/156/97 and A/VN/1194/04 were propagated in 
Madin Darby Canine Kidney (MDCK) cells and the viral RNA was extracted from the 
culture supernatants using a RNA-isolation kit (Roche, Almere, the Netherlands). 
Subsequently, cDNA was synthesized from the vRNA using Superscript reverse-
transcriptase (Invitrogen, Carlsbad, California, USA) and the AGCAAAAGCAGG 
oligonucleotide (Eurogentec, Seraing, Belgium) as primer. Next, the HA-genes 
were amplified by PCR using Pfu (Stratagene, La Jolla, California, USA) as heat-
stable DNA polymerase. Primer sequences were extended with the NotI and XhoI 
restriction sites to facilitate directional cloning into the plasmid pBluescriptSK+ 
(Stratagene, La Jolla, California, USA). Primer sequences are available on request. 
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Subsequently, HA gene sequences were excised from these plasmids by NotI /XhoI 
digestion, treated with Klenow polymerase to generate blunt ends and cloned into 
the PmeI site of MVA expression plasmid pIIIdHR-PsynII to generate the MVA vector 
plasmids pIII-HA-HK/97 and pIII-HA-VN/04. Upon transfection in MVA-infected cells 
these plasmids direct insertion of foreign genes into the site of deletion III within 
the MVA genome (31) and allow transcription of the HA target genes under control 
of the vaccinia virus-specific promoter PsynII [302]. Recombinant viruses MVA-HA-
HK/97 and MVA-HA-VN/04 were generated in primary CEF upon transfection with 1 
µg plasmid DNA, infection with 0.05 infectious units / cell MVA isolate F6 (32), and by 
plaque selection on RK-13 cells (29). The recombinant MVA genomes were analyzed 
by PCR to verify HA gene insertion and genetic stability. The production of HA 
antigens by the MVA vector viruses was confirmed by Western blot analysis of CEF 
cell lysates harvested at various time points after infection with MVA-HA-HK/97 or 
MVA-HA-VN/04 (data not shown). One-step and multiple-step growth analysis in CEF 
demonstrated that the replication capacities of MVA-HA-HK/97 and MVA-HA-VN/04 
were comparable to non-recombinant MVA (data not shown). To generate vaccine 
preparations the viruses were amplified in CEF, purified by ultra-centrifugation 
through sucrose and reconstituted in 1 mM Tris/HCl pH 9.0. MVA vaccines were 
used at a dose of 108 PFU diluted in 100µl PBS. Whole-inactivated NIBRG-14 virus, 
a re-assortant vaccine strain based on influenza virus A/Vietnam/1194/04 made by 
reverse genetics was used as positive control. The lyophilised whole-virus antigen 
was reconstituted in distilled water at a concentration of 2µg HA/50µl and mixed 1:1 
with the adjuvant Stimune® (Specol, Cedi-Diagnostics, Lelystad, the Netherlands) 
[303]. Control mice were inoculated with PBS.
Influenza viruses
Influenza viruses A/HK/156/97, A/VN/1194/04 and A/Indonesia/5/05 (A/IND/5/05) 
were grown on MDCK cells. The supernatant was harvested after 3 days. Infectious 
virus titers were determined in Madin Darby Canine Kidney (MDCK) cells as 
described previously [228].
Mice
Female specified pathogen-free 6-8 weeks old C57BL/6J mice were purchased from 
Charles River  (Sulzfeld, Germany). Animals were divided in five groups of 18 mice 
and immunized with PBS, MVA-HA-HK/97, MVA-HA-VN/04, wtMVA, or Stimune®-
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adjuvanted NIBRG-14. Immunizations were performed intra-muscularly, 50ml in the 
left hind leg and 50ml in the right. Four weeks later, blood samples were collected 
and animals were immunized again as described above. After another four weeks, 
again blood samples were collected and each of the five vaccine groups was divided 
into three sub-groups of six animals each. The sub-groups of each vaccine group 
were inoculated with 103 TCID
50
 of influenza virus A/HK/156/97, A/VN/1194/04 or A/
IND/5/05 in 50ml PBS by the intranasal route. A challenge dose of 103 TCID
50
 of the 
respective H5N1 viruses was used since this resulted in the infection and significant 
loss of body weight in > 90% of the mice reproducibly. Six non-immunized animals 
were used as negative controls and were inoculated with 50ml PBS. Animals were 
weighed every day until day 4 after infection and then euthanized by exsanguinations. 
After euthanasia, brain, lungs (inflated with formalin), spleen and intestines were 
taken out.. 
Animals in all groups were properly age-matched at the time point of challenge 
infection. The experimental protocol was approved by an independent Animal ethics 
committee prior to the start of the experiment. Intra-muscular immunizations, 
intranasal infections, blood sampling and euthanasia were carried out under 
anesthesia with inhalative isoflurane. The animals were housed in filter-top cages 
and had access to food and water ad libitum. During the 5 days of infection with the 
H5N1 influenza virus, animals were placed in filter-top cages in bio-safety level 3 
containment facilities. One BSL-3 isolator unit was used per virus.
Virus titers in organ tissues
Organs were snap frozen using a dry ice/ethanol bath and stored at -70°C. 
Organs were homogenized with a Polytron homogenizer (Kinematica AG, Littau-
Lucerne, Switzerland) in transport medium (Hanks medium (MEM)), Glycerol, 
100U/ml penicillin, 100mg/ml streptomycin, polymyxin B, Nystatin, Gentamicin). 
Quintuplicate ten-fold serial dilutions of these samples were used to determine the 
virus titers on confluent layers of MDCK cells.
Serology
After treatment with cholera filtrate and heat-inactivation at 56°C, the sera were 
tested for the presence of anti-HA antibodies. For this purpose a hemagglutination 
inhibition assay (HI) was used following a standard protocol using 1% turkey 
erythrocytes and four HA-units of either influenza virus A/HK/156/97, A/VN/1194/04 
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or A/IND/5/05 [229]. For this purpose reverse genetics viruses were produced from 
which the basic cleavage site was removed. The use of these reverse genetics viruses 
was validated and titers obtained were comparable with those against the wild type 
strains (data not shown). Sera were also tested for the presence of virus neutralizing 
antibodies specific for the three influenza viruses using a micro virus neutralization 
(VN) assay with 100 TCID
50
 of the respective viruses that were produced by reverse 
genetics as described above [230]. Hyper-immune serum obtained from a swan 
immunized twice with inactivated H5N2 influenza virus A/Duck/Potsdam/1402/86 
(Intervet, Boxmeer, the Netherlands) was used as a positive control against the 3 
different influenza A viruses. 
Histopathology
Formalin-inflated lungs were fixed in 10% neutral buffered formalin, embedded in 
paraffin, sectioned at 4mm and stained with hematoxylin and eosin for histological 
evaluation. Sequential slides were stained using an immunoperoxidase method 
method with a monoclonal antibody (Clone HB65 IgG2a (American Type Culture 
Collection)) directed against the nucleoprotein of influenza A virus. A Goat-anti-
mouse IgG2a HRP (Southern Biotech, Birmingham, Alabama, USA) was used as 
the secondary antibody. The peroxidase was revealed using diamino-benzidine as 
a substrate, resulting in a deep red precipitate in the nuclei of influenza A virus-
infected cells and a less intense red-staining of the cytoplasm. The sections were 
counterstained with hematoxylin. 
Statistical analysis
Data for viral titers and antibody titers were analyzed using the two-sided Student’s 
t test and differences were considered significant at P < 0.05.
Results
Serology
Upon a single vaccination with MVA-HA-HK/97 mice developed antibody responses 
against the homologous virus strain with geometric mean titers (GMTs) of 1629 and 
239 measured in HI- and VN-assays, respectively. These antibodies however, did not 
cross-react with the influenza virus strains A/VN/1194/04 or A/IND/5/05 (Figure 1). 
Four weeks after the booster vaccination the homologous antibody GMTs in the HI- 
and VN-assays were 1370 and 744, respectively. 
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Again no cross-reaction was observed with the other H5N1 strains. The MVA-HA-
VN/04 vaccine preparation was less immunogenic, since after the first vaccination 
none of the mice developed HI antibodies against the homologous strain and only 
one animal developed VN antibodies. After a second dose all animals responded and 
the GMT increased to 20 and 64 as measured by HI- and VN-assays, respectively. 
The antibodies induced by MVA-HA-VN/04 vaccination cross-reacted with the 
H5N1 strain A/HK/156/97 and to a limited extent with the strain A/IND/5/05. The 
adjuvanted NIBRG-14 vaccine preparation, which was included in the experiments 
as a positive control induced robust antibody responses against the homologous A/
VN/1194/04, which cross-reacted with the strain A/HK/156/97 and A/IND/5/05 both 
in the HI- and VN-assays.
Clinical signs
From day two post-infection onwards, mice immunized with PBS or wtMVA 
developed clinical signs like hunched posture, rapid breathing, ruffled fur and 
decreased muscle strength irrespective of the influenza H5N1 virus that was used 
for infection. These clinical signs were not observed in mice infected with influenza 
virus A/HK/156/97 or A/VN/1194/04 after vaccination with MVA-HA-HK/97 or MVA-
Figure 1 Antibody responses induced by vaccination. Antibody titers against the three challenge 
viruses: influenza virus A/HK156/97 (     ), A/VN/1194/04 (     ) and A/IND/5/05 (     ) were measured by HI-assay (A+B). 28 days after the first immunization (A) and 28 days after the second immunization 
(B). Titers are presented as GMT (Log 2). Antibody titers against the three different challenge-viruses 
were measured by VN-assay (C+D). 28 days after the first immunization (C) and second immunization 
(D). Titers are presented as GMT (Log 2). 
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HA-VN/04. MVA-HA-VN/04 vaccination also prevented the development of clinical 
signs caused by infection with influenza virus A/IND/5/05. The observed protection 
against clinical signs correlated with reduced loss of bodyweight after infection 
(Figure 2). In PBS and wtMVA immunized mice an average loss of bodyweight of 
16.2% and 11.5% was observed post infection with influenza virus A/HK/156/97 
(Figure 2A) or 16.9% and 10.4% post infection with influenza virus A/VN/1194/04 
(Figure 2B), respectively. This was largely prevented by vaccination with MVA-HA-
HK/97 or MVA-HA-VN/04 (Figure 2). Also infection with influenza virus A/IND/5/05 
(Figure 2C) caused severe loss of bodyweight in PBS- or wtMVA-immunized control 
mice (16.9% and 18.6% respectively), which was significantly reduced by vaccination 
with MVA-HA-VN/04 but not by vaccination with MVA-HA-HK/97.
Virus replication in organs
Infectious virus titers were determined in brains, intestines, lungs and spleens on 
day 4 post-infection with influenza viruses A/HK/156/97 (Figure 3A), A/VN/1194/04 
(Figure 3B) or A/IND/5/05 (Figure 3C). After infection, the highest virus replication 
was observed in the lungs with average lung virus titers of 107.9, 107.8 and 108.9 TCID50/
gram tissue for PBS control mice infected with influenza viruses A/HK/156/97, A/
VN/1194/04 or A/IND/5/05 respectively. Mice vaccinated with wtMVA were not 
protected and similar average virus titers were found in the lungs of infected mice. 
In some animals of both groups virus replication could be demonstrated in extra-
respiratory tissues including brain, intestines and spleen (Table 1). Vaccination with 
MVA-HA-HK/97 prevented replication of influenza virus A/HK/156/97 in the lungs 
and other organs completely whereas with MVA-HA-VN/04 vaccination a reduction 
Viruses used for challenge infection
A/HK/156/97 A/VN/1194/04 A/IND/5/05
Vaccine 
preparations
brain
intestines
lung
spleen
>10%
weight
loss
brain
intestines
lung
spleen
>10%
weight
loss
brain
intestines
lung
spleen
10%
weight
loss
wtMVA 1/6 1/6 6/6 4/6 5/6 2/6 0/6 6/6 3/6 4/6 2/6 2/6 6/6 4/6 5/6
MVA-HA-HK/97 0/4 0/4 0/4 0/4 0/4 0/6 1/6 6/6 1/6 1/6 0/6 0/6 6/6 0/6 4/6
MVA-HA-VN/04 2/6 0/6 2/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 2/6 0/6 0/6
NIBRG-14 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6
PBS 0/5 0/5 5/5  3/5 4/5 3/5 2/5 5/5 3/5 5/5 0/6 3/6 6/6 4/6 6/6
Group numbers < 6 are caused by fatalities due to causes not related to the experiment.
Table 1. Positive virus isolation from tissues and weight loss in individual mice after 
challenge infection
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of virus replication in the lungs was observed in four out of six mice.
After challenge infection with influenza virus A/VN/1194/04 it was the other way 
around: vaccination with MVA-HA-VN/04 prevented replication completely, 
whereas vaccination with MVA-HA-HK/97 only partially reduced virus replication. 
This reduction was statistically significant compared to PBS-inoculated mice (p < 
0.05). 
Vaccination with MVA-HA-VN/04 also prevented replication of influenza virus A/
IND/5/05 in the lungs of four out of six mice resulting in reduced average lungs titers 
compared to PBS- and wtMVA-immunized control mice. Vaccination with MVA-
HA-HK/97 did not prevent replication of influenza virus A/IND/5/05 and all six mice 
tested positive (Table 1). Vaccination with the inactivated whole-virus NIBRG-14 
adjuvanted with Stimune® not only prevented replication of the homologous strain 
influenza virus A/VN/1194/04 but also that of A/HK/156/97 and A/IND/5/05.
Pathologic changes and virus replication in the lungs
Four days after infection with each of the three HPAI viruses, the mice were sacrificed 
and their lungs were inflated with formalin and examined by immunohistochemistry 
and histology. For all three viruses, viral antigen expression and lesions depended on 
type of prior immunization. In mice immunized with adjuvanted NIBRG-14, neither 
viral antigen expression nor lesions were observed after infection with any of the 
three viruses (Figure 4D, I, N). After infection with influenza virus A/HK/156/97, 
PBS- and wtMVA-immunized mice had multifocal expression of viral antigen in 
bronchiolar and alveolar epithelial cells. 
Figure 2 Weight loss of mice intra-nasally infected with 103 TCID50 of influenza virus A/HK156/97 (A), 
A/VN/1194/04 (B), or A/ IND/5/05 (C). Mean weight loss is expressed as the percentage of the original 
weight before infection. (*) Indicates a statistically significant difference with (p < 0.05). 
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This was associated with mild necrotizing bronchiolitis, characterized by necrosis 
of bronchiolar epithelial cells and peribronchiolar infiltration by inflammatory cells, 
mainly lymphocytes (Figure 4A, E). 
In contrast, MVA-HA-HK/97 and MVA-HA-VN/04 immunized mice showed neither 
viral antigen expression nor lesions. After infection with influenza virus A/VN/1194/04, 
PBS- and wtMVA-immunized mice had more widespread expression of viral 
antigen in bronchiolar and alveolar epithelium than in A/HK/156/97-inoculated mice 
(Figure 4F, J). This was associated with moderate bronchiolitis and mild interstitial 
pneumonia, characterized by loss of alveolar epithelium and the presence of edema 
fluid and inflammatory cells (mainly neutrophils) in alveolar lumina. MVA-HA-
HK/97-immunized mice appeared to have less viral antigen expression in alveolar 
epithelium than wtMVA- and PBS-immunized mice, but the extent of interstitial 
pneumonia was comparable (Figure 4G). Again, MVA-HA-VN/04 immunized mice 
showed neither viral antigen expression nor lesions (Figure 4H).
After infection with influenza virus A/IND/5/05, not only PBS- and wtMVA-immunized 
mice but also MVA-HA-HK/97-immunized mice had widespread expression of viral 
antigen in bronchiolar and alveolar epithelium (Figure 4K, O, L), associated with 
moderate bronchiolitis and moderate interstitial pneumonia. In contrast, MVA-
HA-VN/04 immunized mice only had viral antigen expression in a few bronchiolar 
epithelial cells, associated with moderate bronchiolitis (Figure 4M).
Figure 3 Virus titers in organ tissue at day 4 after infection with either influenza virus A/HK156/97 (A), 
A/VN/1194/04 (B), or A/ IND/5/05 (C). Results are shown for the wtMVA, MVA-HA-HK/97, MVA-HA-
VN/04, Stimune®-adjuvanted NIBRG-14 and PBS immunized mice. Titers were measured in: brain 
(     ), intestines (     ), lungs (     ) and spleen (     ) and presented as TCID50 per gram tissue (Log10). (*) Indicates an average virus titer below the cut-off value and that all animals tested negative by virus 
isolation.
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Figure 4 Histopathology and immunohistochemistry of the bronchioles and alveoli in lungs of mice 
infected with either influenza virus A/HK/157/97, A/VN/1194/04 or A/ IND/5/05 as indicated. Influenza 
virus A/HK/156/97 infection led to viral antigen expression in cells of the bronchiolar wall of PBS (A) 
and wtMVA immunized mice (E), combined with mild peribronchiolar inflammatory infiltrate, while 
in the lungs of MVA-HA-HK/97 (B), MVA-HA-VN/04 (C) and Stimune®-adjuvanted NIBRG-14 (D) 
immunized mice no viral antigen was detected. Infection with influenza virus A/VN/1194/04 resulted 
in expression of viral antigen in cells of the bronchiolar walls of PBS (F), MVA-HA-HK/97 (G) and 
wtMVA (J) immunized mice, also combined with moderate peribronchiolar infiltrate (except for the 
wtMVA immunized mice). No viral antigen expression or morphological changes were detected in 
MVA-HA-VN/04 (H) and Stimune®-adjuvanted NIBRG-14 immunized mice (I). Infection with influenza 
virus A/IND/5/05 resulted in abundant viral antigen expression in the bronchioles of PBS (K), MVA-
HA-HK/97 (L) and wtMVA (O) immunized mice, combined with moderate peribronchiolar infiltrate. 
Only minimal viral antigen expression was detected in the bronchiolar wall of MVA-HA-VN/04 (M) 
immunized mice, combined with moderate inflammatory infiltrate. No viral antigen was detected in 
the lungs of Stimune®-adjuvanted NIBRG-14 (N) immunized mice after infection with influenza virus 
A/Indonesia/5/05. (full colour figure: APPENDIX VII)
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Discussion
In the light of the pandemic threat caused by influenza H5N1 viruses, the availability 
of sufficient doses of safe and effective vaccines is considered a priority [293, 296]. 
In the present study we have evaluated recombinant MVA expressing the HA genes 
of two different influenza H5N1 viruses for the induction of protective immunity 
against three different influenza H5N1 viruses belonging to two different clades 
[211] in a mouse model. Vaccination with MVA expressing the HA of influenza H5N1 
viruses induced potent antibody responses, which correlated with protection against 
homologous and heterologous challenge infection. For the generation of the MVA 
recombinants, the HA genes were derived from influenza viruses A/HK/156/97 and 
A/VN/1194/04. The co-circulation of antigenically different influenza virus strains 
complicates the development of effective vaccines considerably. Usually protective 
immunity is only induced with vaccines that closely match the circulating strains. 
The viruses used in the present study belong to distinct clades of H5N1 viruses [94, 
211] and are antigenically different [211]. This allowed the assessment of the level 
of cross-protective immunity induced by vaccination against these two viruses. 
Furthermore a third H5N1 variant strain was used for challenge infection of the 
mice: A/IND/5/05, which was antigenically distinct from the other two viruses [296].
The recombinant MVA-HA-HK/97 was highly immunogenic. A single immunization 
already induced antibody responses against influenza virus A/HK/156/97, which 
were further boosted by a second immunization. These antibodies were not cross-
reactive in HI- and VN-assays with A/VN/1194/04 or A/IND/5/05. MVA-HA-VN/04 
was less immunogenic, but after two immunizations good antibody responses were 
observed, not only against the homologous virus but also to A/HK/156/97 and to a 
lesser extent to A/IND/5/05. The observed antibody reactivity pattern is similar to 
that observed with post-infection ferret sera [296]. Thus this asymmetry in antibody 
recognition pattern observed with antibodies induced by MVA-HA vaccination 
resembled that observed with antibodies induced after infection with the original 
influenza viruses [296].The NIBRG-14 vaccine preparation was included in the 
experiments as a positive control and was highly immunogenic in combination 
with the Stimune® adjuvant. This combination not only induced strong antibody 
responses to the homologous influenza virus A/VN/1194/04 but also to the other 
two H5N1 strains.
The HI- and VN-antibody titers measured against the three H5N1 strains correlated 
with protection against challenge infection. The MVA-HA-HK/97 immunized 
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mice were only protected against a homologous challenge infection. Vaccination 
prevented virus replication completely and as a result neither histo-pathological 
changes nor clinical signs were observed in these mice. Although the MVA-HA-HK/97 
induced antibodies did not cross-react with influenza virus A/VN/1194/04, replication 
of this virus was reduced and the immunized animals were protected from clinical 
signs (Table 1). In contrast, no protective effects were seen upon challenge infection 
with influenza virus A/IND/5/05. Although it is known that MVA-vaccination can 
induce strong CTL responses which could have contributed to protection [304], it 
is unknown at present whether H-2b restricted cross-reactive CTL epitopes exist 
on the HA molecule of influenza H5N1 viruses. Immunization with MVA-HA-VN/04 
induced sterilizing immunity against the homologous strain. In addition, strong 
protective effects were observed against the antigenically distinct influenza viruses 
A/HK/156/97 and A/IND/5/05. The replication of these viruses was largely reduced in 
most immunized animals, which correlated with the absence of infected cells in the 
respiratory tract and the lack of clinical signs.
The protection is most likely based on virus-neutralizing HA-specific serum 
antibodies that pass from the circulation into the alveolar epithelium [305]. Thus 
the use of MVA-HA as a candidate vaccine against emerging pandemic H5N1 strains 
has the potential to induce a broad immune response that protects individuals from 
severe clinical signs and histopathological changes in the respiratory tract even when 
the strains causing the infections do not fully match the vaccine antigen. In addition, 
MVA-based vaccines have a number of properties that make them favorable 
vaccine candidates for use in humans. First, recombinant MVA can be considered 
as extremely safe viral vectors because of their distinct replication deficiency in 
mammalian cells and their well established avirulence in vivo [188, 299, 300, 306-308] 
including the safety of MVA in immune-suppressed macaques [187] or the innocuous 
application of high doses of recombinant MVA to HIV-infected individuals [300, 
309, 310]. Second industrial scale manufacturing of MVA vaccines appears feasible 
in recognition of the efforts undertaken to develop MVA as a third generation 
vaccine against orthopoxvirus-related biothreat [311]. Third, MVA vector vaccines 
can deliver multiple heterologous antigens and allow for simultaneous induction of 
high level humoral and cellular immunity [190, 191, 300] providing the possibility to 
develop multivalent vaccines. Since the production of these MVA-based vaccines 
is independent of existing production capacity for conventional influenza vaccines, 
it may help to reduce the envisaged shortage of vaccine doses in the time of an 
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emerging pandemic. Another advantage is that the excellent immunogenicity of 
these vaccines is independent of the use of adjuvants. We acknowledge that the use 
of a safe and effective adjuvant could improve the immunogenicity of conventional 
vaccines and may reduce the antigen quantity required to induce adequate 
antibody responses (dose sparing). Our results with the Stimune®-adjuvanted 
NIBRG-14 whole-inactivated virus underscores this possibility. However, at present 
such potent adjuvant formulations are not considered suitable for use in humans. 
We conclude that MVA-based H5N1 vaccines are promising vaccine candidates with 
favorable properties regarding safety, effectiveness and the potential of rapid large-
scale production, which are important in the face of an emerging pandemic.
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Abstract
Highly pathogenic avian influenza viruses of the H5N1 subtype are responsible 
for an increasing number of infections in humans since 2003. More than 60% of 
the infected individuals succumb and new infections are reported frequently. In 
the light of the pandemic threat caused by these events the rapid availability 
of safe and effective vaccines is desirable. Modified Vaccinia virus Ankara (MVA) 
expressing the HA gene of H5N1 viruses is a promising candidate vaccine 
that induced protective immunity against infection with homologous and 
heterologous H5N1 influenza virus in mice. 
In the present study we evaluated a recombinant MVA vector expressing the 
HA of H5N1 influenza virus A/Vietnam/1194/04 (MVA-HA-VN/04) in non-human 
primates. Cynomolgus macaques were immunized twice and then challenged 
with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) 
to assess the level of protective immunity. Immunization with MVA-HA-VN/04 
induced (cross-reactive) antibodies and prevented virus replication in the upper 
and lower respiratory tract and the development of severe necrotizing broncho-
interstitial pneumonia. Therefore MVA-HA-VN/04 is a promising vaccine 
candidate for the induction of protective immunity against highly pathogenic 
H5N1 avian influenza viruses in man.
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Abstract
Highly pathogenic avian influenza viruses of the H5N1 subtype are responsible 
for an increasing number of infections in humans since 2003. More than 60% of 
the infected individuals succumb and new infections are reported frequently. In 
the light of the pandemic threat caused by these events the rapid availability 
of safe and effective vaccines is desirable. Modified Vaccinia virus Ankara (MVA) 
expressing the HA gene of H5N1 viruses is a promising candidate vaccine that 
induced protective immunity against infection with homologous and heterologous 
H5N1 influenza virus in mice. In the present study we evaluated a recombinant 
MVA vector expressing the HA of H5N1 influenza virus A/Vietnam/1194/04 (MVA-
HA-VN/04) in non-human primates. Cynomolgus macaques were immunized 
twice and then challenged with influenza virus A/Vietnam/1194/04 (clade 1) 
or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity. 
Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and 
prevented virus replication in the upper and lower respiratory tract and the 
development of severe necrotizing broncho-interstitial pneumonia. Therefore 
MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective 
immunity against highly pathogenic H5N1 avian influenza viruses in man.
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Introduction
Since 2003 the number of bird-to-human transmissions of H5N1 influenza viruses 
is increasing and as of the 28nd of February 2008, 369 human cases were reported 
to the World Health Organization of which 234 proved to be fatal [312]. Thus there 
is a risk for the emergence of a pandemic H5N1 strain either through adaption 
of the avian viruses to replication in humans or through the exchange of gene 
segments with seasonal influenza A viruses. To limit the impact of a pandemic 
outbreak caused by these viruses the expedite availability of safe and effective 
H5N1 vaccines is highly desirable [313]. However, the development of such vaccines 
and the production of sufficient vaccine doses for a global vaccination campaign 
is a challenge: the combined vaccine production capacity of all seasonal influenza 
vaccine manufacturers is limited and not sufficient to timely provide sufficient doses 
for a worldwide vaccination campaign. Therefore, there is considerable interest in 
dose-sparing vaccination strategies. For example, the use of potent adjuvants may 
result in a reduction of the amount of hemagglutinin (HA) antigen, required for the 
induction of protective antibody responses. At present, various adjuvants are being 
evaluated in combination with conventional inactivated vaccine preparations and 
these are in various stages of development [141, 142, 156, 158, 314]. 
Alternatively, novel vaccine production technologies are under development to 
overcome the shortage of vaccines in the case of an H5N1-influenza pandemic. Cell 
lines have become available for the production of vaccines as alternative for the 
conventional production in embryonated chicken eggs [100, 106, 113, 315-317]. The 
use of reverse genetics for the generation of vaccine strains will further contribute 
to faster availability of vaccines after the onset of a influenza pandemic [318, 319]. 
Other novel production technologies include the use of recombinant baculoviruses 
for the production of H5 in insect cells [116, 117, 124]. In general, these protein-
based vaccines are poorly immunogenic in immunologically naïve individuals 
and appreciable antibody responses were only induced when a high dose or a 
combination with an adjuvant was used [78, 143, 152]. Since 1997, H5N1 viruses have 
diverged considerably and are now classified into clades and subclades to reflect 
their phylogenetic and antigenic differences [313]. These differences complicate 
vaccine strain selection and ideally vaccines induce cross-clade protective immunity. 
New promising influenza vaccine candidates that may fulfil the described 
requirements include DNA vaccines and viral vectors that express the HA gene of 
H5N1 influenza viruses [176, 177, 297]. We recently have shown that the replication 
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deficient poxvirus modified vaccinia virus Ankara (MVA) expressing the HA gene 
of influenza virus A/Vietnam/1194/04 (H5N1) is highly immunogenic in mice [251]. 
Two immunizations without an adjuvant induced strong antibody responses and 
immunized mice were protected from infection with the homologous virus and 
the heterologous  H5N1 virus A/Indonesia/5/05 [251]. MVA was tested originally in 
>120,000 individuals and proved to be a safe and effective vaccine against small pox 
[183]. The use of recombinant MVA expressing foreign genes as vaccine candidates 
induced protective immunity against diseases caused by viruses, bacteria, parasites 
or tumors from which the antigens were derived. Thus, MVA has an excellent 
safety profile in humans, can be used for the delivery of foreign antigens and can 
be produced at large scale under the requirements of good manufacturing practice 
[189, 191]. Other properties are extreme host-range restriction, easy production at 
biosafety level 1 (BSL-1) conditions in chicken embryo fibroblasts (CEF) and baby 
hamster kidney cells and the possibility of long-term storage (stock piling) [181, 184, 
186, 188, 191]. 
For reasons outlined above, MVA expressing the HA gene of an H5N1 influenza 
virus is an attractive and promising pandemic vaccine candidate. However, the 
immunogenicity and protective efficacy of such vaccines has been demonstrated 
in mice and chickens only [190, 251, 320]. Since the predictive value of these 
models for immunogenicity in humans is limited [320, 321], we wished to evaluate 
a recombinant MVA-H5 vaccine candidate in a non-human primate model to assess 
the induction of protective immunity against H5N1 viruses from two different 
clades. Therefore, we used cynomolgus macaques that develop severe interstitial 
necrotizing pneumonia after infection with H5N1 influenza virus comparable to 
the pathogenesis observed in humans [282, 322]. To this end, a recombinant MVA 
expressing the HA gene of influenza virus A/Vietnam/1194/04 was used to immunize 
cynomolgus macaques twice, which resulted in strong influenza H5 specific, virus 
neutralizing antibody responses. 
Thus-induced immunity provided protection against challenge infection with the 
homologous influenza H5N1 strain from clade 1 and the heterologous strain A/
Indonesia/5/05 from clade 2.1. It was concluded that recombinant MVA is a safe and 
effective vaccine candidate for the induction of protective immunity against H5N1 
influenza viruses and warrants further clinical development.
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Material & Methods
Vaccine preparation
Recombinant MVA expressing the HA gene of influenza virus A/Vietnam/1194/04 
(MVA-HA-VN/04) was prepared as described previously [251]. As parent MVA strain 
MVA clonal isolate F6 was used. To generate final vaccine preparations, the virus 
was amplified in CEF, purified by ultracentrifugation through sucrose, reconstituted 
in 1mM Tris-HCL pH 9.0 and diluted in PBS. 
Influenza viruses
Influenza viruses A/Vietnam/1194/04 (A/VN/1194/04) and A/Indonesia/5/05 (A/
IND/5/05) were cultured in Madin Darby Canine Kidney (MDCK) cells. Infectious 
virus titers were determined in MDCK cells as described previously [228].
Macaques
Colony-bred sero-negative cynomolgus macaques (Macaca fascicularis), 3 years of 
age, were obtained from Grand Forest Scientific Primate Company LTD (Guangxi, 
China). Two weeks prior to the start of the experiment animals were anesthesized 
using a cocktail of ketamin® (Nimatek, Eurovet Animal Health BV, Bladel, the 
Netherlands) and domitor® (Orion Pharma, Espoo, Finland) and a temperature 
logger (DST micro-T ultra small temperature logger, Star-Oddi, Reykjavik, Iceland) 
was placed in the peritoneal cavity. This device recorded the body temperature of 
the animals every 15 minutes. Changes in body temperature were calculated by 
substracting the mean day (4 hours) and night (4 hours) temperature measured on 
4 successive days in the period prior to the challenge from the mean day (4 hours) 
and night temperatures (4 hours) post infection. This was done for each individual 
animal. 
The macaques were immunized twice with a four week interval and received 108.5 
pfu MVA-HA-VN/04 (n=12), 108.5 pfu wtMVA (empty vector control)(n=12) or PBS 
(n=10) intramuscularly in a volume of one ml divided over both legs. Blood samples 
were collected before immunization and four weeks after the first and second 
immunizations. Four weeks after the second immunization each vaccine group was 
divided into two groups of six animals (except for the PBS group that was divided 
in groups of four and six animals respectively) and placed into BSL-3 isolator units. 
The animals were anesthesized and inoculated intratracheally with influenza virus 
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A/VN/1194/04 or A/IND/5/05 at a dose of 1*106 TCID
50
 in 3 ml PBS. After infection, 
the animals were monitored for the development of clinical signs. Before and on 
days 2 and 4 post infection throat and nose swabs were collected under anesthesia. 
Four days post infection the animals were sacrificed by exsanguination under 
anesthesia with ketamin® and dormitor® and necropsies were performed according 
to standard procedures. This time point for euthanasia was chosen since it allowed 
the assessment of gross pathology and histopathology, and the extent of virus 
replication. It was also chosen for ethical reasons since the development of severe 
disease in the non-protected animals was avoided. The experimental protocol 
was approved by an independent animal ethics committee before the start of the 
experiments and performed compliant with National and European legislation.
Serology
After treatment with cholera filtrate and heat-inactivation at 56°C, the sera were 
tested for the presence of anti-HA antibodies. For this purpose a hemagglutination 
inhibition assay (HI) was used following a standard protocol using 1% turkey 
erythrocytes and four HA-units of either influenza virus A/VN/1194/04 or A/IND/5/05 
[229]. For this purpose viruses were produced from which the basic cleavage site 
in HA, associated with high virulence, was deleted by reverse genetics. The use 
of these reverse genetics viruses in the HI assay was validated and the obtained 
antibody titers were comparable with those against the wild type strains (data 
not shown). Sera were also tested for the presence of virus neutralizing antibodies 
specific for the two influenza viruses using a micro virus neutralization (VN) assay 
with the viruses that were produced by reverse genetics as described above [230]. 
In brief, 50 microliter volumes of serial diluted serum samples were incubated with 
100 TCID50 of the viruses for one hour at 37°C and then the mixture was added to 
MDCK cells. After one hour, the cells were washed and subsequently cultured in 
Eagles Minimal Essential Medium containing bovine serum albumin (BSA, fraction 
V 0.3%), 4mg/ml trypsin, L-glutamin 2mM, penicillin 100U/ml, streptomycin 100mg/
ml  NaHCO
3
 0.15%, Hepes 20mM, non-essential amino acids 0.1 mM. After five 
days, residual virus replication was assessed by measuring HA activity in the culture 
supernatants. Hyper-immune serum obtained from a swan immunized twice with 
inactivated H5N2 influenza virus A/Duck/Potsdam/1402/86 (Nobilis influenza® 
H5N2 Intervet International, Boxmeer, the Netherlands) was used as a positive 
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control against the two influenza viruses. For calculation purposes serum samples 
with an antibody titer of <10 were arbitrarily assigned a titer of 5. 
Virus titers in organ tissues
Tissue samples were snap-frozen using a dry ice/ethanol bath and stored at -70°C. 
The tissues were homogenized with a Polytron homogenizer (Kinematica AG, Littau-
Lucerne, Switzerland) in transport medium (Hanks medium (MEM) containing: 
10% Glycerol, 100U/ml penicillin, 100mg/ml streptomycin, polymyxin B, Nystatin, 
Gentamicin, 7,5% NaHCO3, 1M Hepes). Quintuplicate ten-fold serial dilutions of 
these samples were used to determine the virus titers in confluent layers of MDCK 
cells. 
Histopathology and immunohistochemistry
Formalin-inflated lungs were fixed in 10% neutral buffered formalin and then cross-
sections were made and embedded in paraffin, sectioned at 4 mm and stained with 
hematoxylin and eosin for histologic evaluation. Sequential slides were stained 
using an immunoperoxidase method with a monoclonal antibody (Clone HB65 
IgG2a (American Type Culture Collection)) directed against the nucleoprotein of 
influenza A virus. A Goat-anti-mouse IgG2a HRP (Southern Biotech, Birmingham, 
Alabama, USA) was used as secondary antibody. The peroxidase was revealed using 
diamino-benzidine as a substrate, resulting in a deep red precipitate in the nuclei of 
influenza virus-infected cells and a less intense red-staining of the cytoplasm. The 
sections were counterstained with hematoxylin. 
Results
Vaccine induced antibody responses
In order to assess the ability of the MVA-HA-VN/04 vaccine to induce antibody 
responses, HI and VN serum antibody titers were measured after one and two 
immunizations. After the first immunization the MVA-HA-VN/04 immunized 
animals developed antibody responses against influenza virus A/VN/1194/04 with 
geometric mean titers of 20.9 (seven out of twelve animals) and 8.5 (four out of 
twelve animals) measured in the HI and VN assay respectively (Fig 1A, B). All animals 
(n=12) had developed an antibody response after the second immunization and the 
mean HI titer to this virus increased to 207.6 and the mean VN titer to 156.2 (Fig 
1A, B). Antibody responses directed to influenza virus A/IND/5/05 HA were detected 
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in two out of twelve animals with a geometric mean titer of 6.9 in the HI assay, 
four weeks after the first immunization (Fig 1A). After the boost immunization four 
animals had detectable antibody responses with geometric mean HI and VN titers of 
8.9 and 8.2 respectively (Fig 1A, B). None of the PBS or wtMVA immunized animals 
developed antibody responses against influenza virus A/VN/1194/04 or A/IND/5/05.
Clinical signs after infection
Before the start of the experiment a telemetric transponder was implanted in the 
abdominal cavity of every animal to record body temperature during the course 
of the experiment. The body temperature of every animal followed a strict day-
night cycle during the experiment. Administration of the MVA-HA-VN/04 vaccine 
preparation did not affect the cycle and the mean day and night body temperatures 
(data not shown). After infection with influenza virus A/VN/1194/04 all animals 
in the PBS group and 5 out of six animals in the wtMVA group developed a fever 
within the first day (Figure 2A, B, G, H, J, K) with average body temperatures of 
38.6°C and 38.8°C for the PBS and wtMVA immunized animals respectively during 
the subsequent twenty-four hours. The mean body temperature did not decline to 
the base level on day 3 and 4 in the PBS and wtMVA immunized group respectively 
(Fig G, H). Following infection with influenza virus A/IND/5/05 the animals in the 
PBS and wtMVA immunized group developed average fevers of 39.1°C and 38.9°C 
respectively (Figure 2D, E, M, N, P, Q).
Figure 1 Antibody responses induced by immunization with MVA-HA-VN/04. Antibody titers against 
two H5N1 influenza viruses: A/Vietnam/1194/04 (black bars) and A/Indonesia/5/05 (grey bars) were 
measured in a hemagglutination inhibition (HI) assay (A) and virus neutralization (VN) assay (B) 28 
days after the first and second immunization. Data are geometric mean titers (GMTs).  
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Figure 2 Body temperature recorded before and after infection with influenza virus A/Vietnam/1194/04 
(A-C) or A/Indonesia/5/05 (D-F). The animals were immunized with PBS, wtMVA or MVA-HA-VN/04 as 
indicated. Changes in body temperature of individual animals after infection with influenza virus A/
Vietnam/1194/04 (G-L) or A/Indonesia/5/05 (M-R) were calculated for each individual animal. Each dot 
represents an individual animal. Line colors in Figure 2A-C correspond with dot colors in figure 2G-L. 
Line colors in Figure 2D-F correspond with dot colors in figure 2M-R. (full colour figure: APPENDIX VIII)
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The mean body temperature of these animals remained elevated, mainly during the 
night, in the four-day-period after infection (Fig 2M, N). The body temperature in the 
MVA-HA-VN/04 immunized animals maintained its day-night cycle and remained 
normal after infection with influenza virus A/VN/1194/04 (Fig 2C) except for a small 
rise during day 1 and the following night (Fig 2I, L).After infection with influenza 
virus A/IND/5/05 body temperature and day-night cycle were normal (Fig 2F, O, R).
Figure 3 Virus titers in the throat after infection with an H5N1 influenza virus. Virus titers were 
determined in  throat swaps that were taken on day 2 (black bars) and 4 (white bars) after infection 
with influenza virus A/Vietnam/1194/04 (A) or A/Indonesia/5/05 (B). Titers are presented as TCID
50
 per 
ml (log
10
). (*All animals tested negative by virus isolation resulting in an average virus titers below the 
cut-off value)
Figure 4 Virus titers in the lungs after infection with H5N1 influenza viruses. Virus titers were determined 
on day 4 after infection in the lungs of animals that were infected with either A/Vietnam/1194/04 (black 
bars) or A/Indonesia/5/05 (grey bars). Virus titers are presented as TCID
50
 per gram lung (log
10
). (*All 
animals tested negative by virus isolation resulting an average virus titers below the cut-off value.)
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Virus detection in the upper respiratory tract
In order to determine the virus titers in the upper respiratory tract, nose and throat 
swabs were collected on day 0, 2 and 4 after infection. On day 2 after infection with 
influenza virus A/VN/1194/04 throat swaps were positive for all animals in the PBS 
group and five out of six animals in the wtMVA group with mean titers of 102.9 (SD=100. 
8) and 102.4 (SD=101.1) respectively (Fig 3A). The titers were lower on day 4 in both the 
PBS group (two out of four animals were positive) and in the wtMVA group (one 
positive animal) with geometric mean titers of 101.2 (SD=100.8) and 100.7 (SD=100.6) 
respectively. After infection with influenza virus A/IND/5/05 the titers were slightly 
higher for all animals in the PBS and wtMVA group with mean titers on day 2 of 103.4 
(SD=100.7) and 102.6 (SD=100.2) respectively (Fig 3B). On day 4 the titers had declined 
to 101.9 (SD=101.6) (three animals positive) in the PBS group and 101.4 (SD=101.8)(two 
animals positive) in the wtMVA group. Virus was not detectable in the throat of the 
MVA-HA-VN/04 immunized animals neither on day 2 or 4 after infection with either 
the homologous or heterologous virus (Fig 3A, B). The nose swaps were negative for 
all animals in both challenge groups and on both days (data not shown).
Figure 5 Macroscopic lesions of the lungs after infection with H5N1 influenza virus. The lungs of animals 
immunized with PBS (A, D), wtMVA (B, E) or MVA-HA-VN/04 (C, F) were fixed in formalin on day 4 after 
infection with influenza virus A/Vietnam/1194/04 (A-C) or A/Indonesia/5/05 (D-F). The arrows indicate 
consolidated areas present in the lungs of PBS and wtMVA immunized animals after infection (A, B, D, 
E). Lungs from the MVA-HA-VN/04 immunized animals had no macroscopical lesions (C, F). (full colour 
figure: APPENDIX IX)
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Virus detection in organs
Lungs, brain and spleen were tested for the presence of infectious virus on day 4 
after infection. Virus was detectable in the lungs of all animals in the PBS and wtMVA 
groups infected with influenza virus A/VN/1194/04 (Fig 4) with mean titers of 105.0 
(SD=100.5) and 104.9 (SD=100.7) TCID
50
/gram tissue respectively. After infection with 
influenza virus A/IND/5/05 higher infectious virus titers were detected in the animals 
that received PBS or wtMVA with mean titers of 105.8 (SD=101.1) and 105.8 (SD=101.2) 
TCID50/gram tissue respectively. In the lungs of MVA-HA-VN/04 immunized animals 
no virus was detected regardless the virus that was used for infection (Fig 4). No 
virus was detected in the brain or spleen obtained from any of the animals.
Pathology in the lungs
Lungs were dissected and inflated with formalin on day 4 after infection to examine 
pathology. Macroscopically multifocal to coalescing consolidation characterized 
by depressed, dark red and firm areas was seen in the PBS and wtMVA immunized 
animals after infection with either of the two H5N1 influenza viruses (Figure 5A, B, 
Figure 6 Histopathologic analysis of the lungs on day 4 after infection with influenza virus A/
Vietnam/1194/04 (A, B, C) or A/Indonesia/5/05 (D, E, F). Histopathological changes were comparable 
in PBS and wtMVA inoculated animals with extensive lesions in the lungs of these animals. There 
was mild necrosis, edema, hyperthropy and hyperplasia of type II pneumocytes combined with 
peribronchiolar and –vascular infiltration. The epithelium of some bronchioles is denuded due to 
necrosis of the epithelial cells. (A, B, D, E). In the lungs of the MVA-HA-VN/04 immunized animals no 
histopathological changes were observed (C,F). (full colour figure: APPENDIX IX)
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D, E), with a range of 45-90% affected tissue. These lesions were far less extensive (± 
5%) or even absent in the MVA-HA-VN/04 immunized groups (Figure 5C, F).
In order to examine the lungs in more detail cross-sections were made and used for 
histological analysis. By histopathology, the main lesions were seen in the alveoli 
and bronchioli. The PBS and wtMVA immunized animals infected with influenza 
virus A/VN/1194/04 had a multifocal, moderate to severe, necrotizing broncho-
interstitial pneumonia. 
Infection of the PBS and wtMVA immunized animals with the A/IND/5/05 strain 
resulted in an over all more severe pathology than seen with the first virus. The 
pneumonia was characterized by variable intra-alveolar amounts of proteinaceous 
fluid (edema) and eosinophilic fibrillar material (fibrin), cellular debris, moderate 
numbers of alveolar macrophages and few neutrophils and eosinophils (Figure 
6A, B, D, E). In the alveolar septa, there was multifocal karyorrhexis, karyolysis 
and loss of detail of epithelial cells (necrosis), infiltration with few neutrophils and 
eosinophils, and mild hypertrophy and hyperplasia of type II pneumocytes. In the 
bronchioles, there was multifocal loss of epithelial cells and intraluminal edema 
fluid and cellular debris. There was perivascular and peribronchioar infiltration 
with many lymphocytes and plasma cells, and few macrophages, neutrophils and 
eosinophils (Figure 6A, B, D, E). In the MVA-HA-VN/04 immunized animals both 
after infection with influenza virus A/VN/1194/04 and A/IND/5/05, there was a 
multifocal mild broncho-interstitial pneumonia characterized by few intra-alveolar 
macrophages, neutrophils and eosinophils, and few lymphocytes and plasma cells 
in the alveolar septa, perivascular and peribronchiolar (Figure 6C, F). The bronchus-
associated lymphoid tissue (BALT) was hyperplastic and appeared to be activated 
when compared to the PBS and wtMVA inoculated animals. 
Detection of virus-infected cells by immunohistochemistry
After infection with influenza virus A/VN/1194/04 the lungs from the PBS and wtMVA 
immunized animals showed viral antigen expression (Fig 7A, B). Particularly alveolar 
epithelial cells showed antigen expression as well as a few alveolar macrophages. 
The infected cells were predominantly associated with the pulmonary lesions. In 
the lungs of the PBS and wtMVA immunized animals after infection with influenza 
virus A/IND/5/05 (Fig 7D, E), the viral antigen expression involved the same cell types 
and location as seen after infection with influenza virus A/VN/1194/04 but was more 
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extensive in these animals. No virus-infected cells were detectable in the lungs of 
MVA-HA-VN/04 immunized animals infected with influenza virus A/VN/1194/04 or 
A/IND/5/05 (Fig 7C, F). 
Discussion
The aim of this study was to evaluate the capacity of the MVA-HA-VN/04 vaccine 
to induce protective immunity against highly pathogenic H5N1 influenza viruses 
in a non-human primate model. Cynomolgus macaques were immunized twice 
with MVA-HA-VN/04 and then challenged with influenza virus A/VN/1194/04 
or A/IND/5/05, strains from clade 1 and 2.1 respectively [313]. Immunization of 
cynomolgus macaques with MVA-HA-VN/04 induced virus-specific HI and VN 
antibodies that in the majority of the animals cross-reacted with the heterologous 
strain A/IND/5/05 from clade 2.1. Despite the absence of cross-reactive antibodies in 
some of the animals they were all protected against infection with the homologous 
and the heterologous strain. A similar result was obtained in the mouse model [251]. 
Apparently, the induction of cross-reactive antibody responses that are below the 
detection limit were sufficient for protection against infection with the heterologous 
strain. This observation is in concordance with results obtained in other H5N1 
Figure 7 Detection of virus-infected cells in the lungs four days post infection with H5N1 influenza 
viruses. Immunohistochemistry was used to stain cells that are positive for the presence of viral antigen 
showing a deep red staining in the nucleus. Influenza viruses A/Vietnam/1194/04 (arrows indicate 
single infected cells) or A/Indonesia/5/05 antigen expression was seen in alveolar epithelial cells and 
some alveolar macrophages of PBS (A, D) and wtMVA (B, E) inoculated animals. No viral antigen was 
observed in the lungs of MVA-HA-VN/04 immunized animals (C, F). (full colour figure: APPENDIX X)
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vaccination-challenge experiments in mice and ferrets [156, 251]. 
Our data show that vaccination with MVA-HA-VN/04 prevented virus replication 
and the development of fever and severe interstitial pneumonia after challenge 
infection. The pathogenesis of infection with influenza viruses A/VN/1194/04 and A/
IND/5/05 in cynomolgus macaques was characterized by infection of predominantly 
pneumocytes resulting in a necrotizing broncho-interstitial pneumonia. This 
resembled the pathogenesis observed after infection of macaques with influenza 
virus A/HK/156/97 [282, 322] or that seen after infection of man with H5N1 
highly pathogenic avian influenza viruses [323, 324]. Apparently, the infection of 
pneumocytes is sufficient for the development of interstitial pneumonia in primates, 
regardless the type of pneumocytes (type I or type II) that are infected [15, 323, 325]. 
H5N1 viruses bound to epithelial cells of the lower respiratory tract of cynomolgus 
macaques, most likely through the preferential usage of the (SA)-α2,3-Gal receptor.
Collectively, the MVA-HA-VN/04 vaccine preparation proved to be highly effective 
in inducing protective immunity in primates against homologous and heterologous 
H5N1 influenza viruses. The reduction of viral shedding from the lower and upper 
respiratory tract may reduce the risk of human-to-human transmission and may 
therefore limit the viral spread in the population if this vaccine is used in humans to 
reduce the impact of the pandemic [326, 327].
The MVA-HA-VN/04 immunization was very well tolerated. Measurement of the 
body temperature of the animals was not only used as a clinical outcome of the 
challenge infection, it also allowed monitoring systemic reactions upon vaccination. 
After MVA-HA-VN/04 or wtMVA vaccination no rise in body temperature was 
observed in any of the vaccinated animals. This is in concordance with the excellent 
safety profile of (recombinant) MVA in humans [183]. This safety profile also extends 
to immune compromised subjects since it has been shown that MVA does not 
replicate in severly immuno-suppressed macaques [187]. 
The presence of pre-existing anti-vector immunity may not be a major concern for 
the efficacy of MVA-HA-VN/04 vaccine although this remains to be demonstrated. 
In mice, MVA vaccine efficacy was hardly affected by pre-existing immunity [185]. 
More importantly, repeated administrations of a recombinant MVA vaccine to 
humans boosted specific immune responses directed against the recombinant 
antigen 5T4 [182]. Therefore, it can be envisaged that immunization of individuals 
that received smallpox vaccination in the past, and repeated applications of MVA-
HA-VN/04 should be feasible.
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In combination with other favourable properties such as good stability, which would 
allow stock-piling of the vaccine, rapid and easy production at large scale under BSL-
1 conditions makes recombinant MVA-HA an attractive and promising candidate 
as a pandemic influenza virus vaccine. Based on the data presented here, further 
clinical development of MVA-HA vaccines seems warranted. 
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Abstract
Human infections with highly pathogenic avian influenza viruses of the H5N1 
subtype, frequently reported since 2003, result in high morbidity and mortality. 
It is feared that these viruses become pandemic, therefore the development 
of safe and effective vaccines is desirable. MVA-based H5N1 vaccines already 
proved to be effective when two immunizations with high doses were used. 
Dose-sparing strategies would increase the number of people that can be 
vaccinated when the amount of vaccine preparations that can be produced is 
limited. Furthermore, protective immunity is induced ideally after a single 
immunization. Therefore the minimal requirements for induction of protective 
immunity with a MVA-based H5N1 vaccine were assessed in mice. To this end, 
mice were vaccinated once or twice with descending doses of a recombinant MVA 
expressing the HA gene of influenza virus A/Vietnam/1194/04. The protective 
efficacy was determined after challenge infection with the homologous clade 1 
virus and a heterologous virus derived from clade 2.1. 
It was concluded that MVA-based vaccines allowed significant dose-sparing 
and afford cross-clade protection, also after a single immunization, which are 
favorable properties for an H5N1 vaccine candidate.
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Introduction
Over 400 human cases of infections with highly pathogenic avian influenza (HPAI) 
viruses of the H5N1 subtype have been reported since 2003. More than 60% of these 
cases had a fatal outcome and new cases continue to be reported frequently.[32] 
Once these viruses become transmittable from human-to-human by adaption to 
their new host, a new influenza pandemic is imminent. Neutralizing antibodies 
against H5N1 viruses are virtually absent in the human population and already nine 
different clades of antigenically distinct viruses have been identified.[52] Therefore, 
the development of safe and effective vaccines that, ideally, induce cross-clade 
immunity has high priority.[52, 318, 319] The implementation of reverse genetics for 
the generation of vaccine strains and cell culture technology contribute to the rapid 
availability of pandemic influenza vaccines.[98, 100, 106, 113, 116, 117, 124, 315-317] 
In addition, the use of adjuvants  can increase the immunogenicity of seasonal and 
pandemic influenza vaccines and may lower the amount of antigen needed for the 
induction of protective antibody responses.[78, 139, 142, 152, 158]
The development of alternative novel generations of influenza vaccines may 
mitigate the envisaged shortage of vaccine doses in the future. For example, 
vector vaccines based on recombinant adenovirus or poxvirus expressing selected 
influenza virus genes  have been shown to be immunogenic and to afford protection 
against infection with H5N1 virus in animal models.[167, 176, 177, 190, 251, 297, 
328] Especially the replication-deficient modified Vaccinia virus Ankara (MVA), 
constitutes an attractive vaccine production platform. This virus was originally 
developed as a vaccine against small pox and has been administered to >120.000 
humans without significant side effects.[183] In addition, administration of MVA to 
immunocompromised individuals is safe and does not lead to systemic disease often 
associated with the application of replicating vaccinia virus.[187, 300] Its potential 
as vaccine candidate has been demonstrated for a number of infectious pathogens 
(for review see Rimmelzwaan and Sutter).[329] Recently, we have demonstrated 
that immunization with a recombinant MVA expressing the HA gene of influenza 
H5N1 virus A/Vietnam/1194/04 (MVA-HA-VN/04) induced protective immunity 
against infection with the homologous and a heterologous antigenically distinct 
virus  in mice and macaques.[251, 328] In these studies animals were immunized 
twice with relative high doses (>108 pfu) of recombinant MVA. However, to stretch 
the number of individuals that can be vaccinated with any given amount of vaccine 
preparation that can be produced it would be desirable if dose-sparing can be 
142
mva-ha: single shot and dosesparing
CH
AP
TE
R 
8
achieved. Furthermore, when a pandemic is imminent, there might not be enough 
time to induce protective immunity with a two-dose immunization regimen. Thus, 
ideally, protective immunity is induced after immunization with lower doses and 
preferable after a single immunization, which are key elements in the development 
of pandemic influenza vaccines. In the present study, we determined the minimal 
requirements for the induction of protective immunity with MVA-HA-VN/04 against 
the homologous virus and against an antigenically distinct H5N1 strain. 
Two immunizations with MVA-HA-VN/04 at doses 10,000-fold lower than used 
previously [251] significantly reduced weight loss and mortality caused by challenge 
infection with influenza viruses A/Vietnam/1194/04 (clade 1) and A/Indonesia/5/05 
(clade 2.1). Strikingly, also protection against the development of clinical signs and 
mortality was achieved with a single immunization with 105 pfu of MVA-HA-VN/04. 
The clinical protection correlated with a reduction of virus replication and lung 
pathology.
Thus, apart from the favorable properties already attributed to recombinant MVA 
[329], the possibilities of dose sparing and single shot immunization regimens 
makes this vector even more attractive as a pandemic influenza vaccine candidate.
Material & Methods
Vaccine preparation
Recombinant MVA expressing the HA gene of influenza virus A/Vietnam/1194/04 
(MVA-HA-VN/04) was prepared as described previously.[251] MVA clonal isolate F6 
served as the parental MVA virus. To generate final vaccine preparations, the virus 
was amplified in chicken embryo fibroblasts (CEF), purified by ultracentrifugation 
through sucrose, reconstituted in 1mM Tris-HCL pH 9.0 and diluted in PBS.
Viruses
Influenza viruses A/Vietnam/1194/04 (A/VN/1194/04) and A/Indonesia/5/05 (A/
IND/5/05) were cultured in Madin Darby Canine Kidney (MDCK) cells. Infectious 
virus titers were determined in MDCK cells as described previously.[228]
Animals
Female specified pathogen free 6-8 weeks old C57BL/6J mice were purchased from 
Charles River (Sulzfeld, Germany) and were age-matched at the time point of the 
first immunization. Mice were immunized once with MVA-HA-VN/04 at a dose of 
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103, 104, 105, 106, or 108 pfu in a volume of 100ml intramuscularly in the hind legs 
(20 mice per dose). A second group of animals was immunized twice with MVA-HA-
VN/04 at a dose of 103, 104, 105, or 106 pfu (20 mice per dose). For the control groups 
mice were immunized with wildtype MVA (wtMVA) (106 (two shot) or 108 pfu (single 
shot)) (n=60) or PBS (n=56).
Four weeks after the last immunization blood was drawn from the animals and 
they were infected with 103 TCID
50
 of the homologous influenza virus A/VN/1194/04 
or 103 TCID
50
 of the heterologous strain influenza virus A/IND/05/05. Virus was 
inoculated intranasally in a volume of 50ml and the challenge dose was chosen since 
it resulted in a lethal infection in >90% mice reproducibly (data not shown). Four and 
fourteen days after challenge infection mice were euthanized and their lungs were 
resected. Blood sampling, the intranasal infection, and euthanasia were carried out 
under anesthesia with inhalative isoflurane. The animals were housed in individual 
ventilated cage units (IVC-units) and had access to food and water ad libitum. During 
the infection with the influenza A/H5N1 viruses, animals were housed in type 3 cages 
placed in bio-safety level 3 containment facilities. The experimental protocol was 
approved by an independent animal ethics committee and the experiments were 
conducted according to national and international guidelines.
Serology
After treatment with cholera filtrate and heat-inactivation at 56°C, the sera were 
tested for the presence of anti-HA antibodies. For this purpose a hemagglutination 
inhibition (HI) assay was used following a standard protocol using 1% turkey 
erythrocytes and four HA-units of influenza virus A/VN/1194/04 and A/IND/5/05.
[229] For this purpose reverse genetics viruses were produced from which the basic 
cleavage site in the HA molecule was deleted. The antibody titers obtained with 
these viruses were comparable with those obtained with the wild type strains (data 
not shown). Sera were also tested for the presence of virus neutralizing antibodies 
specific for the two influenza viruses using a micro virus neutralization (VN) assay 
with the viruses that were produced by reverse genetics as described above [230]. In 
brief, 50µl volumes of serial diluted serum samples were incubated with 100 TCID50 
of the viruses for one hour at 37°C and then the mixture was added to MDCK cells. 
After one hour, the cells were washed and subsequently cultured in Eagles Minimal 
Essential Medium containing bovine serum albumin (BSA, fraction V 0.3%), 4mg/
ml trypsin, L-glutamin 2mM, penicillin 100U/ml, streptomycin 100mg/ml  NaHCO
3
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0.15%, Hepes 20mM and non-essential amino acids 0.1 mM. After five days, residual 
virus replication was assessed by measuring HA activity in the culture supernatants. 
Hyper-immune serum obtained from a swan immunized twice with inactivated 
H5N2 influenza virus A/Duck/Potsdam/1402/86 (Nobilis influenza® H5N2 Intervet 
International, Boxmeer, the Netherlands) was used as a positive control against the 
two influenza viruses. For calculation purposes serum samples with an antibody 
titer of <10 were arbitrarily assigned a titer of 5.
Lung virus titers
Lungs were snap frozen on dry ice with ethanol and stored at -70°C. Subsequently 
they were homogenized with a FastPrep-24® (MP Biomedicals, Eindhoven, The 
Netherlands) in transport medium (Hanks medium (MEM), lactalbumin, glycerol, 
penicillin, streptomycin, polymyxin B, nystatin, gentamicin) and centrifuged briefly. 
Quintuplicate ten-fold serial dilution of these samples were used to determine the 
virus titers on confluent layers of MDCK cells as described previously.[228]
Histopathology and immunohistochemistry
Formalin-inflated lungs were fixed in 10% neutral buffered formalin and then cross-
sections were made and embedded in paraffin, sectioned at 4 mm and stained with 
hematoxylin and eosin for histological evaluation. Sequential slides were stained 
using an immunoperoxidase method with a monoclonal antibody (Clone HB65 
IgG2a (American Type Culture Collection)) directed against the nucleoprotein of 
influenza A virus. a Goat-anti-mouse IgG2a HRP (Southern Biotech, Birmingham, 
Alabama, USA) was used as secondary antibody. The peroxidase was revealed using 
diamino-benzidine as a substrate, resulting in a deep red precipitate in the nuclei of 
influenza A virus-infected cells and a less intense red-staining of their cytoplasm. 
The sections were counterstained with hematoxylin.
Statistical analysis
Data for weight loss and viral titers were analyzed using the two-sided Student’s t 
test and differences were considered significant at P<0.05. 
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Results
Antibody responses induced by immunization with MVA-HA-VN/04
After a single immunization with MVA-HA-VN/04, only  mice that received a dose 
of 106 or 108 pfu developed detectable antibody titers (Table 1). Four weeks after 
immunization these animals had HI geometric mean titers (GMT) of 6.8 (SD=1.8) and 
15.7 (SD=2.6) against the homologous virus (A/VN/1194/04) and 5.5 (SD=1.4) and 
6.1 (SD=1.8) against the heterologous virus (A/IND/5/05), respectively. As shown in 
table 1, also virus-neutralizing antibodies were detected after a single immunization 
with 106 or 108 pfu with GMT  5.4 (SD=1.4) and 5.7 (SD=1.5) against the homologous 
strain respectively. Only mice immunized with 108 pfu of MVA-HA-VN/04 developed 
virus neutralizing antibody titers against the heterologous strain. Mice that received 
two immunizations with 103, 104, 105 or 106 pfu of MVA-HA-VN/04 developed HI GMT 
of 6.3 (SD=2.1), 16.2 (SD=3.8), 77.1 (SD=4.2) and 71.9 (3.3) respectively against the 
homologous strain. Those that received 105 and 106 pfu also developed detectable 
HI antibodies against the influenza virus A/IND/5/05 with GMT 7.7 (SD=2.6) and 7.7 
(SD=2.3). In the VN assay, antibodies against the homologous strain were detected 
with GMT of 5.5 (SD=1.6), 18.0 (SD=4.4) and 15.2 (SD=3.9) in mice immunized with 
104, 105 or 106 pfu of MVA-HA-VN/04, respectively. The mice that were immunized 
twice with 105 and 106 pfu developed virus-neutralizing antibodies against the 
heterologous strain with GMT of 7.5 (SD=2.9) and 6.2 (SD=2.0).
Protection against clinical signs after infection with influenza A/H5N1 virus
From two to three days p.i. onwards, unprotected control animals started to develop 
clinical signs, irrespective of the challenge virus that was used, although infection with 
influenza A/IND/5/05 caused more severe disease. Mice that received PBS or wtMVA 
Table 1: Antibody titers1 after immunization with MVA-HA-VN/04 
HI single shot two shot
106 108 103 104 105 106
A/VN/1194/04 6.8 (1.8) 15.7 (2.6) 6.3 (2.1) 16.2 (3.8) 77.1 (4.2) 71.9 (3.3)
A/IND/5/05 5.5 (1.4) 6.1 (1.8) - - 7.7 (2.6) 7.7 (2.3)
VN single shot two shot
106 108 103 104 105 106
A/VN/1194/04 5.4 (1.4) 5.7 (1.5) - 5.5 (1.6) 18.0 (4.4) 15.2 (3.9)
A/IND/5/05 - 5.4 (1.4) - - 7.5 (2.9) 6.2 (2.0)
1titers are expressed as GMT (SD)
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once or twice displayed reduced muscle strength, and around day 4 p.i.  hunched 
back posture and heavy breathing. A similar clinical presentation was observed in 
mice that received one or two immunizations with 103 pfu MVA-HA-VN/04 and that 
were subsequently infected with influenza virus A/IND/5/05.  These mice eventually 
succumbed from infection or had to be taken out of the experiment because they 
reached humane endpoints. Mice that received a single immunization with 104 or 
105 pfu MVA-HA-VN/04, and those vaccinated twice with 103 pfu, developed mild 
clinical signs after infection with the homologous influenza virus A/VN/1194/04. 
Also mice vaccinated twice with 104 pfu but infected with the heterologous strain 
A/IND/5/05 had a mild clinical outcome of infection and recovered from infection. 
Mice vaccinated once with 106 or 108 pfu and those vaccinated twice with 105 or 
106 pfu did not show any clinical signs after infection regardless the virus that was 
used for infection. In general, the severity of the clinical signs correlated with the 
extent of weight loss. Mice vaccinated once with doses > 105  pfu did not loose 
weight after infection with influenza virus A/VN/04 and fully recovered (Figure 1). 
After challenge infection with A/IND/5/05 some weight loss was observed, but it was 
limited considerably compared to control mice or those vaccinated with doses of 
Figure 1 Bodyweight after infection with influenza virus A/Vietnam/1194/04 (A, C) and influenza virus 
A/Indonesia/5/05 (B, D). Animals were infected four weeks after a single immunization (A, B) with: 
PBS, wtMVA, 103, 104, 105, 106 or 108 pfu of MVA-HA-VN/04. A second group of animals was infected 
four weeks after two immunizations (C, D) with PBS, wtMVA, 103, 104, 105 or 106 pfu of MVA-HA-VN/04. 
(*Indicates weight loss of the proportion of animals in this group that survived post day 6 infection)
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<105 pfu MVA-HA-VN/04. Two vaccinations with doses as low as 104 pfu of MVA-HA-
VN/04 fully protected mice from weight loss after infection with the homologous 
strain. Even two vaccinations with 103 pfu prevented severe weight loss observed 
in PBS control mice and those vaccinated with 108 pfu of the empty vector. Two 
vaccinations with doses >104 pfu also protected mice from severe weight loss after 
infection with influenza virus A/IND/5/05
Survival after infection with influenza A/H5N1 virus
Mice that developed severe clinical signs after H5N1 infection and that showed 
weight loss of more than 20%  were euthanized for ethical reasons. Mice that 
received a single shot of PBS, wtMVA or the lowest dose of MVA-HA-VN/04 (103 pfu) 
did not survive past day 7 p.i. with influenza virus A/VN/1194/04 and A/IND/5/05, and 
most of them reached humane endpoints six days p.i. (Table 2). Mice immunized 
once with 104 pfu MVA-HA-VN/04 had a survival rate of 25% after infection with both 
the homologous and heterologous virus. A single vaccination with 105 pfu MVA-HA-
VN/04 resulted in 100% survival after infection with the homologous virus and 50% 
after infection with influenza virus A/IND/5/05. A single vaccination with a dose of 
>106 pfu MVA-HA-VN/04 prevented mortality caused by infection with both viruses.
Two immunizations with 103 pfu MVA-HA-VN/04 protected 67% of mice from 
death caused by infection with A/VN/04, but not that caused by infection with the 
heterologous strain A/IND/5/05 (Table 2). Two immunizations with a dose >104 pfu of 
MVA-HA-VN/04, protected mice completely against mortality caused by infection 
with both influenza viruses.
Table 2: Survival after influenza A/H5N1 infection in single shot immunized mice
single 
shot
controls MVA-HA-VN/04(1)
PBS wtMVA 103 104 105 106 108
A/Vietnam/1194/04 0/4 0/4 0/4 1/4 4/4 4/4 4/4
A/Indonesia/5/05 0/4 0/4 0/4 1/4 2/4 4/4 4/4
two 
shot
controls MVA-HA-VN/04(1)
PBS wtMVA 103 104 105 106
A/Vietnam/1194/04 0/4 0/4 2/3(2) 4/4 4/4 4/4
A/Indonesia/5/05 0/4 0/4 0/4 4/4 4/4 4/4
(1)Dose of MVA-HA-VN/04 in pfu (immunization in a total volume of 100μl)
(2)One animal had to be euthanized before infection due to a complication unrelated to the 
experiment
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MVA-HA-VN/04 vaccination reduces virus replication in the lungs
After one vaccination
Lungs were tested for the presence of infectious virus on day 4 post infection (p.i.). 
After infection with influenza virus A/VN/1194/04 of mice vaccinated with PBS or 
wtMV, the mean virus titers were 108.3 (SD=100.2) and 107.9 (SD=100.5), respectively 
(Figure 2A). These titers were significantly higher than that of mice that were 
vaccinated with  MVA-HA-VN/04 at a doses of 104, 105, 106 or 108 pfu (p<0.05). The 
mean virus titer in mice immunized once with 103 pfu of MVA-HA-VN/04 was 107.5 
(SD=100.2) which was still significantly lower than that of mice that received PBS 
(p<0.05). Four days post infection with influenza virus A/IND/5/05 the mean virus 
titers in the PBS vaccinated and wtMVA vaccinated mice were 108.5 (SD=100.6) and 
108.7 (SD=100.1) respectively (Figure 2B). Mice vaccinated with a dose of 103 pfu MVA-
HA-VN/04 had similar mean virus titer of 108.5 (SD=100.8). Vaccination with higher 
doses of MVA-HA-VN/04 resulted in lower lung virus titers. The extent of virus 
replication was vaccine dose dependent. The mean A/IND/5/05 virus titers for mice 
vaccinated with 104, 105, 106 or 108 pfu were 107.6 (SD=100.6), 106.7 (SD=101.4), 107.1 
(SD=100.6) and 103.7 (SD=102.8), respectively.
Figure 2 Virus replication in the lungs on day 4 post infection with influenza virus A/Vietnam/1194/04 
and A/Indonesia/5/05 in mice that received one (A, B) or two (C, D) immunization(s) of: PBS, wtMVA 
or 103, 104, 105, 106 or 108 (single shot only) pfu of MVA-HA-VN/04.(* indicates a statistical significant 
difference with the PBS immunized group (p<0.05) (** indicates a significant difference with both the 
PBS and wtMVA immunized group (p<0.05)(*** indicates a statistical significant difference with the 
wtMVA immunized group). 
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After two vaccinations
As shown in figure 2C, two immunizations with MVA-HA-VN/04 resulted in 
significant lower lung virus titers four days after infection with the homologous virus 
A/VN/1194/04 compared to the PBS or empty vector inoculated mice, regardless the 
vaccine dose that was used. In mice vaccinated with vaccine doses > 105 , infectious 
virus was not detected. Four days p.i. with influenza virus A/IND/5/05 infectious 
virus could not be detected in the lungs of mice that were vaccinated twice with 105 
pfu of MVA-HA-VN/04. In mice vaccinated twice with 106 pfu the mean virus titer 
in the lungs was 103.6 (SD=101.7), which was significantly lower than that in the PBS 
and wtMVA immunized control mice which had mean titers of 108.5 (SD=100.3) and 
108.8 (SD=100.6) respectively (Figure 2D). Also vaccination with a dose of 104 pfu of 
MVA-HA-VN/04 significantly reduced the virus titers of A/IND/05 compared to PBS 
control mice.
Vaccination prevents histopathological changes in the lungs after influenza A/H5N1 
infection
Upon infection with influenza viruses A/VN/1194/04 and A/IND/5/05, unprotected 
control mice inoculated with PBS or empty vector developed a moderate to severe 
broncho-interstitial pneumonia within four days (Figure 3). Histopathological 
changes were located in multifocal to coalescing lesions with more than 50% 
of the lungs affected. The lesions were characterized by marked inflammatory 
peribronchiolar lymphocytic infiltrates and occasionally proteinaceous fluid. There 
was necrosis in the bronchiolar epithelium resulting in cellular debri in the lumen. 
All these histopathological changes were located in multifocal to coalescing lesions 
with more than 50% of the lung affected. Similar lesions were observed in mice 
vaccinated with 103 pfu of MVA-HA-VN/04. Mice that were immunized once with 
104, 105 or 106 pfu of MVA-HA-VN/04, or twice with 104 pfu were partially protected 
against homologous and heterologous challenge infection. They displayed moderate 
changes in the lung: moderate peribronchiolar lymphocytic infiltrate and mild 
necrosis in the bronchiolar walls (Figure 3). Fourteen days p.i. normal architecture 
of the lung was restored in animals from these groups, apart from some residual 
peribronchiolar lymphocytic infiltrate and mild hyperplasia and hypertrophy of the 
bronchiolar and alveolar epithelium, consistent with regeneration. Mice vaccinated 
once with 108 pfu of MVA-HA-VN/04 or twice with >105 pfu displayed virtually no 
histopathological changes in the lung four days p.i. (Figure 3) or at later time points 
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p.i. with influenza viruses A/VN/1194/04 or A/IND/5/05.
Detection of virus-infected cells by immuno-histochemistry
The presence of influenza virus-infected cells in the lungs was detected using a 
monoclonal antibody against the viral nucleoprotein, resulting in a red-brown 
precipitate in the nucleus and less in the cytoplasm. Four days p.i. with influenza 
virus A/VN/1194/04 infected cells were abundantly present in the lungs of control 
mice that received PBS or empty vector once or twice or mice vaccinated with 
103 pfu of MVA-HA-VN/04. Also after infection with influenza virus A/IND/5/05, 
virus-infected cells were abundantly present in the lungs of the control mice. A 
single vaccination with 103, 104, 105 or 106 pfu of MVA-HA-VN/04 did not prevent 
replication of influenza virus A/IND/05. The antigen-expressing cells were epithelial 
cells in the alveolar wall (type I and type II like pneumocytes) and bronchiolar 
epithelial cells in most of the bronchiolar walls (Figure 3). Mice vaccinated with 104, 
105 or 106 pfu of MVA-HA-VN/04 once or twice with 103 pfu were partially protected 
against the homologous virus and had virus-infected cells, predominantly type II like 
pneumocytes, at multiple foci in their lungs (Figure 3). A few single infected cells 
were detected in the lungs of animals that had received a single immunization with 
108 pfu MVA-HA-VN/04 and virus-infected cells were virtually absent in animals that 
had received two immunizations with >105 pfu of MVA-HA-VN/04 (Figure 3). No 
virus was detectable in any of the animals fourteen days after infection.
Discussion
In the present study, the minimal requirements were assessed for the induction of 
protective immunity in mice against antigenically distinct influenza A/H5N1 viruses 
with a recombinant MVA expressing the HA gene of a clade 1 influenza A/H5N1virus. 
Two immunizations with a dose as low as 104 pfu of MVA-HA-VN/04 were sufficient 
for the induction of protective immunity not only against the homologous strain but 
also against the antigenically distinct strain A/IND/5/05 from clade 2.1.1. A dose of 
104 pfu is 10.000 fold lower than the dose of 108 pfu that was used in previous studies 
that demonstrated the protective potential of MVA-HA-VN/04 vaccine candidate in 
mice and macaques.[251, 328] Thus, substantial less vaccine preparation is needed 
for the induction of protective immunity in mice. The possibility of dose-sparing 
would increase the number of individuals that can be vaccinated, with any amount 
of vaccine preparation, considerably.
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It was indicated on the website of a manufacturer of MVA based vaccines (www.
bavarian-nordic.com) that the production capacity would range in tens of millions 
of doses, assuming a dose of 108 pfu. If it can be confirmed that also in humans 
a dose of 104 pfu is still effective, enough vaccine doses can be made for a global 
vaccination campaign. Thus the problem of the envisaged shortage of pandemic 
Figure 3 Histopathological changes and immunohistochemistry of the lungs after infection with 
influenza A/H5N1 virus. Representative pictures were selected for the different classifications. 
Magnification: overview (10x), bronchiole (20x), alveoli (40x). (full colour figure: APPENDIX XI)
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influenza vaccines could be addressed with the use of the recombinant MVA 
technology. Another important issue that complicates the development of effective 
H5N1 vaccines is the co-circulation of antigenically distinct viruses. 
At present, nine different clades of A/H5N1 viruses have been identified and ideally 
vaccines will induce protective immunity against multiple clades of these viruses. 
Two immunizations with MVA-HA-VN/04 afforded cross-clade protection. It should 
be noted that also protective effects were observed with low doses MVA-HA-VN/04 
in the absence of detectable antibody responses specific for the two viruses used for 
challenge infection. It is possible that when low doses of vaccine are used antibody 
responses are induced below the detection limit, but which still afford some level 
of protection. Alternatively, it is possible that vaccination with low doses MVA-HA-
VN/04 primed for secondary antibody responses. With higher doses of MVA-HA-
VN/04 detectable antibodies were induced which indicated that the magnitude of 
the antibody responses is dependent on the vaccine dose.
In our mouse model, vaccination with two doses of >104 pfu of MVA-HA-VN/04 
reduced virus replication upon challenge infection significantly, which correlated 
with a reduction of histopathological changes in the lung and a reduction in the 
presentation of clinical signs, such as weight loss. Only with a high dose of MVA-HA-
VN/04 (> 105  pfu) sterilizing immunity was induced. 
When a pandemic is imminent the rapid induction of protective immunity by 
vaccination is desirable and may prevent morbidity and mortality in selected 
population groups like health care workers or those at high risk for complications 
associated with infection with influenza viruses. Under these circumstances 
the instant induction of protective virus-specific immune responses by a single 
immunization without the need for a booster vaccination would be ideal. In the 
present study, we showed that a single immunization with MVA-HA-VN/04 protected 
mice from severe disease caused by infection with the homologous strain or the A/
Indonesia/5/05 strain, especially when a high dose (108 pfu) was used. However, also 
vaccination with lower doses in the range of 105-106 pfu afforded clinical protection, 
in particular against the homologous strain. In contrast to two immunizations, it was 
not possible to induce sterilizing immunity after a single immunization with MVA-
HA-VN/04. Collectively, we conclude that in addition to well established favorable 
properties of MVA based vaccines such as superior safety, its good stability allowing 
stock-piling, high expression of genes of interest and good immunogenicity 
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without the use of adjuvants, they also allow dose sparing. Two immunizations with 
relatively low doses of MVA-HA-VN/04 induced protective immunity against H5N1 
viruses derived from different antigenically distinct clades. This vaccination strategy 
would be attractive for prepandemic vaccination, when there is still enough time 
for prime-boost regimens. Since there could be uncertainty about the strain that 
ultimately would cause a pandemic, the possibility to induce cross-clade immunity 
may afford broad protective immunity against a variety of different strains. When 
the induction of protective immunity becomes more urgent, a single immunization 
with a high dose might afford rapid protection against infection with the emerging 
pandemic strain.  Of course the minimal requirements for the induction of 
protective immunity by MVA-HA-VN/04 vaccination need to be confirmed in 
humans. However, the potential of recombinant MVA-H5 vaccine was confirmed 
in non-human primates [328] and therefore we anticipate that also in humans dose 
sparing and single shot regimens are feasible. In this respect the presence of anti-
vector immunity is considered to be a potential draw back of MVA based vaccines. 
However, since MVA is fully replication deficient, pre-existing immunity is unlikely 
to affect the immunogenicity of these vector vaccines.[182, 185] Thus recombinant 
MVA is promising as a H5N1 vaccine candidate, but of course this technology can 
be applied to other subtypes of influenza viruses as well. For example, it would 
be of interest to evaluate its potential as candidate vaccine against the pandemic 
influenza A/H1N1 virus that spread worldwide within two months, causing more 
than 52,000 reported cases, including over 231 deaths as of June 22nd 2009.[52]
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Part I: CTL and heterosubtypic immunity
Seasonal influenza A viruses of the H1N1 and H3N2 subtype cause epidemic outbreaks 
annually. In addition, new subtypes originating from other species are introduced in 
the human population sporadically, which may spark a pandemic. Currently there 
are two novel viruses, emerging from birds and swine, that form a threat to public 
health. First, highly pathogenic avian influenza A/H5N1 viruses are transmitted 
from birds frequently since 2003, predominantly in South-East Asia. Second, swine 
influenza A/H1N1 virus that originated from Mexico spread worldwide within two 
months after the first human cases were reported in April 2009 and resulted in the 
first influenza pandemic of the 21st century.[51] Antibodies against these two viruses 
are virtually absent in the human population but cross-reactive pre-existing virus-
specific T cells may contribute to protective heterosubtypic immunity. 
Heterosubtypic immunity is induced after previous infection(s) with influenza A virus 
of the H1N1 or H3N2 subtype and can provide a certain level of protection against 
subsequent infection with an influenza virus of an alternative subtype. In chapter 2, 
we demonstrated this in a mouse model using two viruses of different subtypes that 
have identical internal proteins and thus also share the NP-gene, containing the 
immunodominant CTL epitope NP
366-374
, restricted by H2-Db. CTL responses against 
this epitope were monitored using H2-Db/NP
366-374
 tetramerstaining. C57BL/6J mice 
(H2-Db) were infected with influenza A virus X-31 (H3N2) and subsequently with 
influenza virus A/PR/8/34 (H1N1) that is lethal to mice. X-31 primed animals were 
protected against the A/PR/8/34 infection, in the absence of virus-neutralizing 
antibodies. Protection correlated with a significant increase in tetramer-positive 
CD8+ CTL after challenge infection. To assess the effectiveness of heterosubtypic 
immunity induced by infection with seasonal influenza virus against highly 
pathogenic A/H5N1 viruses a second study was performed using more relevant 
virus strains. In this study, mice were primed with human influenza virus A/HK/2/68 
(H3N2) and four weeks later they were challenged with a lethal dose of influenza 
virus A/IND/5/05 (H5N1) as was described in chapter 3. Although primed animals 
developed clinical signs, the virus was cleared from their lungs and they survived 
the H5N1 infection. An expansion of NP
366-374
 epitope specific CD8+ CTL that cross-
reacted with the H5N1 NP
366-374 
epitope variant was seen in the protected animals 
after challenge infection with the H5N1 strain. Adoptive transfer of serum from 
H3N2-infected animals to naïve mice did not confer protection against subsequent 
H5N1 infection (data not shown).
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Because effective vaccination prevents influenza virus infection it might also 
interfere with the induction of virus-specific T cells and heterosubtypic immunity. 
In chapter 4 we demonstrated in a mouse model that vaccination against human 
influenza A/H3N2 virus prevented the induction of (cross-reactive) virus-specific 
CTL otherwise induced after infection with that virus. Prevention of the induction 
of a heterosubtypic immune response by prior vaccination against the H3N2 virus 
resulted in the loss of protection against secondary infection with HPAI A/H5N1 
virus. The three studies described above demonstrate that protection based on 
heterosubtypic immunity correlates with the expansion of cross-reactive virus-
specific CTL. In chapter 5 it was shown that human virus-specific T cells, induced by 
previous infection(s) with seasonal influenza A virus cross-reacted with HPAI A/H5N1 
virus to a great extent. Thus, humans previously infected with seasonal influenza A 
viruses possess influenza specific CTL that cross-react with heterosubtypic influenza 
virus strains like H5N1 [72, 73], which may afford a certain degree of protection 
against infection with these viruses. Vaccination against seasonal influenza A viruses 
may interfere with the induction of heterosubtypic immunity as we demonstrated 
in chapter 4. Therefore, the recommendation to vaccinate all healthy children 6-59 
months of age in the USA and some other countries should be reconsidered in the 
light of these findings. Annual vaccination against seasonal influenza may render 
subjects in this age group immunological naïve with regard to their T cell immunity 
and more susceptible to infection with pandemic viruses of other subtypes.
In humans, the correlation of pre-existing CTL responses with heterosubtypic 
immunity was demonstrated by McMichael et al.[67] More circumstantial evidence 
was provided by Epstein et al who demonstrated that subjects who experienced an 
H1N1 infection before 1957 less likely developed severe influenza during the 1957 
H2N2 pandemic.[71] The disproportionate age distribution of HPAI A/H5N1 and 
new influenza A/H1N1 cases also suggests that pre-existing immunity to influenza 
viruses may contribute to protection against infection with an influenza A virus 
of a novel subtype.[259, 330] Young subjects were more at risk to develop severe 
disease, which may be attributed to the fact that this age group less likely has 
been exposed to seasonal influenza A viruses and thus have not mounted a (cross-
reactive) CTL response to a novel subtype, although other confounding factors can 
not be excluded. 
Ideally, also vaccines induce this type of broad protective heterosubtypic immunity. 
Thus, the development of vaccines that aim at the induction of cross-reactive CTL 
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responses against conserved viral antigens may be an attractive approach for the 
induction of protective immunity against a variety of influenza A virus subtypes as 
discussed in chapter 1.[247, 331, 332]  
Part II: MVA-based H5N1 influenza vaccines
In the light of the current pandemic threats there is a need for safe and effective 
vaccines that can be produced rapidly at large scale. MVA-based vaccines fulfil 
all these criteria and are attractive pandemic influenza vaccine candidates.[329] 
Therefore, we evaluated  recombinant MVA expressing the HA genes of HPAI 
H5N1 virus A/Hongkong/156/97 (MVA-HA-HK/97) and A/Vietnam/1194/04 (MVA-
HA-VN/04) in mice first (chapter 6). Mice were immunized and subsequently 
challenged with HPAI H5N1 viruses derived from antigenically distinct clades: A/
Hongkong/156/97 (clade 0), A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 
2.1). Vaccination with MVA-HA-HK/97 afforded protection against the homologous 
virus only, whereas immunization with MVA-HA-VN/04 provided protection against 
all three H5N1 viruses. 
Since promising results were obtained in mice it was decided to further evaluate 
the most promising vaccine candidate, MVA-HA-VN/04, in non-human primates. 
To this end, cynomolgus macaques were immunized and subsequently challenged 
with HPAI H5N1 viruses A/Vietnam/1194/04 or A/Indonesia/5/05. As described in 
chapter 7, immunization with MVA-HA-VN/04 induced protective immunity against 
infection with the homologous and the heterologous virus. 
For the studies described in chapters 6 and 7, high vaccine doses (108 pfu) were 
used for immunization. The feasibility of dose-sparing and single shot vaccination 
regimens was explored in chapter 8. Dose-finding indicated that the administration 
of two doses of 104 pfu of MVA-HA-VN/04 was immunogenic and afforded 
protection against infection with the homologous strain and the antigenically 
distinct A/IND/5/05 strain.  In addition, similar results were obtained after a single 
immunization with 108 pfu. Thus, the use of recombinant MVA-HA is a promising 
approach in situations in which urgent induction of protective immunity is needed 
e.g. during a pandemic outbreak. However, when insufficient vaccine doses are 
available for a global vaccination campaign with a high dose single shot regimen, 
it may be decided to give two immunizations with a low dose, owing that there is 
enough time to allow protective immunity to develop. The minimal requirements 
for the induction of protective immunity in humans with MVA-HA-VN/04 need to 
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be assessed in clinical trials. The seed vaccine strain lots then need to be prepared 
in cells that are certified for vaccine production under GMP conditions. The vaccine 
production in CEF cells also has to be optimized or be adapted to a continuous 
cell line.[329] Thus the use of MVA as a platform for the production of pandemic 
influenza vaccines is promising as was demonstrated for H5N1 viruses. 
With the influenza A/H1N1 pandemic we anticipate that MVA-based vaccines 
expressing the H1 gene of these viruses also could be promising vaccine candidates. 
Since it cannot be predicted which influenza A subtypes will cause future pandemics 
it may be an attractive strategy to clone the HA genes of a number of different 
influenza A subtypes, which has been shown to be transmitted to humans including 
H1N1, H2N2, H5N1, H7N7 and H9N2. This way, seed vaccine strains are readily 
available before the start of a pandemic with one of these viruses. Since it was 
demonstrated that cross-clade protection could be induced with one MVA-HA-
VN/04 vaccine, but not with MVA-HA-HK/97, there is a risk that the HA genes of 
choice may not induce the antibodies of the proper specificity. In contrast, the 
pandemic influenza A/H1N1 viruses are antigenically homogeneous and a single 
vaccine strain (A/California/04/2009 or A/California/05/2009) most likely could 
protect against all currently circulating new influenza A/H1N1 strains.[50] Since 
it has been shown that MVA-based vaccines also induce cell-mediated immunity, 
recombinant MVA expressing the influenza virus NP or M1 genes may be attractive 
vaccine candidates for the induction of cross-protective CTL responses. The 
addition of gene(s) encoding the relatively conserved internal proteins or other 
influenza virus proteins, like NA and M2, may broaden the protective potential of 
MVA vaccines expressing the HA gene.  
A potential problem with the use of MVA is interference with the induction of specific 
immunity to the target antigen by pre-existing anti-vector immunity induced by 
vaccination against small pox or the use of other recombinant pox viral vectors. 
This is especially relevant for vaccination against influenza since these vaccines are 
administered repeatedly on an annual basis, which may reduce vaccine efficacy over 
time. However, it has been demonstrated that pre-existing immunity to the vector 
did not affect the immune response to the target protein to a great extent.[182, 185] 
Nevertheless, this issue should be addressed in clinical trials evaluating MVA-based 
influenza vaccines.
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Concluding remarks
The work described in this thesis focused on the protective potential of 
heterosubtypic immunity against potentially pandemic influenza viruses and the 
preclinical evaluation of MVA-based pandemic influenza vaccine candidates. The 
results from these studies were discussed in the light of the current pandemic 
threats. The basis for heterosubtypic immunity is not fully understood, however 
virus specific CTL recognizing conserved epitopes most likely play an important 
role in this type of immunity. Since the presence of pre-existing memory CTL 
contributes to accelerated clearance of the virus infection, it may afford protection 
against severe disease and mortality. In addition to the beneficial effects of 
heterosubtypic immunity in individual patients, it may also have a favorable effect 
at the population level since it can reduce the extent and duration of viral shedding 
and thus the spread of virus. This way, the severity of pandemic outbreaks may be 
dampened. The current outbreak of new influenza A/H1N1 viruses provides a unique 
opportunity to investigate the protective effect of heterosubtypic immunity against 
these potentially pandemic viruses and to elucidate the correlates of protection 
underlying this type of immunity. Once these correlates of protection have been 
identified, it opens the possibilities for the development of vaccines that can induce 
broadly protective immunity. At present, antibodies directed to the hemagglutinin, 
is the only accepted correlate of protection and vaccines are licensed based on 
serological outcome of immunization. Therefore, the induction of antibodies specific 
for the virus causing the (pandemic) influenza outbreak is a minimal requirement, 
but the induction of heterosubtypic immunity, whatever the correlates may be, will 
broaden the protective potential of influenza vaccines. The co-circulation of various 
antigenically distinct clades of A/H5N1 viruses complicates the selection of a single 
vaccine strain. 
We have demonstrated that with the use of a MVA-based vaccine expressing the HA 
gene of one H5N1 influenza virus cross-clade protective immunity could be induced. 
Other favorable properties of MVA based vaccines like excellent safety profile and 
good immunogenicity, warrants further evaluation of these vaccine in clinical trials. 
Since protective immunity could be induced at very low doses it may be the vaccine 
preparation of choice for the vaccination of large populations. Facing a pandemic 
outbreak, ideally protective immunity is induced after a single administration of 
vaccine, which was possible with a high dose of MVA-based vaccine. 
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Collectively, the results obtained in the present studies confirmed the protective 
potential of heterosubtypic immunity, which may be at the basis for the development 
of novel vaccines and intervention strategies.  In addition, the evaluation of MVA-
based vaccines indicated that it might be a promising novel generation of influenza 
vaccines. Eventually, these developments will help limiting the impact of future 
influenza pandemics.
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Het influenza A virus wordt getypeerd op basis van zijn twee oppervlakte eiwitten: 
hemagglutinine (HA) waarvan er 16 subtypes zijn, en neuraminidase (NA) waarvan 
er 9 subtypes zijn. Voorbeelden van influenza A virus subtypes zijn: H1N1, H3N2 
en H5N1. Influenza A virussen, oorspronkelijk afkomstig uit watervogels, kunnen 
mensen infecteren en veroorzaken “de griep”. De griepepidemie is een jaarlijks ter-
ugkerend fenomeen dat plaats heeft gedurende de winter maanden. Hierbij wordt 
in Nederland gemiddeld 1% van de bevolking ziek en uiteindelijk overlijden er in ons 
land elk jaar ongeveer 1000 mensen aan de gevolgen van griep, met name ouderen. 
Het virus infecteert de cellen van de bovenste luchtwegen (neus, keel en luchtp-
ijp) en veroorzaakt hier een ontsteking die zich onder andere uit in de vorm van 
luchtwegklachten en veelal gepaard gaat met koorts en een gevoel van algehele 
malaise. Ouderen en risicogroepen (patiënten met hart- en vaatziekten, diabetes, 
etc) wordt aangeraden jaarlijks de griepprik te halen, een vaccin dat bestaat uit 
representatieve humane influenza A/H1N1 en A/H3N2 virussen en een influenza B 
virus. De componenten van het vaccin dienen jaarlijks onder de loep genomen te 
worden om na te gaan of ze afdoende matchen met de circulerende influenza virus-
sen. Indien ze teveel verschillen dienen er nieuwe kandidaat-virussen geselecteerd 
te worden die in het nieuwe vaccin komen. 
Op het moment dat een nieuw influenza virus geïntroduceerd wordt in de bevolking 
door overdracht van dier (bijv vogel of varken) op mens hebben we te maken met 
een virus dat potentieel pandemisch is. De wereldbevolking heeft geen immuniteit 
opgebouwd tegen een dergelijk virus en is daardoor extra kwetsbaar  voor tijdens 
een dergelijke uitbraak. In de 20ste eeuw hebben 3 pandemieën plaatsgevonden, in 
1918 (Spaanse griep), 1957 (Aziatisch griep) en 1968 (Hong Kong griep). De eerstge-
noemde was verantwoordelijk voor meer dan 25-50 miljoen doden, en eiste meer 
slachtoffers dan de Eerste Wereldoorlog.
In de 21ste eeuw  zijn reeds meerdere introducties van nieuwe influenza virus sub-
types geregistreerd. Vanaf 2003 zijn er continu introducties van hoog pathogene 
influenza A/H5N1 virussen in de humane populatie, deze variant wordt ook wel 
vogelgriep genoemd en is hoofdzakelijk terug te vinden in Zuidoost Azië. Voorals-
nog zijn deze virussen niet in staat om effectief van mens op mens over te gaan. In 
2003 zorgde een uitbraak van aviaire influenza A/H7N7 virussen in pluimvee voor 89 
infecties in mensen waaronder een dierenarts die uiteindelijk is overleden aan de 
gevolgen hiervan.
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De meest recente introductie van een nieuw influenza A virus vond plaats in het 
voorjaar van 2009 in Mexico. Het nieuwe influenza A/H1N1 virus, een reassortant 
van 3 virussen, is overgedragen van varken op mens en heeft zich binnen korte 
tijd aangepast aan zijn nieuwe gastheer. Binnen 3 maanden zijn meer dan 52.000 
mensen geïnfecteerd geraakt waarvan er meer dan 230 zijn overleden. Het virus is 
in staat om effectief van mens op mens over gedragen te worden en op 11 juni 2009 
kondigde de Wereldgezondheids Organisatie fase 6 af, wat inhoudt dat de eerste 
influenza pandemie van de 21ste eeuw een feit is.
Heterosubtypische immuniteit
De humane bevolking heeft geen antistoffen opgebouwd tegen deze nieuwe influ-
enza stammen zoals hierboven beschreven en is daardoor meer vatbaar voor in-
fectie met deze virussen.  Eerdere infectie(s) met influenza A virussen tijdens de 
normale griepepidemieën kan een zekere mate van bescherming bieden tegen een 
vervolg infectie met een nieuw influenza virus zoals de vogelgriep of de Mexicaanse 
griep. Deze vorm van immuniteit wordt ook wel heterosubtypisch immuniteit ge-
noemd. Het is bekend dat T cellen, op basis van herkenning van geconserveerde 
delen van het influenza virus in staat zijn om te kruisreageren met virussen van bi-
jvoorbeeld het H5N1 subtype.
In hoofdstuk 2 hebben we heterosubtypische immuniteit gedemonstreerd in een 
model met muizen die geïnfecteerd worden met twee verschillende subtypes 
griepvirussen waarvan de interne eiwitten hetzelfde zijn. Ook het nucleoproteine 
(NP) van deze virussen is identiek en bevat het immunodominante cytotoxische T 
cel (CTL) epitoop NP366-374, gerestricteerd door H2-Db. CTL responsen tegen dit 
epitoop werden uitgelezen met behulp van tetrameren gebaseerd op een MHC – 
NP366-374 complex. C57Bl/6J (H2-Db) muizen werden geïnfecteerd met influenza 
A virus X-31 (H3N2) en vervolgens met influenza virus A/Puerto Rico/8/34 (H1N1) 
dat lethaal is voor muizen. De X-31 geïnfecteerde dieren waren beschermd tegen 
de secundaire infectie in de afwezigheid van kruisreagerende antilichamen. Besch-
erming correleerde met een significant sterkere inductie van virus-specifieke CTL 
na challenge infectie. De effectiviteit van een heterosubtypische immuun respons 
geïnduceerd door infectie met een humaan influenza A virus (H3N2) tegen een 
hoog pathogeen influenza A/H5N1 virus hebben we uitgezocht zoals beschreven in 
hoofdstuk 3. Daarin wordt beschreven hoe infectie met het humane influenza virus 
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A/Hong Kong/2/68 muizen beschermd tegen sterfte als gevolg van een secundaire 
infectie met het lethale influenza H5N1 virus A/Indonesia/5/05. Ondanks dat de di-
eren wel ziek werden waren ze in staat het virus te klaren en te overleven. Expansie 
van virus-specifieke CTL (o.a. uitgelezen met tetrameren), kruisreagerend met het 
H5N1 virus, was aantoonbaar in de overlevende dieren. Transfusie van serum van 
een beschermde muis naar een naïeve muis beschermde het dier niet tegen infectie. 
Effectieve vaccinatie tegen humaan influenza A virus voorkomt infectie en zou 
daarom ook kunnen interfereren met de inductie van virus-specifieke  T cellen en 
heterosubtypische immuniteit. In hoofdstuk 4 wordt een muis model beschreven 
waarin we aantonen dat vaccinatie tegen humaan influenza A/H3N2 virus interfer-
eert met de inductie van (kruisreagerende) virus-specifieke CTL. Met het wegvallen 
van deze cellulaire immuniteit waren de dieren niet meer beschermd tegen een se-
cundaire infectie met het H5N1 virus. 
Bovenstaande studies demonstreren dat bescherming op basis van heterosubtypis-
che immuniteit correleert met de expansie van kruisreagerende virus-specifieke 
CTL. In het 5e hoofdstuk wordt beschreven dat humane CTL, gericht tegen en ges-
timuleerd met humaan influenza A virus in staat zijn om, cellen die eiwitten van 
hoog pathogeen influenza A/H5N1 virus tot expressie brengen, te herkennen en te 
elimineren en ze kunnen cellen geïnfecteerd met het H5N1 virus herkennen. Het is 
dus goedwel mogelijk dat mensen met een geschiedenis van humane influenza A 
virus infectie(s) over een bepaalde mate van T cel immuniteit beschikken die tot op 
zekere hoogte bescherming zou kunnen bieden tegen infectie met heterosubtypis-
che influenza virussen (bijv. H1N1 of H5N1). 
Vaccinatie tegen de griep zou kunnen interfereren met de inductie van heterosub-
typische immuniteit zoals is beschreven in hoofdstuk 4. Daarom is het wenselijk om 
de aanbeveling, om alle kinderen in de leeftijd van 6-59 maanden te vaccineren, 
zoals die er ligt in de VS en in verschillende Europese landen te herzien. Jaarlijkse 
vaccinatie tegen humane influenza virussen zou namelijk kunnen resulteren in een 
populatie die volledig naïef is voor influenza virussen en daarmee extra vatbaar 
wordt voor nieuwe influenza stammen die worden geïntroduceerd in de humane 
populatie. Idealiter bevatten vaccins ook componenten die heterosubtypische im-
muniteit induceren waarmee ze een bredere bescherming zouden kunnen bieden 
tegen nieuw (pandemische) influenza virussen.
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Influenza A(H5N1) vaccins gebaseerd op MVA
Met het oog op de Mexicaanse grieppandemie en de dreiging uitgaande van andere 
potentieel pandemische virussen zoals H5N1 is het duidelijk dat, om de wereld te 
beschermen tegen dit soort virussen, de ontwikkeling van veilige en effectieve vac-
cins die snel en op grote schaal geproduceerd kunnen worden hoge prioriteit heeft. 
Vaccins gebaseerd op het MVA-platform zijn aantrekkelijk pandemische influenza 
vaccin kandidaten. MVA staat voor Modified Vaccinia virus Ankara, een gemodifi-
ceerd replicatie-deficiënt pokkenvirus dat gebruikt kan worden als vehikel voor 
‘vreemde’ antigenen. 
In hoofdstuk 6 is de evaluatie van de MVA-H5N1 kandidaat vaccins: MVA-HA-Hong 
Kong/156/97 (MVA-HA-HK/156) en MVA-HA-Vietnam/1194/04 (MVA-HA-VN/04) 
beschreven. Deze vaccins zijn gebaseerd op een MVA vector die het HA-gen van 
de verschillende H5N1 virussen tot expressie brengt. C57Bl/6J muizen ontvingen 
twee vaccinaties en werden vervolgens, 4 weken na de 2e vaccinatie geïnfecteerd 
met antigeen-verschillende H5N1 virussen: A/Hong Kong/156/97 (clade 0), A/Vi-
etnam/1194/04 (clade 1) of A/Indonesia/5/05 (clade 2.1). Vaccinatie met MVA-HA-
HK/97 induceerde alleen homologe bescherming terwijl de dieren die twee shots 
met MVA-HA-VN/04 hadden gehad beschermd waren tegen alle drie de virussen. 
Deze veelbelovende resultaten waren de aanleiding voor een vervolg experiment 
met het beste kandidaat vaccin, MVA-HA-VN/04, in cynomolgus makaken. Deze 
dieren kregen ook twee vaccinaties waarna ze geïnfecteerd werden homoloog of 
heteroloog H5N1 virus zoals beschreven in hoofdstuk 7. De gevaccineerde dieren 
waren beschermd tegen de infectie met beide virussen.
De doses van MVA-HA-VN/04 zoals deze gebruikt zijn in hoofdstuk 6 en 7 zijn rela-
tief hoog (≥108 pfu). De haalbaarheid van dosisverlaging en de inductie van immu-
niteit na één vaccinatie staat beschreven in hoofdstuk 8. Twee vaccinaties met een 
dosis 10.000x lager dan zoals gebruikt in hoofdstuk 6 en 7 waren nog steeds effec-
tief in de inductie van bescherming dit gold tevens voor een enkele vaccinatie met 
een hoge dosis (108 pfu). Het gebruik van MVA-HA is dus een veelbelovende optie 
op momenten dat dringend beschermende immuniteit verworven dient te worden 
zoals bijvoorbeeld tijdens een pandemie. Desalniettemin, mocht er te weinig vaccin 
zijn voor een wereldwijde vaccinatie campagne gebaseerd op één vaccinatie met 
een hoge dosis dan is er de mogelijkheid om twee keer te vaccineren met een la-
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gere dosis, tenminste als er genoeg tijd is voor de ontwikkeling van beschermende 
immuniteit. De minimale eisen voor MVA-HA vaccins in mensen dienen uitgezo-
cht te worden in klinische trials. De vaccins dienen dan geproduceerd te worden 
in cellijnen die geschikt zijn voor het maken van vaccins onder GMP condities. De 
productie zoals die nu plaatsvindt in CEF cellen dient geoptimaliseerd te worden of 
vervangen te worden door productie in een continue cellijn. Samenvattend, MVA 
is een veelbelovend platform voor pandemische influenza vaccins zoals we hebben 
gedemonstreerd voor influenza A/H5N1 virus.
Voor het nieuwe pandemische influenza A/H1N1 virus achten we het aannemelijk dat 
op MVA-gebaseerde vaccins die het HA-gen van dit virus tot expressie brengen ook 
veelbelovend zijn. Aangezien het schier onmogelijk is om te voorspellen welke influ-
enza A virus subtypes verantwoordelijk zullen zijn voor toekomstige pandemieën is 
het een aantrekkelijke strategie om de HA genen van meerdere pandemische kan-
didaten, influenza A virussen die aantoonbaar op de mens zijn overgedragen zoals: 
H2N2, H5N1, H7N7, H9N2, te kloneren. Zo kunnen we beschikken over een data-
bank met subtype-specifieke vaccins voordat deze virussen pandemisch worden. 
Echter, we hebben aangetoond dat niet met elk MVA-H5 vaccin kruis-reagerende 
immuniteit kan worden geïnduceerd en er bestaat dus het risico dat een vaccin uit 
de databank niet de antilichamen met de juiste specificiteit induceert. Daarentegen, 
de pandemische influenza A/H1N1 virussen zijn antigeen homogeen en een enkele 
vaccin-stam (A/California/04/2009 of A/California/05/2009) zal naar alle waarschijn-
lijkheid in staat zijn om bescherming te induceren tegen alle circulerende influenza 
A/H1N1 stammen.
Het is aangetoond dat MVA-vaccins ook in staat zijn om cellulaire immuniteit te in-
duceren. Daarom zou het opnemen van genen coderend voor interne eiwitten zoals 
NP en M1 van het influenza virus in een recombinant MVA vaccin een attractieve op-
tie zijn voor een vaccin dat kruis-beschermende CTL moet induceren. De toevoeg-
ing van de relatief geconserveerde interne eiwitten of andere eiwitten zoals het NA 
en M2 kan de beschermende capaciteit van een MVA-HA vaccin verbeteren. 
Een potentieel probleem met het gebruik van MVA-vaccins is de interferentie van 
aanwezige anti-vector immuniteit, geinduceerd door vaccinatie tegen pokken of 
eerder gebruik van recombinante pokken-vectoren, met de inductie van antigeen-
specifieke immuniteit. Dit is met name relevant voor vaccinatie tegen humane influ-
enza virussen aangezien deze jaarlijks worden toegepast en uiteindelijk eventuele 
interferentie zou kunnen leiden tot verminderde vaccin doeltreffendheid. Eerdere 
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studies hebben echter aangetoond dat de aanwezigheid van anti-vector immuniteit 
niet teveel stoort met de inductie van immuniteit tegen het recombinante antigeen 
dat de vector tot expressie brengt. Toch is dit een kwestie die in ogenschouw moet 
worden genomen in klinische trials met MVA influenza vaccines.
Conclusie
Het werk dat hier besproken is beschrijft de potentie van heterosubtypische immu-
niteit om te beschermen tegen potentieel pandemische influenza virussen en de 
preklinische evaluatie van op MVA gebaseerde pandemische influenza vaccin kan-
didaten. De resultaten van de studies zijn besproken in het context van de huidige 
pandemie en pandemische dreigingen.
Hoewel de mechanismen van heterosubtypische immuniteit nog niet volledig 
helder zijn is het zeer aannemelijk dat virus-specifieke CTL gericht op gecon-
serveerde epitopen een belangrijk aandeel hebben in deze immuun respons. Gez-
ien het feit dat aanwezigheid van memory T cellen correleert met versnelde klaring 
van het virus zou het ook bij kunnen dragen aan de bescherming tegen ernstige 
ziekte en sterfte bij influenza virus infecties. Naast het positieve effect voor indi-
viduele patiënten kan T cel immuniteit ook op populatie niveau een belangrijke rol 
van betekenis spelen omdat heterosubtypische immuniteit de mate en duur van 
virus-uitscheiding kan reduceren en hiermee de verspreiding van het virus kan in-
dammen. Op deze manier zou de ernst van een pandemische uitbraak beperkt kun-
nen worden. De huidige pandemie met het Mexicaanse griepvirus voorziet ons van 
een unieke gelegenheid om het beschermende effect van heterosubtypische immu-
niteit tegen een daadwerkelijk pandemisch virus te onderzoeken en daarnaast de 
onderliggende mechanismes te verduidelijken. Als deze eenmaal uitgekristalliseerd 
zijn kunnen deze gebruikt worden als aangrijpingspunt voor de ontwikkeling van 
vaccins die een bredere immune respons induceren. Tot op heden zijn antistoffen 
tegen het HA de enige maat voor de immunogeniteit die geaccepteerd wordt voor 
de registratie van vaccins. Het induceren van serologische responsen gemeten aan 
de hand van deze antistoffen is dan ook de minimale vereiste voor nieuwe pande-
mische vaccins. Daar staat tegenover dat, wat de onderliggende werkingsmecha-
nismen ook mogen zijn, de inductie van heterosubtypische immuniteit de breedte 
van de immuunrespons zal vergroten.
Het co-circuleren en parallele introducties van verschillende antigeen verschillende 
influenza A/H5N1 virussen bemoeilijkt de selectie van één vaccin stam. We hebben 
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aangetoond dat met behulp van een MVA vaccin dat het HA van één H5N1 virus 
tot expressie brengt kruisreagerende beschermende immuniteit geïnduceerd kan 
worden. Tezamen met de overige kwaliteiten van op MVA-gebaseerde vaccins zoals 
het excellente trackrecord wat betreft veiligheid in de mens en de goede immu-
nogeniteit, rechtvaardigen verdere evaluatie van deze vaccins in klinische trials. 
Aangezien beschermende immuniteit kon worden verkregen met lage doses zou 
het wel eens een vaccin kandidaat kunnen zijn voor massale vaccinatie campagnes. 
Oog in oog met een pandemische uitbraak zou beschermende immuniteit idealiter 
geïnduceerd worden met één enkele vaccinatie en we hebben aangetoond dat dit 
mogelijk is met het MVA-HA vaccin.
Heterosubtypische immuniteit zou aan de basis kunnen staan van de ontwikkeling 
van nieuwe vaccins en interventie strategieën en MVA is een veelbelovend influenza 
vaccin-platform. In de toekomst zullen deze ontwikkelingen bijdragen aan het in-
perken van het aantal mensen dat ziek wordt en sterft als gevolg van (pandemische) 
influenza.   
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Dames en heren, vrienden, kennissen en collega’s. Promoveren is een mooie zaak, 
en al helemaal als het gaat om een onderwerp als influenza. Een onderwerp dat zo 
breed benaderd kan worden dat er dan ook vele mensen, binnen en buiten ons lab, 
aan werken en een bijdrage hebben geleverd aan dit boekje. Dat maakt ook dat er 
op de kaft van dit proefschrift eigenlijk nog wat extra namen zouden mogen staan 
want zoals het welbekende cliché luidt: promoveren doe je niet alleen, en dus zie 
hier: het dankwoord.
Om te beginnen wil ik graag mijn promotor Prof. Dr. A. Osterhaus en co-promotor 
Dr. G. Rimmelzwaan bedanken. Beste Ab, voor mijn sollicitatie-gesprek werd mij 
al op het hart gedrukt dat ik me moest voorbereiden op een pittig gesprek. Niets 
was minder waar, tijdens mijn gesprek met jou werd me nog maar weer eens 
duidelijk dat het een goede zaak was geweest dat ik had gereageerd op de baan 
van promovendus aan de afdeling Virologie van het Erasmus MC. Je scherpe blik 
en altijd kritische visie maakt dat je als AIO nooit de context uit het oog verliest en 
pragmatisch en toepassingsgericht blijft werken. Daarnaast was er de eeuwige strijd 
tussen Amsterdam en Brabant die, gebaseerd op het aantal kampioensschalen in de 
afgelopen 4 jaar,  duidelijk in het voordeel is voor de laatstgenoemde. 
Beste Guus, als echte Ajacied een PSV’er aannemen getuigd van lef. En dan ook nog 
eens iemand die voorheen bar weinig met virussen had gedaan. Door jou tomeloze 
enthousiasme en inzicht heb ik het promoveren tussen de influenza virussen als een 
waar feest ervaren. Altijd hadden we meerdere projecten tegelijk draaien en als het 
ene paper weg was lag de draft van de volgende alweer klaar. Op maandagmorgen 
de wedstrijden doorspreken samen met Ron (volgens mij heb ik nog pils tegoed van 
het seizoen 2006-2007 J) en natuurlijk die legendarische CL wedstrijd Arsenal-PSV 
met een glansrol voor Alex die we in Bergschenhoek hebben bekeken. Ook wil ik jou, 
Janet en jullie meiden bedanken voor de gastvrijheid waarmee jullie me altijd hebben 
ontvangen. Het schrijven van artikelen was en is voor mij een groot leerproces. 
Langzaam maar zeker blijft er steeds meer overeind en jou onvermoeibare hulp bij 
het schrijven heeft hiertoe een onmisbare bijdrage geleverd. Bedankt voor alle hulp, 
adviezen en wijze raad en gezellige pils- en whiskyuurtjes en we gaan het komend 
jaar vrolijk verder.
Dan mijn paranimfen, Gerrie en Rogier, of moet ik zeggen, de 3 handen op 1 buik. 
Gerrie, vanaf het begin ben je betrokken geweest bij een aantal van mijn projecten. 
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Af en toe waren ‘t mega-titraties en ander stampwerk dat we dan met z’n tweeen 
doorwerkten. Dan waren het weer FATT-assays en ELIspots die uiteindelijk tot een 
schitterend paper hebben geleid. Jouw energie en onverschrokkenheid waarmee je 
grote essays aanpakt zijn bewonderenswaardig, net als je vermogen tot relativeren 
en het genieten van je welverdiende vakanties. Ook je telefoongesprekken met 
Charles (alsof je een pasverliefd stelletje hoort) zijn geliefd binnen onze kamer. 
Bedankt voor al je energie, kennis en kunde en binnenkort kunnen je gaan genieten 
van een heerlijke lange vakantie J
Rogier, maat, op 1 september 2005 begon ik als AIO en hoorde ik dat twee weken 
later mijn eerste stagiaire zou beginnen, een dierenarts, werd er duidelijk bijgezegd. 
De slechte reputatie van dierenartsen op het lab is op jou niet van toepassing. Je 
pikte alles gruwelijk snel op en met wat pipetteer-lesjes maakte je je ‘t labwerk snel 
eigen. Dat je een veelbelovend onderzoeker bent bleek al snel en ik twijfelde daarom 
ook geen moment toen gevraagd werd of je geschikt zou zijn als AIO. Onze goede 
samenwerking in het najaar van 2005 konden we dan ook vervolgen vanaf mei 2007 
en met veel plezier en succes tot gevolg. We vullen elkaar prima aan en daar waar 
nodig ondersteunen we elkander. Naast professionele samenwerkingen vormen we 
ook een prima duo waar het gaat om slappe klets, rare fratsen, het bouwen van 
mooie feestjes en het wegwerken van onnoemelijke hoeveelheden chips! Bedankt 
voor je bijdrage aan dit proefschrift en dat we nog maar veel mogen samenwerken.
Geert, ook jij verdient een eigen alinea. Op het gebied van dier-experimenten heb 
jij me ontzettend veel bijgebracht, zowel qua kennis als kunde. Daarnaast was je 
altijd gezond kritisch over de opzet en uitvoering van de experimenten. We hebben 
samen een aantal zeer grote experimenten gedaan waaronder het MVA-experiment 
in Bilthoven waarvoor ik ook je collega’s wil bedanken. Ondanks alle drukte en stress 
was er altijd ruimte voor een goed gesprek of een vrolijke, al dan niet schunnige 
noot, wat het werken tot een waar feest maakte.
Dan de vrienden en vriendinnen van de Virologie en de 19e: Robbie, Willem, Koert, 
Robin, Hans, Stella I, Stella II, Lisette, David, Erhard, Joyce, Maarten, Gijs, Rory, 
Monique, Werner, Josanne (na je stage bij mij kom je binnenkort weer terug naar de 
17e) en natuurlijk alle anderen. Werken met collega’s zoals op de 3e, 17e en 19e maakt 
dat je niet anders dan fluitend naar je werk kan gaan.
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Tiny en Nella, als kamer- en groepsgenoten wil ik jullie bedanken voor de goede 
samenwerking, alle hulp en adviezen en de hele gezellige tijd in de gaafste kamer 
van het faculteitsgebouw: Ee1771.
Een aantal mensen ontbreken nog en deze wil ik dan ook even persoonlijk bedanken:
Eefje, als Brabantse matties hebben we het vanaf het begin prima met elkaar 
kunnen vinden. Allebei ADHD, allebei Carnavals-addicts en voor velen misschien iets 
te aanwezig. Maar niemand kon zeggen dat het saai was als 1 van ons in de buurt 
was. Hoewel we niet vaak direct hebben samengewerkt was je nooit te beroerd om 
ff te helpen met sequenties en dergelijke. Ik ben erg blij dat je mijn buurvrouw bent 
geworden.
Emmie en Vincent, Meneer en mevrouw Munster-de Wit, heb ontzettend veel van 
jullie geleerd en vele mooie dingen met jullie beleefd, ff een kort resumé: battle for 
the JID-cover, Mojito’s sushi en bubbelen in Villamoura, Full Throttle, Spiritualien-
reizen en de altijd mooie verjaardagen. Bedankt en alle succes van de wereld voor 
jullie USAvontuur. 
Na het ene stel nu het andere, Sander en Miranda. Sander, maat van het eerste uur, 
vele pilsjes, platen en feestjes hebben we samen versleten. En tussendoor nog ff tijd 
vinden om het over werk te hebben. Ik weet dat je nogal emotioneel bent aangelegd 
dus ik zal niet te ontroerend worden want ik weet niet of het papier water bestendig 
is. Miranda, als je niet op Sanders’ schoot zat zat je wel in je Mac. Je vermogen 
om door te blijven gaan ondanks nachtenlang doorhalen en werken heb ik altijd 
intrigerend gevonden. Af en toe weer een slaap-refill en dan was je weer de oude. 
Patrick (uit te spreken als Petturrriiiiiik!), altijd bezig met van alles en altijd 
met van alles bezig. Je huis, timmeren, nieuwe SOPs, je perfectionisme is 
bewonderenswaardig. Ook met jou vele pilsjes, platen en feestjes versleten. Samen 
met Sander vormen we een prima House-uitvoering van de Drie Musketiers.
Martin (alter Befhäse), altijd enthousiast en alles over voor anderen. Heb nog nooit 
iemand zichzelf zo snel een taal eigen zien maken. En de trip naar Keulen was 
legendarisch.
Imke, onvermoeibaar en altijd enthousiast. Ik herken veel van mezelf in jou en denk 
dat de afdeling Virologie blij mag zijn met een collega zoals jij. 
Corine, onze eerste experimenten hadden veel overlap en daarna waren het vooral 
205
CHAPTER 12
dankwoord
de sociale gelegenheden waar we elkaar troffen met als hoogtepunten onze duo-
presentatie op tv (gaaf!) en de trip naar Dakar. Khaossou, merci aussi!
Debby, Lonneke, Judith, Parafine Peter en Thijs,. Ik heb heel veel van jullie mogen 
leren op het gebied van pathologie. Jullie waren altijd in voor een mooie discussie en 
een goeie buurt. De nieuwste bekroning op onze samenwerking is de cover op JID.
(Oud)Sinterkerstcommissie-leden, ik wil jullie bedanken voor alle schitterende uren 
en dagen die we in de filmpjes en feesten hebben gestopt. Was vereerd dat ik het 
stokje mocht overnemen van Rocco (Willem, bedankt!) en heb het met heel veel 
plezier gedaan.
De flugroep: Theo, Salin, Juthatip, Pascal, Oanh, Monique, Björn, Kim, Chantal (how 
are you mate) en natuurlijk Ron. Bedankt voor alle behulpzaamheid, wijze raad, 
discussies en gezelligheid op Flu-I en II.
Daarnaast wil ik natuurlijk iedereen van de afdeling virologie (3e en 17e) en de bedrijven 
op de 19e bedanken voor hun bijdrage, hoe groot of hoe klein ook, aan dit proefschrift 
en aan de schittterende tijd die mijn promotie-periode heeft mogen zijn. Simone, 
Loubna, Sabine, Wim, Sumeira, Carola, Fernanda en natuurlijk “kan ik niet, hebben 
we niet, krijg je niet, maar misschien toch wel” – Robert. Ook wil ik de mensen van 
het EDC en in het speciaal, Ed en Dennis bedanken voor hun ondersteuning bij een 
aantal van onze experimenten. Graag wil ik ook mijn voorgangers: Theo, Jacco en 
Femke bedanken voor de erfenis die ze voor me hebben achtergelaten.
Gerd und Yasemin. Vielen Dank für alles was sie getan haben für die MVA-Studien. 
Es war super in Langen (Dagmar, Melanie, Tobias, Astrid und Yolanda, Danke Sehr) 
und Ich hoffe das wir nog viel zusammenarbeiten sollen. 
Dank ook aan alle leden van het NIVAREC-consortium: de groep van Jan Wilschut 
aan het UMCG en Solvay Biologicals.
Zonder diploma geen promotie dus wil ik ook graag even wat mensen uit mijn 
studie-tijd bedanken. Allereerst Andrea, Hans, Hans, Eric en Judith en alle anderen 
bij de afdeling TDO die mijn afstudeerstage tot een zeer mooie en leerzame periode 
hebben gemaakt. En dan natuurlijk de vrienden en vriendinnen van de welzeer edele 
Budblaffers: Anke, Anne, Dennis, Elles, Femke, Fons, Harald, Hub, Jasper, Jentjes, 
Koos, Lars, Marcel, Rene, Rob en Zairah. De feestjes, Risoul en Serre Chevalier, 
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brakke college’s, milk&fruits, potjes voetbal voor de faculteit, Hou-je en Hoogeveld 
(alwaar de vonk oversprong tussen mijn lief en mij). In 1 woord: legendarisch.
Ik wil de familie Bongers en Kreijtz bedanken voor hun belangstelling en interesse 
voor mijn onderzoek, ik ga nu dan eindelijk afstuderen/promoveren. Juul, Joep, 
Wout en Stijn, bedankt voor de altijd mooie stapavondjes/uitstapjes in Rotterdam.
Uje, Zeland en Volkel de gekste! Roel & Rianne, Evelien & Joost, Marieke & Harben, 
Maryono & Charlotte, Erik & Kristel, bedankt voor alle interesse de afgelopen jaren. 
Het was altijd goed om weer omringd te zijn door goede vrienden na een periode 
hard werken. 
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wat jullie voor Suzanne en mij hebben gedaan en ook ik ben nu van Vorstenbosche 
Boy, via Udenaar en Rotterdammer dan toch ook een Volkelnaar geworden.
En dan nu de allerbelangrijkste alineas uit dit epistel. 
Lieve Floor en Janko, zusje en schoonbroeder. Jullie zijn een heel belangrijk 
onderdeel van mijn leven. We hebben ’t allemaal ontzettend druk en zien elkaar 
eigenlijk veel te weinig. Maar als we bij elkaar zijn is het altijd één groot feest. Jullie 
interesse en vrolijkheid hebben mij altijd gestimuleerd in mijn werk en ik ben trots 
op de manier waarop jullie je carrières zo mooi aan het opbouwen zijn en daarnaast 
gewoon blijven genieten van het leven. En ons volgende feestje wordt er vast één 
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Lieve Papa en Mama, ons pap en mam. Zonder jullie was er nooit een letter van 
dit proefschrift op papier gekomen. Jullie hebben mij gemaakt tot wie ik nu 
ben. Een warm nest en onvoorwaardelijke steun voor alles wat jullie kinderen 
ondernemen. Jullie hadden de wetenschapper in mij al vroeg ontdekt en hebben 
deze altijd geprikkeld met bezoekjes aan musea en dierentuinen, tripjes naar 
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en ‘dinosauruseieren’ die ik weer in het bos had gevonden. Honderden kilometers 
voor ons op en neer gereden, bulten was verwerkt en altijd een luisterend oor en een 
helpende hand. Later, op zondagavond nog ff kletsen met ons mam op de bank en 
dan toch weer te laat te bed. Op vrijdagmiddag gezellig bijbuurten met ons pap in 
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dankwoord
de auto vanuit Rotterdam om dit vervolgens nog eens dunnetjes en lichtelijk luider 
over te doen aan de keukentafel als Floor, Janko, Suzanne en ik weer eens met z’n 
allen bij jullie in Uden zijn.
Zoals jullie samen genieten van zowel de grote maar vooral ook kleine dingen in ’t 
leven is inspirerend voor me. Lekker wandelen, een heerlijk stuk chocolade, gewoon 
een vogeltje dat even op de schutting komt zitten of gewoonweg met z’n zesjes wat 
eten en buurten. Het is altijd zo vanzelfsprekend en fijn dat jullie er voor ons zijn 
maar ik wil het bij deze dan toch voor altijd op schrift vastleggen: ik hou van jullie. 
Lieve Suzanne, mijn dank voor jou is met geen pen te beschrijven. Ze zeggen dat 
promoveren zwaar is, en dat zal ook best, maar met jou aan mijn zijde was alle 
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lab, lichtelijke bezorgheid was er bij jou als ik wat teveel werkte en me niet helemaal 
hield aan de (bami)schijf van vijf. Maar bovenal laat je me vaak weten trots op me 
te zijn en dat voelt ontzettend goed. Ik ben ook ontzettend trots op jou: een nieuwe 
opleiding die je met zoveel stress begon en met zoveel klasse hebt afgerond om 
vervolgens meteen een droombaan in de wacht te slepen, gevolgd door nog maar 
weer een extra opleiding. Heb ontzettend veel respect voor de manier waarop je dit 
hebt volbracht. Naast al je studies en je werk was ’t feit dat we zo ver uit elkaar zaten 
en allebei druk waren niet altijd even makkelijk: ik in Rotterdam, jij in Volkel, jij vrij, 
ik werken, of andersom. Maar samen hebben we ’t allemaal prima-deluxe volbracht 
en nu zijn we dan eindelijk samen in ons eigen stulpje. Als jij uit je avonddienst komt 
nog ff heerlijk samen op de bank en na je nachtdienst zorg ik dat je in een warm bedje 
terechtkomt. Ik heb het ontzettend fijn met jou en we hebben samen al zoveel gave 
dingen gezien, gedaan en meegemaakt. Ons nieuwe avontuur begint nu in Volkel en 
wie weet waar het ons allemaal gaat brengen. Eén ding weet ik zeker: ons avontuur 
kent geen grenzen want samen kunnen wij de hele wereld aan. Ik hou van je kleine…
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Chapter 2 - Figure 5 Histology of the lungs of mice infected with either influenza virus X-31, influenza virus 
A/PR/8/34 or both sequentially. A+B: lung of a naive mouse 4 days after PR/8 infection with flooding of the 
alveoli (A) and peri-broncheolar and –vascular lymphoid infiltrate (B). (C+D) lung of an X-31 experienced 
mouse 4 days after PR/8 challenge lacking flooding of the alveoli (C) and stronger peri-brocheolar and –
vascular lymphoid infiltrate (D). (E+F) lung of a naive mouse 7 days after PR/8 infection, The alveoli are filled 
with cell debri and fluid, and type II pneumocyte hyperplasia is seen in the alveolar walls (E) combined with 
strong peri-brocheolar and –vascular lymphoid infiltrate (F). (G+H) lung of an X-31 experienced mouse 7 
days after PR/8 challenge, with mild type II pneumocyte hyperplasia (G) and marked peri-brocheolar and 
–vascular lymphoid infiltrate (H).  (I+J) lung of an X-31 experienced mouse on day 28 after PR/8 challenge 
with normal looking alveoli (I) and a peri-brocheolar and –vascular lymphoid cuff (J).
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Chapter 2 - Figure 6 Mouse lung sections stained for influenza virus A NP. Cytoplasm of influenza A virus 
infected cells stains red, the nuclei stain deep red (A) naive mouse on day 4 after infection with influenza 
A virus A/PR/8/34 with virus antigen positive epithelial cells alining the bronchiole, and positive cells in the 
alveoli (B) naïve mouse on day 7 p.i.. with virus antigen positive cells in the alveoli (C) X-31 experienced mouse 
on day 4 after infection with Influenza virus A/PR/8/34 with virus antigen positive cells around the bronchioles 
(D) X-31 experienced mouse on day 7 p.i. lacking virus antigen positive cells. 
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Chapter 3 - Figure 3 Histopathology was examined in the lungs of mice after infection with influenza virus 
A/IND/5/05. Four days after infection the lungs of H3N2-primed animals showed a multifocal mild broncho-
interstitial pneumonia with mild inflammatory infiltrates consisting of predominantly lymphocytes and 
neutrophils (A). The mock-infected control mice (B) and RSV-primed mice (C) displayed a multifocal moderate 
necrotizing broncho-interstitial pneumonia with marked infiltration, consisting of inflammatory cells, mainly 
neutrophils and lymphocytes, in the alveoli. 
Chapter 3 - Figure 4 Detection of virus-infected cells by immunohistochemistry in the lungs of influenza virus 
A/IND/5/05 (H5N1)-infected mice on day 4 p.i. in mice primed by infection with influenza virus A/HK/2/68 
(H3N2) (A), mock-infected mice (B), or RSV-primed mice (C).
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APPENDiX iv
Chapter 4 - Figure 2 Outcome of infection with IAV HK/68 (H3N2). Mice were inoculated with IAV HK/68 
(groups 2 (p), 3 (O), 6 (¢) and 7 (Ï)) or PBS (groups 1 (Â), 4 (s) and 5 (¯)). (A) Body weight after 
infection was determined daily and expressed as the percentage of the original body weight before infection. 
(B) Lung virus titers measured on day 4 p.i. in mice from the indicated experimental groups. Horizontal bars 
represent the average titers of five mice. The dotted line represents the cut-off value for obtaining a positive 
result. *This mouse from group 6 had before infection an HI antibody titer of 40. (C) Vaccination prevented 
the induction of iBALT after infection. Twenty-eight days post infection with IAV HK/68 iBALT was detected 
in mice from group 3, but not in mice from group 2. Lung tissue sections were stained with HE. (D) Virus-
specific CD8+ T cell responses detected 28 days post infection. Splenocytes of mice from the indicated 
experimental groups were tested for the presence of CD8+ T cells that bound the H2-Db NP
HK 
Tetramer. 
Horizontal bars represent the average of 2-4 mice. The difference in %CD8+ Tm+ T cells between groups 2 
and 3 was statistically significant (P=0.030).
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Chapter 4 - Figure 4 Histopathological analysis and immunohistochemistry of the lungs of mice infected 
with IAV IND/05. Mouse lung sections were stained for influenza A virus nucleoprotein. Cytoplasm of infected 
cells stain red, the nuclei of infected cells stain deep red. In the groups without a history of productive A/
H3N2 infection, including group 2 (A,B), infection with IAV IND/05 led to severe histopathological changes 
and to viral antigen expression in cells of the bronchiolar walls and in the alveoli (group 4: E,F and group 5: 
G,H). In mice of groups 3 (C,D) and 7 (I,J) that had experienced a productive infection with IAV HK/68 only 
moderate histopathological changes were observed and virus infected cells were detected sporadically (see 
insert in panel D). For more information please see text.
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Chapter 5 - Figure 1 The presence of known CTL epitopes in H5N1 strains. The percentage of H5N1 viruses 
with an epitope sequence identical to human influenza viruses (white bars) is shown in Figure 1. The black 
bars indicate the percentage of H5N1 viruses with one or more amino acid substitutions in the epitope 
sequence. The absolute numbers of each variant of an epitope are shown in Figure 1B, each color represents 
a single variant (sequences can be found in table 1). For this analysis almost 900 H5N1 viruses were analyzed 
for which sequence information was available in the influenza sequence database [290].
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Chapter 6 - Figure 4 Histopathology and immunohistochemistry of the bronchioles and alveoli in lungs of 
mice infected with either influenza virus A/HK/157/97, A/VN/1194/04 or A/ IND/5/05 as indicated. Influenza 
virus A/HK/156/97 infection led to viral antigen expression in cells of the bronchiolar wall of PBS (A) and 
wtMVA immunized mice (E), combined with mild peribronchiolar inflammatory infiltrate, while in the lungs 
of MVA-HA-HK/97 (B), MVA-HA-VN/04 (C) and Stimune®-adjuvanted NIBRG-14 (D) immunized mice no viral 
antigen was detected. Infection with influenza virus A/VN/1194/04 resulted in expression of viral antigen in 
cells of the bronchiolar walls of PBS (F), MVA-HA-HK/97 (G) and wtMVA (J) immunized mice, also combined 
with moderate peribronchiolar infiltrate (except for the wtMVA immunized mice). No viral antigen expression 
or morphological changes were detected in MVA-HA-VN/04 (H) and Stimune®-adjuvanted NIBRG-14 
immunized mice (I). Infection with influenza virus A/IND/5/05 resulted in abundant viral antigen expression 
in the bronchioles of PBS (K), MVA-HA-HK/97 (L) and wtMVA (O) immunized mice, combined with moderate 
peribronchiolar infiltrate. Only minimal viral antigen expression was detected in the bronchiolar wall of 
MVA-HA-VN/04 (M) immunized mice, combined with moderate inflammatory infiltrate. No viral antigen was 
detected in the lungs of Stimune®-adjuvanted NIBRG-14 (N) immunized mice after infection with influenza 
virus A/Indonesia/5/05.
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Chapter 7 - Figure 2 Body temperature recorded before and after infection with influenza virus A/
Vietnam/1194/04 (A-C) or A/Indonesia/5/05 (D-F). The animals were immunized with PBS, wtMVA 
or MVA-HA-VN/04 as indicated. Changes in body temperature of individual animals after infection 
with influenza virus A/Vietnam/1194/04 (G-L) or A/Indonesia/5/05 (M-R) were calculated for each 
individual animal. Each dot represents an individual animal. Line colors in Figure 2A-C correspond 
with dot colors in figure 2G-L. Line colors in Figure 2D-F correspond with dot colors in figure 2M-R. 
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Chapter 7 - Figure 5 Macroscopic lesions of the lungs after infection with H5N1 influenza virus. The lungs of 
animals immunized with PBS (A, D), wtMVA (B, E) or MVA-HA-VN/04 (C, F) were fixed in formalin on day 4 
after infection with influenza virus A/Vietnam/1194/04 (A-C) or A/Indonesia/5/05 (D-F). The arrows indicate 
consolidated areas present in the lungs of PBS and wtMVA immunized animals after infection (A, B, D, E). 
Lungs from the MVA-HA-VN/04 immunized animals had no macroscopical lesions (C, F). 
Chapter 7 - Figure 6 Histopathologic analysis of the lungs on day 4 after infection with influenza virus A/
Vietnam/1194/04 (A, B, C) or A/Indonesia/5/05 (D, E, F). Histopathological changes were comparable in PBS 
and wtMVA inoculated animals with extensive lesions in the lungs of these animals. There was mild necrosis, 
edema, hyperthropy and hyperplasia of type II pneumocytes combined with peribronchiolar and –vascular 
infiltration. The epithelium of some bronchioles is denuded due to necrosis of the epithelial cells. (A, B, D, E). 
In the lungs of the MVA-HA-VN/04 immunized animals no histopathological changes were observed (C,F).
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Chapter 7 - Figure 7 Detection of virus-infected cells in the lungs four days post infection with H5N1 
influenza viruses. Immunohistochemistry was used to stain cells that are positive for the presence 
of viral antigen showing a deep red staining in the nucleus. Influenza viruses A/Vietnam/1194/04 
(arrows indicate single infected cells) or A/Indonesia/5/05 antigen expression was seen in alveolar 
epithelial cells and some alveolar macrophages of PBS (A, D) and wtMVA (B, E) inoculated 
animals. No viral antigen was observed in the lungs of MVA-HA-VN/04 immunized animals (C, F).
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Chapter 8 - Figure 3 Histopathological changes and immunohistochemistry of the lungs after infection with 
influenza A/H5N1 virus. Representative pictures were selected for the different classifications. Magnification: 
overview (10x), bronchiole (20x), alveoli (40x).
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